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Abstract 
Novel nanoscale materials with advanced functionalities have attracted increasing attention in 
the fields of drug delivery, diagnostics and medical imaging. Nanoparticles possess sizes in 
the range of cellular compartments and are therefore capable to enter living cells via 
mechanisms like endocytosis. This allows them to function as carrier systems to locally 
deliver fragile, water-insoluble or harmful cargo to the respective target site and thus 
overcome degradation, permeation or toxicity problems. In addition, a targeted delivery of the 
cargo can achieve higher local drug dosages while preventing severe side effects. These 
positive characteristics of nanoparticle-based therapies are extensively studied in the field of 
cancer treatment. Mesoporous silica nanoparticles (MSNs) have been widely reviewed as 
promising delivery system for chemotherapeutics. They also hold great promise as 
nanocarriers for immune-modulating drugs which are applied in cancer immunotherapy to 
induce an augmented antitumor T cell response of the immune system. MSNs possess very 
large surface areas which enable high drug loading contents and thus an overall reduced 
dosage to be effective. Furthermore, their particle and pore size can be easily tuned allowing 
them to accommodate a wide variety of different guest molecules. In addition, they are easily 
functionalized on their in- and outside, thus allowing perfectly tailored host-guest as well as 
particle-cell interactions. Due to this spatial control, guest molecules can be trapped inside the 
pores until the capping system opens up upon a certain stimulus. Here, a wide variety of 
stimuli-responsive capping systems exists, ranging from polymers over metal oxides to 
protein caps or complete coatings by supported lipid bilayers. Furthermore, to enhance 
passive or active targeting, (bio) polymer shells like polyethylene glycol can be added around 
the particles to achieve a so-called stealth effect and thus enable passive accumulation in the 
tumor via the enhanced permeability and retention (EPR) effect. On the other hand, targeting 
ligands covalently attached to the outer surface of the MSNs may enable active receptor-
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mediated uptake into tumor cells. Lastly, the surface of the particles can be modified in a way 
that they are specifically taken up by innate immune cells which is the goal of cancer vaccines 
belonging to the field of cancer immunotherapy. Nevertheless, there is still a great need for 
improvement of well-established systems like mesoporous silica nanoparticles (MSNs) as 
well as for the synthesis of novel biomaterials. Aspects like the successful loading and 
controlled release of drugs, stability and degradation issues of the delivery system in 
biological fluids, favoured particle-cell interactions especially successful targeting versus 
rapid clearance of the nanocarrier and of course safety and toxicity profiles of the hosts have 
to be carefully evaluated in vitro and specifically in vivo. 
This thesis focuses on the implementation of well-known MSNs as delivery vehicles for 
various types of cargo. The impact of fine-tuning the inner surface of the particles on the 
loading and release behaviour of the respective drug is shown with in cuvette and in vitro 
cellular delivery experiments. Furthermore, the choice of the capping system also has a 
tremendous influence on the release performance. In addition, the impact of surface 
functionalization, e.g. through capping systems, on particle-cell interactions is especially 
discussed for the indirectly active targeting approach of MSNs to antigen-presenting cells 
(APCs). The biocompatibility and toxicity of the carrier system is evaluated in vitro and in 
vivo as it is a crucial aspect for future clinical applications. Furthermore, the possibilities of 
the nanocarrier to deliver more than one guest at a time and the associated enhanced 
performance of the system are reported. To underline the flexibility of MSNs, not only small 
molecules are chosen as cargo but also the encapsulation of large biomolecules is discussed. 
In addition, different binding strategies of cargoes to the inside of the pores are described with 
regard to the intended application of the carrier system. At last a novel biomaterial with a 
different host-guest interaction is introduced and applied in cellular delivery experiments. 
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The first part of this thesis focuses on the evaluation of mesoporous silica nanoparticles as 
appropriate carrier for immune-stimulant cargo. For this purpose, amine-functionalized MSNs 
with and without pH-responsive polymer capping system are assessed regarding their 
biocompatibility, toxicity, and immune-modulatory properties, all aspects of great relevance 
for future clinical applications. It is shown that MSNs are rapidly and efficiently taken up by 
specialized antigen-presenting cells (APCs) such as dendritic cells (DCs). This preferred 
uptake of MSNs by APCs is the target in nanoparticle-based cancer vaccines. By enhanced 
uptake into DCs, the key players of the innate immune system, a successful DC maturation 
can be achieved followed by a potent tumor-specific T cell activation. Another important 
requirement is that the carrier system exhibits no toxicity and no immune-modulatory 
properties itself. It is shown that MSNs possess a favourable toxicity profile and induce 
marked apoptosis only when used in very high concentrations of 200 µg mL
-1
. Further, 
unloaded MSNs initiated only a slight immune response in primary murine immune cells, 
meaning they did not upregulate any activation markers such as co-stimulatory molecules or 
proinflammatory cytokines. Summarizing, the particles represent a non-toxic and non-
inflammagenic delivery system which is preferentially taken up by specialized antigen-
presenting cells. To assess if this MSN system can principally function as carrier for immune-
modulatory cargo with regard to cancer immunotherapy applications, the particles were 
loaded with Resiquimod (R848) and coated with the pH-responsive polymer PVP as capping 
system. The MSN-PVP system was internalized via endocytosis into the acidic environment 
of the APCs’ lysosome, which triggered pH-dependent R848 release. R848 is a synthetic Toll-
like receptor agonist and is capable of inducing a potent immune response by activating 
dendritic cells and thus starting the cascade of a successful T cell response and tumor cell 
killing. The release of delivered R848 caused significant upregulation of the above mentioned 
 
X 
 
activation markers. In summary, it was demonstrated that MSNs possess indeed the 
appropriate characteristics for an optimal carrier system of immune-modulatory cargo.  
To implement the gained knowledge and explore the possibilities of MSNs as drug delivery 
system, MSNs are investigated in detail as pH-responsive carrier system for R848 in the 
succeeding chapter. To examine the full potential of the drug delivery system, the 
aforementioned polymer cap was compared to a protein-based one with respect to their R848 
loading and release behaviour. The two different capping systems differ in their opening and 
closure mechanisms. Whereas the polymer system works reversibly upon pH-dependent (de-) 
protonation of the PVP group, the biotin-avidin complex is irreversibly detached through pH-
dependent cleavage of the connecting acetal linker. Time-based fluorescence release 
measurements in cuvette demonstrated that the R848 release of the avidin-capped system is 
superior to that of the PVP-coated MSNs. This was further confirmed in a cell-based assay. 
The easy functionalization of MSNs allows for choosing the most efficient capping system as 
well as the optimal pore interior for each cargo. To optimize the loading behaviour of R848 
into MSN-avidin, we incorporated phenyl moieties inside the pores and compared them with 
amine-functionalized particles. The latter showed electrostatic repulsion and thus hampered 
cargo uptake whereas phenyl functionalized MSNs showed great loading in the correct buffer. 
To allow the hydrophobic effect to act between cargo and pore wall, the SSC20x buffer with 
the kosmotropic citrate ions was determined to be the best loading buffer. Due to the fact that 
MSNs will be injected subcutaneously into mice in future applications, they only reach the 
draining lymph node (LN) with dendritic cells (DCs), after being taken up by them. This 
implies that particles have to prove a long-term stability until they are all ‘picked up’ by DCs 
and delivered to the LN to avoid systemic distribution of R848 due to premature release. This 
long-term stability of the capping system was examined with a time-based release experiment 
over 60 h at 37 °C. Avidin coated MSNs proved to achieve tight capping under physiological 
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pH and showed strong release of the R848 cargo when the environmental pH was decreased 
to 5.5 or lower. It was shown that MSNs are rapidly taken up by APCs and mainly 
accumulated in migratory DCs in the draining LN after subcutaneous injection into mice. 
Particles loaded with R848 induced a potent DC activation as shown in the upregulation of 
co-stimulatory and MHC molecules as well as cytokine production. Remarkably, the 
supernatant of the loaded particles did not induce an immune response, proving the tightness 
of the capping system. To explore the possibilities of the MSN system further, simultaneous 
delivery of antigen and adjuvant was monitored. The co-delivery of both agents in the same 
particles showed superior T cell activation. In sum, it was demonstrated that MSNs hold 
indeed great promise as carrier system for immune-stimulant R848 to antigen-presenting 
cells. In addition, they show high potential to be used in further cancer vaccine applications to 
achieve a locally induced immune activation while preventing adverse systemic effects.  
Besides these small molecules, also larger biomolecules rely on transporting systems for an 
improved performance in various application fields. Here, large-pore mesoporous silica 
nanoparticles (LP-MSNs) are promising nanocarriers for the targeted delivery of 
macromolecules. Chapter 5 of this thesis discusses the diversity of multifunctional stellate 
large-pore MSNs regarding the impact of different incorporated organosilanes on the 
mesopore structure and the particle morphology. Furthermore, an adapted version of the 
delayed co-condensation method for small-pore particles was transferred to create spatially-
segregated core-shell large pore MSNs. The particles were further functionalized with stimuli-
responsive linkers, namely the pH-responsive acetal linker described in chapter 4 and a redox-
sensitive disulfide linker, to enable controlled cargo release. This was followed by attachment 
of DBCO derivatives allowing for mild cargo conjugation via copper free click chemistry. 
The successful release of the model cargo TAMRA dye was triggered with specific buffer or 
redox conditions and monitored via time-based fluorescence measurements as well as in vitro 
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fluorescence microscopy experiments. The covalent conjugation of the cargo described here 
via mild click-chemistry can be of high importance in application fields of biocatalysis. Here, 
it is of interest to immobilize enzymes to allow for continuous industrial processes. The 
potential of the stellate LP-MSNs as enzyme support is described in chapter 6 of this thesis. 
Silica-based supports for enzyme immobilization are widely used, as their porous system can 
protect the fragile cargo from external degradation forces. Furthermore, covalent 
immobilization into MSNs allows for easy recovery of the ‘biocatalyst’ in comparison to the 
tedious work-up of free enzymes. Here, mild copper-catalyzed click chemistry was applied to 
immobilize two different enzymes, namely horseradish peroxidase and carbonic anhydrase, 
into the large pores of azide-functionalized stellate MSNs. The concave shape of the pores 
allowed for easy diffusion of the large biomolecules into the pores prior to covalent 
attachment. In addition, this pore shape also enables the quick diffusion of substrates to the 
immobilized enzymes and thus enhances the overall catalytic performance. The successful 
immobilization of the biomolecules inside the silica support was characterized with several 
methods including IR-spectroscopy, gas sorption, and TGA measurements. In addition, their 
potential as biocatalysts was investigated with model catalytic activity measurements. Here, 
colorimetric assays were applied for the respective enzymes to monitor the catalytic activity 
over several cycles with simple washing and centrifugation steps of the particles in between. 
It was shown that the enzymes remained stable and active in the pores, thus proving the 
benefits of covalent immobilization inside mesoporous silica nanoparticles. 
Besides the above-mentioned successful implementations of already existing mesoporous 
silica nanoparticles for various applications, the last chapter of this thesis is concerned with 
the synthesis of a novel biomaterial. Here, a completely organic and covalently crosslinked 
material based on β-cyclodextrins (CDs) is introduced. This soft material consists of small 
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nanoparticles with sizes of ~ 150 nm, which are highly water-dispersible. Covalently labeled 
CD nanoparticles showed rapid uptake in HeLa cells within 30 minutes, whereas lipid bilayer 
coating of the particles inhibited the uptake in this short period of time. This suggests that CD 
NPs are endocytosed via a sugar-receptor mediated pathway. Their ability to form inclusion 
complexes between the cyclodextrin rings and various cargos was demonstrated with the 
loading of the nuclei staining dye Hoechst and the chemotherapeutic doxorubicin, 
respectively. Both cargos were efficiently delivered without notable premature leakage. Upon 
acidification in the endosomes both cargos were successfully released, as seen in strong nuclei 
staining or potent cell killing, respectively. Thus, the novel sugar-based material holds great 
promise as alternative biocompatible drug carriers. 
In summary, the great potential of multifunctional MSNs as carrier system in various fields 
was demonstrated in this work. MSNs with different pore sizes, morphologies, and post-
synthetic functionalizations were tailored to meet the requirements of a non-toxic and non-
inflammagenic carrier system as well as a support material for large biomolecules. Their 
promising potential as stimuli-responsive delivery systems was demonstrated in vitro and in 
vivo. To expand the spectrum of talented biocompatible carriers, a novel sugar-based 
nanomaterial was introduced with promising cellular delivery characteristics. The future aim 
is to implement these functionalization methods and materials further to enable delivery of 
multiple drugs in one carrier and thus combine different synergistic cancer treatments as for 
example chemotherapy and cancer immunotherapy. 
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1. Introduction 
1.1 Mesoporous silica nanoparticles 
Mesoporous silica nanoparticles (MSNs) represent a class of promising inorganic drug 
carriers. They are well-known for their large surface areas, their high thermal stability and 
their tunable pore sizes and shapes.
1
 Furthermore, they can be functionalized easily on their 
inside with spatial control to perfectly tune the interaction between cargo and host to achieve 
very high loading and release efficiencies. Not only the interior of the MSNs can be modified 
but also the outside of the spatially segregated core-shell bifunctional particles. The exterior 
surface can be equipped with matching functionalities to allow covalent binding of targeting 
ligands, endosomal escape agents and most importantly different capping systems to ensure 
tight sealing of the pores. Those closure mechanisms are always chosen in a way to open up 
upon certain stimuli. The stimuli can be either external ones like light, heat, a magnetic field 
or the like or the opening of the pores can be evoked by internal stimuli, like changes of pH, 
redox reactions or enzyme mediated degradations.  
Those characteristics make MSNs a promising material that meets many requirements of a 
successful drug delivery vehicle.  
The description mesoporous is defined by the International Union of Pure and Applied 
Chemistry (IUPAC) as a term describing porous materials with pore sizes between 2 and 
50 nm.
2
 Furthermore, the term ‘nanoparticles’ is strictly speaking only to be used for particles 
with sizes in at least one dimension smaller than 100 nm.
3
 The MSNs used in this thesis are 
spherical and show sizes between 50 nm and 200 nm. Due to the fact that in this size range 
the properties of the particles do not change as drastically as they change from a nanoparticle 
in comparison to bulk material, we will still call them mesoporous silica nanoparticles.  
1. Introduction  
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The story of MSNs begins almost 30 years ago in 1990/1992, when two independent groups, 
namely Yanagisawa et al. and Kresge et al., reported surfactant-templated periodic 
mesoporous materials for the first time.
4-5
 The need for larger pores was great due to the 
arising restrictions in the use of microporous zeolites, especially in the field of catalysis.
6
 
Larger pores would enable a faster diffusion of larger reactants into the catalytic material.
7
 
Especially the work of the Kresge group with their invention to use quaternary ammonium 
salts as templating molecules paved the way for MSNs. With their new templating approach 
in micellar form, they achieved either hexagonal (MCM-41) or cubic (MCM-48) pore 
structures with pore sizes around 3 nm (MCM: Mobil Crystalline Material). Furthermore, they 
were able to show the positive effect of pore swelling agents leading to expanded pore sizes 
of up to 10 nm. As time would show it should take some years until the control over the 
synthesis of colloidally stable solutions would be gained.
8
 
Besides the MCM family, a couple of years later, the SBA family (Santa Barbara Amorphous) 
emerged.
9-10
 Whereas, MCMs are synthesized under basic conditions and with the use of 
cationic surfactants, SBAs are produced in acidic media with the help of templating non-ionic 
triblock copolymers. The change of pH and surfactant results in thicker pore walls and higher 
thermal stability. Nowadays, MCM-41 with its 2D hexagonal pore structure, MCM-48 with 
its 3D cubic pore structure and SBA-15 with its likewise 2-dimensional hexagonal 
mesostructure represent the most studied and commonly used mesoporous silica materials.
11
 
To date, there is a large number of different synthesis and functionalization routes available 
resulting in particles with size ranges from about 20 nm to 500 nm and pore size ranges 
between about 2 nm and 30 nm.
12-14
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1.1.1. Small-pore MSNs 
In the beginning of research on mesoporous materials, the particle sizes were in the 
micrometer range. In the biomedical field, one of the main research areas of MSNs nowadays, 
the use of micrometer-sized particles is limited due to a size-dependent efficiency in cellular 
uptake since their size is too big.
15-16
 In 2001, the new potential property of MCM-41 particles 
to act as drug delivery vehicles was shown for the first time by means of loading and release 
studies with ibuprofen.
17
 After this discovery, efforts were being made to achieve controlled 
nanometre-sized, spherical mesoporous silica nanoparticles. Grün and co-workers achieved 
sub-micrometer sized spherical MCM-41 particles by addition of cationic surfactant in a 
modified Stöber synthesis.
18-19
 In the classical picture, the template enables micelle formation 
and electrostatic interaction between negatively charged silicates and positively charged 
template. The following base-catalyzed hydrolysis and condensation of the tetraalkyl silicates 
then takes place on the surface of the micelles and therefore leads to a mesopore formation.
20
 
Cai et al. as well as Ostafin and co-workers gained particles in the nanometre range due to 
extremely low silicate and surfactant concentrations.
21-22
 Lin and Tsai also worked with very 
diluted solutions resulting in even smaller nanoparticles at a low pH of 5.6.
23
 Furthermore, the 
group of Mann achieved nanoparticles by a quenching and dilution method of the reaction 
mixture after very short reaction times with subsequent neutralization.
24
 These developments 
all show the production of mesoporous silica nanoparticles via a simple synthesis route. The 
drawback though is the used large reaction volume to avoid particle agglomeration. This can 
lead to a difficult product isolation and therefore results in low product yields. To overcome 
this hurdle, a synthesis route developed in our group employs the chelating base 
triethanolamine (TEA) instead of the commonly applied NaOH.
25
 Employing this polyalcohol 
in the synthesis as a weak base, enables the use of lower pH values in the synthesis. This 
leads, in combination with the complexing behaviour of TEA, to well-defined non-
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agglomerated MSNs.
26
 As a templating agent CTAC (cetyltrimethylammonium chloride) is 
employed and ammonium fluoride is added to achieve spherically shaped MSNs. The 
resulting colloidally stable, spherical nanoparticles show sizes of around 80 nm and pore 
diameters of 4 nm. The porous system shows a wormlike structure suggesting a seed-growth 
mechanism, which is possibly induced through the reduced reaction rate in the condensation 
step through the chelating effects of TEA. Tuning the ratio between TEA and TEOS leads to a 
range of available particle sizes between 50 and 100 nm.
27
 To actually access and open up the 
mesopore system, the template has to be removed. This can be either achieved via calcination 
or by extraction methods. Calcination is typically performed at elevated temperatures for a 
certain period of time. It can lead to agglomeration and pore shape deformation and can only 
be applied for unfunctionalized silica particles. Therefore, extraction is the method of choice 
used in our group. For this, the particles are redispersed in a basic ethanolic solution and 
heated under reflux at 90 °C for 45 min. Subsequently, the particles are centrifuged and 
redispersed in an acidic ethanolic solution and heated a second time under the same 
conditions. This very mild extraction method can also be applied for silica particles 
functionalized with organic moieties. The resulting small-pore MSNs were already 
successfully used by Bein and co-workers to deliver small molecules, chemotherapeutics and 
dyes as model cargoes in vitro.
28-31
  
Additionally to the making of the above described silica particles, recently the ‘breaking’ 
process attracted also attention. Degradation products play, besides other parameters as size, 
surface charge etc. (discussed below), also an important role in the toxicity profile of the 
particles. The silica framework consists mainly of –Si-O- bonds, which represent quite stable 
chemical connections with a bond energy of 452 kJ/mol. Nevertheless, hydrolytic breakage 
through nucleophilic attack can occur in aqueous media. The resulting silicic acid (Si(OH)4) 
can leach out from the silica matrix. It is non-toxic and can be easily excreted by urine.
32-33
 As 
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shown by Möller and Bein, the conditions chosen for the synthesis of the mesoporous silica 
nanoparticles strongly affect their degradation behaviour (see Figure 1-1).
34
 MSNs produced 
under acidic pH show a very high stability in aqueous media due to the thicker pore walls 
resulting from this synthesis route. The higher the pH chosen in the reaction, the thinner and 
less condensed are the resulting pore walls and the faster does degradation occur. Notably, 
unfunctionalized particles are significantly more stable than core-shell functionalized particles 
produced via a site-specific delayed co-condensation approach (described below). This can be 
explained with the lower amount of fully condensed –Si-O- building blocks due to the 
introduction of organic moieties. The resulting –Si-R or –Si-OH bonds apparently offer more 
opportunity for nucleophilic attack. 
 
Figure 1-1. Differences in degradation behaviour depending on the synthesis conditions of (un-) functionalized 
mesoporous silica nanoparticles. Adapted with permission from “Degradable Drug Carriers: Vanishing 
Mesoporous Silica Nanoparticles” by K. Möller and T. Bein, Chem. Mater. 2019, 31 (12), 4364-4378. Copyright 
2019 by the American Chemical Society.
34
 
Concluding, the degradation behaviour can be fine-tuned by choosing the respective reaction 
conditions and (organo-)silanes. Altogether, MSNs represent tunable, multifunctional and 
well-tailored host systems for a variety of guests, as will be discussed below. The successful 
use of small-pore MSNs as carrier system for immunostimulant cargo is described in chapters 
3 and 4 in this thesis.  
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1.1.2. Large-pore MSNs 
Besides the above mentioned small-sized cargoes, there is the need to delivery larger guests. 
Especially fragile molecules like siRNA and other biomolecules like proteins and enzymes 
may be degraded fast and easily in biological media. Therefore, encapsulation in a carrier 
system is needed. To be able to accommodate those larger guests, great efforts have been 
made towards achieving silica particles with larger pores. The different approaches can be 
summarized in two general pathways: (a) Using additional swelling agents in combination 
with commonly used surfactants, or (b) applying amphiphilic copolymers or larger surfactants 
(commonly with a prolonged alkyl chain).
35
 As mentioned above, already the Kresge group 
showed the effect of a pore-swelling agent resulting in pore sizes of up to 10 nm.
27
 Stucky et 
al. achieved SBA-15 with pore sizes of up to 30 nm by using amphiphilic block copolymers 
poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) in 
addition with the pore-expanding mesitylene (1,3,5-trimethylbenzene, TMB).
10, 36
 In both 
cases the pore sizes are enlarged, but in particles of micrometer size. Especially for the listed 
fragile biomolecules above, the particle size is again a crucial factor for efficient cellular 
delivery. Han and Ying reported in 2004 a fluorocarbon-surfactant-mediated synthesis 
yielding nanometer-sized particles (50-300 nm) with large pores (tunable between 5-30 nm).
37
 
They applied pH values between 1.6 and 1.8, which resulted in a slow hydrolysis of silica 
precursors, followed by their co-assembly with nonionic triblock copolymer surfactant 
(EOxPOyEOx; ethylene oxide (EO) and propylene oxide (PO)) into well-defined mesophases. 
Cationic fluorocarbon surfactant FC-4, which was added simultaneously, remained at the 
periphery of the forming particles due to its immiscibility with the copolymer surfactant. This 
surrounding of the silica particles by FC-4 limited their growth and led to nano-sized large-
pore MSNs (LP-MSNs). By choosing different copolymers and partial addition of pore 
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swelling agent TMB in the FC-4-supported synthesis, they were able to achieve five different 
mesostructures as shown in Figure 1-2. 
 
Figure 1-2: Five different mesostructures resulting from fluorocarbon-surfactant-mediated synthesis. (a) IBN-1 
(3D cubic (Im3m) with template F127). (b) IBN-2 (3D cubic (Fm3m) with template F127+TMB). (c) IBN-3 
(mesocellular foam with template P65+TMB). (d) IBN-4 (2D hexagonal (p6m) with template P123). (e) IBN-5 
(disordered with template F108). Adapted with permission from “Generalized Fluorocarbon-Surfactant-
Mediated Synthesis of Nanoparticles with Various Mesoporous Structures” by Y. Han and J. Y. Ying, Angew. 
Chem. Int. Ed. 2004, 44 (2), 288-292. Copyright 2004 by John Wiley & Sons, Inc.
37
 
This fluorocarbon-assisted approach was further developed by Gao et al. using low 
temperatures (10 °C) during the synthesis and a subsequent hydrothermal treatment to gain 
MSNs with pore entrances of 17 nm.
38
 This modified method was adapted by our group to 
introduce organic functionalities via a co-condensation approach.
27
 In this quite tedious 
synthesis approach, challenges were encountered when chargeable functional groups like 
amino or mercapto groups were co-reacted. By applying 5 mol% instead of 1 mol% of 
mercapto groups the particles became nearly dense and lost their large porous system. These 
limitations and the harsh conditions restrict the use of this synthesis route.  
Besides the fluorocarbon-surfactant-mediated approach, there is also the possibility to use 
pore swelling agents in combination with commonly used templating molecules. The organic 
auxiliary molecules can be accommodated in the hydrophobic interior of the surfactant 
micelles. Commonly used pore expanding agents are triisopropyl benzene (TIPB), mesitylene 
(TMB), trioctylamine (TOA), decane, N,N-dimethylhexadecylamine (DMHA) and tri-
octylmethylammoniumbromide (TOMAB).
27, 39-43
 With the use of these agents or even 
combinations thereof, pore sizes can be enlarged up to 5 nm. For larger biomolecules and, 
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e.g., plasmid-DNA these pores may still be too small. It has to be mentioned that work in our 
group showed that particles with 5 nm pores are sufficient for the efficient delivery of fragile 
siRNA.
44
 In comparison to the above described large-pore MSNs synthesized under acidic 
conditions, particles with medium-sized pores even showed a higher efficiency.
27
 
Besides the need to synthesize MSNs with larger pores (> 5 nm), a very simple approach is 
useful for possible upscaling of the reaction. Recently, Zhang et al. published a synthesis 
route using mild conditions yielding large-pore MSNs at the kilogram scale.
45
 The sol-gel 
synthesis uses cetyltrimethylammonium (CTA
+
) as a template and small organic amines 
(SOAs) as additives. By use of tosylate (Tos
-
) counterions and almost neutral pH, they 
achieved a stellate pore morphology with pore mouth sizes of 10-15 nm. Changing the 
counterion to Br
-
 leads to a quasi-spherical raspberry-like morphology as can be seen in 
Figure 1-3.  
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Figure 1-3: Synthesis routes at low and high pH with resulting different templating conditions are shown. 
Reprinted with permission from “Facile Large-Scale Synthesis of Monodisperse Mesoporous Silica Nanospheres 
with Tunable Pore Structure” by Zhang, K.; Xu, L.-L.; Jiang, J.-G.; Calin, N.; Lam, K.-F.; Zhang, S.-J.; Wu, H.-
H.; Wu, G.-D.; Albela, B.; Bonneviot, L.; Wu, P., J. Am. Chem. Soc. 2013, 135 (7), 2427-2430. Copyright 2013 
by the American Chemical Society.
45
  
The authors explain this difference by either weak or strong templating conditions. This 
means the counterion tosylate competes more with the negatively charged silanol groups in 
regard of the adsorption onto the positively charged micelles (CTA
+
) than Br
-
 does. This 
effect is even stronger at low concentrations of SOAs (= low pH) and leads to an increase of 
Tos
-
 anions in the MSNs, resulting in an unorganized stellate structure. Contrary at higher pH 
values, the silanolate density is high enough to replace the Tos
-
 anions efficiently and 
therefore leading to a more organized worm-like structure, as shown on the right side of 
Figure 1-3. 
The resulting conical pore shape of stellate large-pore MSNs can be successfully loaded with 
larger biomolecules. An adapted synthesis recipe developed in our group enables 
functionalization of stellate LP-MSNs in a co-condensed way as discussed in chapter 5. 
Moreover, the use of large-pore particles as successful enzyme support is shown in chapter 6 
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of this thesis. A general overview of enzyme immobilization in large-pore mesoporous silica 
nanoparticles is given below. 
1.1.3. Functionalization of mesoporous silica nanoparticles 
One of the great advantages of mesoporous silica nanoparticles is the simple functionalization 
of the interior and exterior surface. Besides PMOs, periodic mesoporous organosilicas, which 
were reported by three independent groups in 1999, in which Si atoms are bridged by applied 
ethane groups or the like,
46-48
 there are generally two possible ways to introduce organic 
functionalities into the silica framework. One distinguishes between a post-synthetic grafting 
process and a co-condensation approach. Whereas, grafting with template molecules still 
present in the MSNs may lead to functionalization only or predominantly on the surface of the 
particles, co-condensed MSNs show a homogenous distribution of the organic moieties. The 
grafting process of the exterior surface can take place with the template-filled particles right 
after the synthesis. This is followed by template removal and functionalization of the pore 
interior with another group.
49
 However, due to the fact that mesopores are large enough to 
allow diffusion of grafting agents into the template-filled pores, a spatial control of 
functionalities is difficult to achieve with this method.
50
 Particles used in this thesis are 
therefore prepared by a site-selective co-condensation approach developed in our group 
(Figure 1-4).
51
 This method gives great control over the amount and density of the 
incorporated functionalities. Depending on the time of addition to the reaction mixture, 
functionalities can be solely attached to the inside of the pores or exclusively found on the 
external surface as shown in Figure 1-5. The resulting systems are called core-shell particles. 
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Figure 1-4: Schematic depiction of sequential co-condensation reactions leading to core-shell MSNs. Shown in 
green is the synthesized core of the MSNs with an incorporated organic moiety R1. In a second step an interlayer 
of pure tetraethyl orthosilicate (TEOS) is added (shown in blue). And in the final step the second organic moiety 
(R2, shown in red) is placed on the exterior of the particles. Reprinted with permission from “Multifunctional 
Mesoporous Silica Nanoparticles as Universal Platform for Drug Delivery” by C. Argyo, V. Weiss, C. Bräuchle 
and T. Bein, Chem. Mater. 2014, 26 (1), 435-451. Copyright 2014 by the American Chemical Society.
1 
To prove that this approach leads to spatial control of functionalization, Cauda et al. 
performed fluorescence quenching studies with dye-functionalized MSNs (fluorescein 
isothiocyanate, FITC) and external gold nanoparticles.
50
 It could be shown that the energy 
transfer between FITC and the gold NPs takes only place when FITC was added to the 
external surface of amine-functionalized MSNs. In the case of aminopropyltriethoxy silane 
(APTES) added to the core of the particles, no quenching occurred due to the greater distance 
between FITC, attached inside, and external Au NPs. This great possibility of spatially-
controlled functionalization can be used to accommodate guest molecules on the one hand, 
and optimize the external surface on the other hand by means of attachment of targeting 
ligands, endosomal escape agents and capping systems to ensure desired interactions with 
cells and membranes in biological systems.
1
 The variety of possible functionalizations is 
depicted in Figure 1-5. 
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Figure 1-5: Multifunctional MSNs. Reprinted with permission from “Multifunctional Mesoporous Silica 
Nanoparticles as Universal Platform for Drug Delivery” by C. Argyo, V. Weiss, C. Bräuchle and T. Bein, Chem. 
Mater. 2014, 26 (1), 435-451. Copyright 2014 by the American Chemical Society.
1
  
The attachment of gatekeepers to the external surface of the particles enables tight pore 
sealing and prevents premature release of the cargo. The first example of a successful capping 
system was shown by Victor Lin and his group in 2003.
52
 They applied a CdS-cap and 
showed stimuli-responsive release of vancomycine and adenosine triphosphate (ATP) loaded 
MSNs upon addition of disulfide-bond reducing agents like dithiotreitol (DTT). Other 
examples of pore capping groups are bulky molecules such as proteins, superparamagnetic 
iron oxide nanoparticles (SPIONs), ZnO nanolids, β-cyclodextrins or gold nanoparticles.
53-60
 
A second, very efficient pore sealing method is the coating of the complete particle. Examples 
hereof are supported lipid bilayers (SLB), (bio-) polymers, calcium carbonate and 
oligonucleotides.
28, 61-70
 The attachment of the polymer polyethylene glycol (PEG) 
additionally brings a stealth effect, leading to longer circulation times in the blood stream 
instead of rapid clearance. This is a crucial factor when the nanoparticles are supposed to 
accumulate passively in the tumor via the enhanced permeability and retention (EPR) effect 
which is described below.  
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Concluding, functionalization of MSNs leads to multifunctional nanoparticles which can be 
applied in different areas. In the following, their use in enzyme immobilization as well as in 
drug delivery is discussed.  
1.1.4. Enzyme immobilization in mesoporous silica systems 
Enzymes possess very interesting characteristics for the application in biocatalysis. They 
show a high catalytic efficiency even under mild reaction conditions, which makes them user 
and bio-friendly. Furthermore, they possess a high stereo- and regio-selectivity, which 
simplifies processes and is important in the production of chiral and optically active 
compounds.
71
 However, there are certain drawbacks, which limit the use of native, 
unprotected enzymes in biocatalysis. If harsher conditions are applied in the reactions, 
enzymes commonly degrade very quickly and become therefore inactive. Furthermore, the 
reuse of enzymes involves the tedious purification and separation thereof, limiting their use in 
a continuous or large-scale process due to high costs. Consequently, encapsulation of the 
enzymes leads to better protection of the fragile cargo and a simplified work-up. There are 
different ways to immobilize enzymes onto solid supports. One of the very early examples of 
using a silica support was shown in 1970 by Johnson and Whateley.
72
 They incorporated the 
enzyme trypsin into a polymerizing silica gel system and could show enhanced long-term 
stability. After the discovery of mesoporous silica particles in the early 90ies, Diaz and 
Balkus were the first to show actual immobilization of cytochrome c, papain and trypsin into 
the pores of MCM-41 via physical adsorption. Furthermore, they proved the limited use of the 
small-pore particles for larger enzymes, as they could not load peroxidase successively onto 
the pores. This immobilization technique relies on very weak interactions and leads therefore 
easily to leaching phenomena.
71
 Another non-covalent immobilization method is to 
incorporate positively charged amine groups into the silica framework and immobilize 
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negatively charged enzymes via electrostatic interactions. This was shown by Ackerman et al. 
by immobilizing negatively charged glucose oxidase (GOX) in the above mentioned amine-
functionalized particles, as well as, positively charged organophosphorus hydrolase (OPH) in 
respectively carboxylic-functionalized SBA-15 MSNs.
73
 Besides the already mentioned 
methods, there are also different forms of covalent enzyme immobilization present. Covalent 
attachment to the support occurs via reaction between certain groups of the protein chains and 
respective functional groups of modified particles as shown in Figure 1-6. 
 
Figure 1-6: Overview of different reaction pathways to attach enzymes covalently to functionalized silica 
supports. E: enzyme. Reprinted from Nano Today, 4 (2), Lee, C.-H.; Lin, T.-S.; Mou, C.-Y., “Mesoporous 
materials for encapsulating enzymes”, 165-179, Copyright 2009, with permission from Elsevier.
71
 
Besides the above mentioned synthesis routes for covalently attached enzyme-host systems, 
there is also a very elegant way to immobilize the biomolecules covalently onto the support. 
An azide-alkyne click-reaction, as shown by Schlossbauer et al..
74
, enables very mild reaction 
conditions and avoids the use of toxic chemicals. It results in very high surface loading 
efficiencies of the enzyme and shows no blocking of the pores. This pore-blocking effect can 
be a disadvantage of the cross-linking method, in which the enzyme is allowed to diffuse into 
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the pore first and the toxic cross-linker glutaraldehyde is added in a second step to produce 
highly loaded and stable enzyme-host conjugates in situ.
75
 
The click-reaction mediated immobilization was successfully employed for two different 
enzymes, which remained active and stable after attachment to the support as is presented in 
chapter 6.  
1.1.5. Mesoporous silica nanoparticles as drug delivery vehicles 
1.1.5.1. Stimuli-responsive drug release 
Mesoporous silica nanoparticles provide many necessary requirements for an ideal drug 
delivery vehicle. Their large surface areas enable high loading capacities, and can therefore 
reduce necessary drug doses and correlated toxicity. Easy functionalization on the inside of 
the pores results in optimized host-guest interactions. In addition, above-mentioned capping 
systems attached to the outer part of the MSNs ensure tight closure of the pores and prevent 
premature release. This enables local delivery of the drug and avoids severe side effects 
induced through systemic drug distribution. Open and closure mechanisms are ‘smart’ and 
rely on certain stimuli. As depicted in Figure 1-7, drug release is either triggered by internal 
stimuli like change of pH, oxidizing or reducing environments or biomolecule induced 
degradation upon arrival in tumor cells or tumor microenvironment. Furthermore, the capping 
systems can also be opened by applying external stimuli like near infrared light (NIR), 
magnetic fields or ultrasound – depending on the respective capping system and target site.
20
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Figure 1-7: Representation of possible internal and external stimuli to trigger drug release from mesoporous 
silica nanoparticles in the tumor microenvironment. Reprinted from Microporous Mesoporous Mater., 236 , 
Moreira, A. F.; Dias, D. R.; Correia, I. J., “Stimuli-responsive mesoporous silica nanoparticles for cancer 
therapy: A review”, 141-157, Copyright 2016, with permission from Elsevier.
20
  
A fully equipped mesoporous silica nanoparticle with stimuli-responsive capping system and 
optimized cargo loading and release efficiencies, conceptually represents an ideal drug 
delivery system.  
1.1.5.2. Toxicity profile 
A further crucial aspect which has to be considered for their biomedical application is the 
particles’ biocompatibility and cytotoxicity profile. To be used as a carrier for drugs, MSNs 
must show a very favourable toxicity profile in the concentration range commonly used. It is 
known that biocompatibility can be influenced by parameters like size, surface charge, and 
porosity.
76-77
 Several groups studied the size effect of MSNs on cellular uptake and correlated 
toxicity. Vallhov et al. compared mesoporous silica nanoparticles with sizes of 270 (± 50) nm 
and 2500 (± 500) nm with comparable surface areas of 520 m
2
/g and 547 m
2
/g respectively, 
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regarding their interaction with dendritic cells (DCs).
78
 They could show that both particle 
types were taken up by human DCs via an energy dependent process, such as endocytosis. 
Nonetheless, their intracellular localization seemed to differ due to great differences in 
affecting the immune cells. The smaller silica particles influenced the dendritic cells only very 
little whereas the larger particles had a significant effect in upregulating certain immune 
markers. Concluding, small-sized MSNs represent ideal drug delivery vehicles, whereas 
larger particles could be used as immune modulators. The work of Mou et al. underlines the 
complexity of endocytosis. He compared the size-dependent particle uptake by HeLa cells 
with monodisperse MSNs in a size range from 30 – 280 nm.
79
 With concentrations of 
100 µg/mL all five differently-sized particles showed only little cytotoxicity and no constraint 
in cell proliferation, but a clearly size-dependent cellular uptake in the order 50 > 30 > 110 > 
280 > 170 nm. These results suggest the optimal particle size of a MSN drug carrier to be 
50 nm. It has to be noted that there are several contradicting studies about the size-dependent 
interaction between particles and cells. For example, the group of Slowing reported a 
relationship between smaller particles and less induced hemolysis of red blood cells, whereas 
Lin and Haynes determined the opposite.
80-81
 Nevertheless, the general cytotoxicity of MSNs 
is explained with the surface silanol groups (Si-OH). They can act as hydrogen donors to form 
bonds with membrane parts or interact with positively charged groups of phospholipids when 
dissociated to SiO
-
.
82
 Such strong interactions can lead to membrane disruption and cell lysis, 
which was shown as hemolysis in red blood cells. 
20, 77
 A second factor leading to toxicity of 
MSNs are reactive oxygen species (ROS) which can be formed between radicals and water 
present on the surface of MSNs. ROS can stimulate certain inflammatory mediators or disrupt 
the cell membrane completely, leading to programmed cell death. To estimate an approximate 
benchmark of ROS producing activity of silica particles, the group of Zink performed 
comparison studies between MSNs, commonly used liposomes, SLB-covered MSNs 
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(“protocells”) and polysterene beads. As shown in Figure 1-8 , the pure MSNs (named 
Nanoporous Cores) generate only a very small amount of ROS in Hep3B cells. On the 
opposite, positively charged liposomes and MSNs covered with them show a much higher 
ROS production (seen in black with MitoSOX Red) and correlating % cell death (shown in 
grey with propidium iodide). 
 
Figure 1-8: Comparison between differently charged liposomes, functionalized polystyrene beads and MSNs 
(unfunctionalized ‘Nanoporous Cores’ or SLB capped, ‘Protocells’) regarding their ROS production and % of 
induced cell death (N-acetylcysteine, NAC, an antioxidant was used as negative control). Reprinted with 
permission from “Mesoporous Silica Nanoparticle Nanocarriers: Biofunctionality and Biocompatibility” by 
Tarn, D.; Ashley, C. E.; Xue, M.; Carnes, E. C.; Zink, J. I.; Brinker, C. J., Acc. Chem. Res. 2013, 46 (3), 792-
801. Copyright 2013 by the American Chemical Society. 
77
 
Additionally, to avoid hemolysis, the surface of unfunctionalized silica particles can be 
treated with polymers or the like.
77, 82
 Besides the size, also the porosity has an impact on the 
particles’ toxicity profile. For example, in the above mentioned hemolysis studies porous 
particles were also compared to nonporous Stöber silica particles. Here, it could be shown that 
porous MSNs have a significantly lower toxicity than dense particles. This can be attributed to 
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the smaller number of surface silanol groups, as well as the smaller possible MSN-cell 
membrane contact area.
80
 Concluding, the possibility to functionalize MSNs in the chosen 
way, enables perfect tailoring of non-toxic porous materials for the respective biomedical 
application. 
1.1.5.3. Passive and active delivery  
In targeted drug delivery there are generally two ways for reaching the target: (i) particles can 
passively accumulate in the tumor tissue, or (ii) can actively target certain cells. Tumors grow 
rapidly in an uncontrolled manner and show certain abnormalities (also see below and Figure 
1-13). In a process called angiogenesis, the tumor forms extensively new blood vessels. This 
leads to leaky vasculature and defect architecture of the cell membrane. Additional impaired 
lymphatic drainage enables accumulation of circulating nanoparticles by entering the tumor 
through fenestrations with sizes of approximately 400 nm.
20, 83
 It is known that very small 
particles are rapidly cleared by renal filtration, medium sized nanoparticles by the liver and 
larger particles by liver and spleen.
20, 84
 Concluding, the correct size and functionalization has 
to be chosen in a way to escape these clearing mechanisms and prolong circulation times to 
enable passive targeting via the EPR effect. As shown by He et al., PEGylation of MSNs 
provides these effects.
84-85
 Nevertheless, delivery via the EPR effect takes place in a passive, 
unspecific way and differs from tumor to tumor as well as from patient to patient.
86
 Therefore, 
great efforts have been made towards attaching targeting ligands onto the surface of MSNs to 
achieve active targeting. Several successful targeting strategies have been proven in vitro.
1, 28, 
33, 87-88
 Recently, Mamaeva et al. showed active targeting in vivo with the well-known folate 
ligand, as well as the Zink group, which proved an enhanced effect of folate-functionalized 
MSNs regarding tumor suppression in vivo.
89-90
 Furthermore, Gary-Bobo and co-workers 
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could imply mannose as successful targeting ligands in vivo, whereas Chen et al. proved 
active delivery with antibody-functionalized particles.
91-92
  
Insights into the mechanisms of the immune system allow for the development of an indirect 
targeting approach. Using nanoparticles in cancer immunotherapy, the targeted sites for drug 
delivery are lymphoid organs. Here, the largest number of T cells can be found, augmenting 
the probability of a successful T cell activation. The automatic uptake of nanoparticles by 
cells of the innate immune system (dendritic cells, macrophages), followed by their transport 
via those cells to the lymph nodes represents, therefore, active indirect targeting. The 
successful implementation of this targeting approach is discussed in chapters 3 and 4. 
In contrast to the large number of successfully in vitro used MSNs as drug delivery agents, the 
number of in vivo reports still remains scarce. Explanations for this might be the lack of 
complete and uniform biodistribution and cytotoxicity studies of MSNs.  
To evaluate the position of MSNs in currently used nanomaterials for therapeutic treatments 
in clinics or clinical trials, the next section will compare MSNs with well-known organic and 
metallic systems. 
1.1.6. Applied nanoparticle-based therapy 
Nanotechnology raises high hopes and expectations for many patients in regard of better 
diagnostic and therapeutic treatments. Early clinical results indicate lower side effects with 
nanoparticle therapeutics achieved through active cellular uptake and local delivery to 
tumors.
93
 In the following some key examples of nanotherapeutics are discussed. 
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1.1.6.1. Polymeric nanoparticles 
Polymeric nanoparticles represent organic, soft materials, which already show great success in 
the clinics. They either consist of polymer-drug conjugates to increase the half-life and 
enhance solubility and biocompatibility of the drug, or of biodegradable polymers for 
controlled release upon acidification in the endosomes. Furthermore, they play a role in the 
synthesis of other drug carriers as described above. Besides representing a drug delivery 
vehicle, polymers are also employed as direct drugs. A famous example is a copolymer, 
randomly composed of L-glutamic acid, L-alanine, L-lysine and L-tyrosine, which is FDA-
approved since 1996 under the name Copaxone. It acts as an immunomodulator to treat 
multiple sclerosis.
94
 The most famous polymer used to enhance biological half-life as already 
described is polyethylene glycol short PEG. There are several FDA-approved PEGylated 
drug-conjugates like PEGylated granulocyte colony stimulating factor, PEGylated interferon 
gamma beta-1a, or Certolizumab, a PEGylated antibody fragment, and many more in clinical 
trials.
95
 A well-established candidate of a biodegradable polymer is polylactide-co-glycolic 
acid (PLGA). It can incorporate several drugs and release them by slow decomposition. 
Loaded with the testosterone inhibiting leuprolide, it is used against symptoms of prostate 
cancer under the tradename Eligard.
96
  
1.1.6.2. Liposomal nanoparticles 
In 1965, the first and simplest form of liposomes was described as spherical vesicle consisting 
of a phospholipid bilayer around an aqueous cavity.
97
 Accommodating drug molecules in their 
interior, they represent powerful and efficient nanotherapeutics of which a large number is in 
clinical trials or already approved. The first FDA-approved nano-drug consisted of PEGylated 
nano-liposomes loaded with the chemotherapeutic doxorubicin. Under the tradename Doxil its 
marketing approval was granted in 1995 for the treatment of ovarian cancer and AIDS-related 
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Kaposi’s carcinoma.
98
 In comparison to the free drug, Doxil delivered 4 to 16-fold higher 
amounts of doxorubicin to malignant cells.
99
 Next to Doxil, there are several other liposomal 
drugs on the market like DaunoXome (loaded with Daunorobicin), Amphotec (loaded with 
Amphotericin B) and Mepact (loaded with Mifamurtide) to name only a few. Furthermore, 
they are also used in viral vaccines, the treatment of fungal diseases and photodynamic 
therapy.
98
 
Besides these promising organic soft nanomedicines described as key representatives among 
others, there is also a large number of inorganic candidates for biomedical applications 
including metallic and metal oxide nanoparticles. 
1.1.6.3. Metallic and metal oxide nanoparticles 
Besides silver, hafnium oxide and others, iron oxide and gold nanoparticles represent two 
promising materials of metal (oxide) nanotherapeutics.
95, 100
 Iron oxide nanoparticles in 
nanomedicine can be used in different ways: (i) in magnetic resonance imaging, (ii) in iron 
replacement treatments for iron-deficient anemia patients (iii) or in tumor therapy as 
superparamagnetic iron oxide nanoparticles (SPIONs) inducing hypothermia.
101-102
 Examples 
of FDA-approved imaging agents in MRI are (carboxy-) dextran-coated iron oxide particles 
like Feridex, Sinerem or Resovist.
103
 Examples of application (ii) are Venofer, Dexferrum, 
Feraheme and more, which are also covered with hydrophilic polymers such as dextran to 
treat anemia related to chronic kidney disease (CKD).
95
 Another promising candidate, named 
Nanotherm, is applied in the treatment of glioblastoma in Germany, while the FDA approval 
is pending.
104
 Here, particles are directly injected into the tumors and subsequent heating via 
an applied external magnetic field results in tumor cell death. Besides iron oxide particles and 
many others, gold nanoparticles seem to be promising materials for cancer treatment. 
Nevertheless, there are no FDA-approved gold-based nanoformulations until now. One of the 
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possible drawbacks is the high affinity of gold to DNA.
95
 A promising candidate is recently 
waiting for its phase II clinical trial, named Aurimune. In a successful phase I, it was shown 
that PEGylated gold nanoparticles could deliver TNF (Tumor Necrosis Factor) to the tumor. 
TNF is supposed to break down the blood vessel architecture to enable succeeding 
chemotherapeutics to penetrate the tumor easily and eliminate it.
105
  
1.1.6.4. Silica nanoparticles 
Despite showing conceptually optimal features for a successful drug delivery vehicle in 
cancer therapy, there are no FDA approved mesoporous silica nanoparticles until now. The 
most promising candidates at the moment are so-called Cornell Dots. Wiesner and his group 
at the Cornell University developed a multimodal silica nanoparticle with a size of around 
7 nm.
106
 As can be seen in Figure 1-9 the particle consists of a fluorophoric Cy5 core and is 
covered with a PEG shell. This shell can be further functionalized, e.g., with a cyclic RGD 
sequence, a well-known targeting peptide for integrins, and a long-lived radiolabel. It is 
supposed to be used for real-time lymph node mapping during the surgery. 
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Figure 1-9: Multifunctional Cornell-Dot.
106
 
This cRGDY-PEG-Cy5.5-C dot is currently waiting for the completion of its clinical trial 
phase 1 and 2 scheduled for April 2019.
107
  
Silica itself is ‘generally recognized as safe’ by the FDA and is frequently taken as dietary 
supplement.
108
 With the above mentioned outstanding characteristics it seems to be a perfect 
candidate for targeted drug delivery in clinical applications. However, besides the already 
described lack of knowledge regarding a detailed safety and biodistribution profile in vivo, 
another difficulty in the translation to clinics is the up-scaling process and reproducibility of 
the sometimes complex multistep syntheses.
33
 Nevertheless, as soon as these hurdles are 
overcome, it is hoped that the first FDA approvals of silica-based nanomedicines can be 
expected. 
A completely different approach for designing promising new drug delivery platforms is 
discussed in the following. 
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1.2 Supramolecular nanoparticles 
Supramolecular nanostructures can be constructed using a cooperation of different non-
covalent interactions such as hydrogen bonding, van der Waals interactions, electrostatics, 
metal chelation, hydrophobic and π-π stacking interaction.
109-110
 The combination of many of 
those interactions leads to a self-assembly into defined structures. This phenomenon is well 
known from nature where the self-assembly of phospholipids via hydrophobic interactions 
forms cell membranes or where DNA forms a double helix via hydrogen bonding, as 
examples.
111
 These materials attract great interest in the fields of biomaterials and drug 
delivery.
109, 111
 A very interesting approach for functional drug delivery is inclusion 
complexation. It describes the combination of several interactions between the components 
‘host’ and ‘guest’. The binding between these two is usually enabled through hydrophobic 
and geometrical fitting effects.
112-113
 Besides crown ethers, calixarenes, cryptands and 
cucurbiturils, cyclodextrins (CDs) are the most widely used hosts.
110, 112, 114-116
 
There are three commonly used types of seminatural macrocyclic oligosaccharides, 
distinguished by the constituent numbers of glucose units. α-CDs possesses six α-D-
glucopyranoside units, β-CDs seven and γ-CDs eight, which are linked by α-1,4-glycosidic 
bonds as shown in Figure 1-10.
112-113
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Figure 1-10: (A) Structure and dimensions of α-, β-, γ-CD.
119
 
They show a conical structure with a hydrophilic external surface and a hydrophobic cavity, 
in which they can accommodate different guest molecules. The sizes of the respective cones 
are shown in Figure 1-10.
117
 CDs have been extensively studied as inclusion delivery vehicles 
due to the increased effective drug solubility and the higher permeability in biological systems 
compared to the free drug as well as the control over drug release and associated smaller 
toxicity.
118
  
Cyclodextrins can be threaded by polymers to form polyrotaxane structures, where bulky end 
groups keep them in place, or pseudorotaxane structures, where CD molecules can move 
freely along the polymer structure.
117
 Liu et al. showed the self-assembly of polyrotaxanes 
made from α-CDs and cinnamic-acid-modified PEG around the chemotherapeutic drug 
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doxorubicin. Due to the fact that the inclusion complex offers an abundant number of 
hydroxyl groups, the loading efficiency was significantly higher than in a pure polymeric 
micelle. Furthermore, the supramolecular host-guest complex showed higher antitumor 
activity in vivo than the free drug. Another very promising example of CD-inclusion complex 
which made its way already into clinical trials is CRLX101.
120
 It uses the potent anti-cancer 
drug camptothecin (CPT) which is rapidly cleared via the renal pathway otherwise. 
Conjugation to β-cyclodextrin-based polymer via a single glycine linker and subsequent self-
assembly into 30 to 40 nm sized nanoparticles enabled sustained intratumoral CPT release 
(structure and formation of NPs can be seen in Figure 1-11). The results of the studies proved 
the drug delivery vehicle to be safe and effective, and to show favorable pharmacokinetics. 
Additionally, promising anti-tumor activity in non-small cell lung cancer (NSCLC) patients 
was observed such that further trials were encouraged. 
 
Figure 1-11: Schematic structure of CRLX101 formation. Reprinted by permission from Springer Nature 
Customer Service Centre GmbH: Springer Nature, Invest. New Drugs, “First-in-human phase 1/2a trial of 
CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid 
tumor malignancies” by Weiss, G. J.; Chao, J.; Neidhart, J. D.; Ramanathan, R. K.; Bassett, D.; Neidhart, J. A.; 
Choi, C. H. J.; Chow, W.; Chung, V.; Forman, S. J.; Garmey, E.; Hwang, J.; Kalinoski, D. L.; Koczywas, M.; 
Longmate, J.; Melton, R. J.; Morgan, R.; Oliver, J.; Peterkin, J. J.; Ryan, J. L.; Schluep, T.; Synold, T. W.; 
Twardowski, P.; Davis, M. E.; Yen, Y.,  31 (4), 986-1000, Copyright 2013.
120
 
A second system which showed already success in clinical trials is called CALAA-01.
121
 It is 
a four-component system and is mixed from two solutions at bedside. As shown in Figure 
1-12 solution 1 contains a polyrotaxane made from cyclodextrin, PEG and adamantane end 
groups, as well as the human transferrin (hTf) protein targeting ligand. Upon mixing with 
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siRNA-containing solution 2, self-assembly into 75 nm-sized nanoparticles takes place. The 
intravenously injected particles represent, according to the authors, the ‘first targeted, 
polymer-based nanoparticle carrying siRNA to be systemically administered to humans’.
121
 
The system was well-tolerated and could act as successful delivery vehicle of siRNA. 
 
Figure 1-12: Schematic representation of self-assembly process of CALAA-01.
121
 
The above mentioned systems all consist of non-covalently bound inclusion complexes which 
have to be orchestrated to optimally self-assemble into a defined structure. Disadvantages 
might be the easy reversibility of the self-arrangement process leading to decreased stability 
of the systems as well as a poor reaction control resulting in heterogenic products. To avoid 
these problems, poly(pseudo)rotaxanes can be covalently crosslinked. An example is the 
crosslinking of α-cyclodextrin threaded onto PEG with epichlorohydrin. Subsequent removal 
of the ‘guest’ PEG resulted in a nanosized drug delivery vehicle which was able to load new 
‘guests’ (Cisplatin) into the cavities.
122
 Gabr et al. presented carboxylate crosslinked β-CD 
nanoparticles as optimal delivery system for Rosuvastatin calcium (ROS).
123
 ROS is used for 
the treatment of various blood lipid metabolic disorders and it is used for the prophylaxis of 
cardiovascular events in patients with diabetes mellitus, renal failure and the like. It is a very 
potent statin with poor aqueous solubility. The authors could show that inclusion complexes 
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with the crosslinked CD particles and ROS lead to a significantly higher oral bioavailability 
shown by an increased drug absorption. Comparisons to the free or marketed drug (tablet) 
underlined the improved results of the delivery system. Despite the promising results, it has to 
be mentioned that the above described crosslinked particles exhibit a broad particle size 
distribution indicating only moderate control over the crosslinking reactions. 
In contrast, chapter 7 of this thesis describes a novel crosslinked cyclodextrin material 
consisting of well-defined nanoparticles which is believed to hold great promise in the field of 
nanotherapeutics. 
1.3 Cancer 
All nanoparticles mentioned above seem to be promising candidates which have the potential 
to enable a perfectly tailored, personalized and localized cancer therapy with increased 
efficacies and safety.
124
 The reason for the high hopes in improved therapeutics and the 
immense attention, not only scientifically, is the second leading cause of death worldwide – 
cancer. Numbers of new cases and mortality rates are constantly rising. The current data from 
the World Health Organisation (WHO) predicted 9.6 million deaths worldwide for 2018, 
meaning that one out of six deaths results from cancer.
125
 The new World Cancer Report is 
supposed to be released this year and will definitely not report lower numbers. Cancer 
develops through uncontrolled cell growth arising from genetic mutations.
126
 The hallmarks 
of cancer proposed by Hanahan and Weinberg, shown in Figure 1-13, summarize the main 
abnormalities of malignant tumor development and cancer progression.
127-128
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Figure 1-13: Ten hallmarks of cancer. Reprinted from Cell, 144 (5), Lee, C.-H.; Lin, T.-S.; Mou, C.-Y., 
“Hallmarks of Cancer: The Next Generation”, 646-674, Copyright 2011, with permission from Elsevier.
128
 
In 2000, the first cycle of hallmarks was published and afterwards supplemented because of 
newly gained knowledge. Two additional points were the tumor-promoting inflammation and 
the avoiding of immune-system based destruction. New insights into the complex interaction 
between the immune system and the cancer cells led to the conclusion that malignant cells can 
evade the immune system’s surveillance up to the point where they harness it for their own 
use.
129
 The body’s immune system is divided into the innate and the adaptive part.
130-131
 The 
innate immune system reacts immediately to pathogens as a first line of defense. Cells like 
phagocytic cells (neutrophils, macrophages), dendritic cells, natural killer (NK) and other 
innate lymphoid cells are present in most tissues, always on the lookout for invading microbes 
or aberrant cells. They play an essential role in the defense mechanism in the first hours or 
days, before the adaptive immune system is activated. Adaptive immunity is mediated 
through recognition of foreign antigens by specific lymphocytes. The two most important 
ones being B and T lymphocytes. Whereas B cells can recognize antigens by themselves, T 
cells only respond to presented antigens. This occurs through specialized antigen presenting 
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cells (APCs) belonging to the innate immune system. Here, dendritic cells (DCs) represent the 
most powerful subset of APCs: They are present in most tissues, express a variety of receptors 
that respond specifically to microbial molecules and are efficient at capturing, processing and 
presenting antigens. They are key players in modulating and initiating the innate as well as the 
adaptive immune system. To achieve successful killing of tumor cells, T cells have to be 
activated in a stepwise series of events as depicted in the cancer-immunity cycle (Figure 1-14) 
introduced by Chen and Mellman.
132
  
 
Figure 1-14: The Cancer-Immunity Cycle shows the stepwise initiation of an anticancer immune response. 
APCs: antigen presenting cells. CTLs: cytotoxic T lymphocytes. Reprinted from Immunity, 39 (1), Chen, 
Daniel S.; Mellman, I. “Oncology Meets Immunology: The Cancer-Immunity Cycle”, 1-10, Copyright 2013, 
with permission from Elsevier.
132
  
First, tumor-associated antigens (TAAs) are released from dying tumor cells. Patrolling 
antigen-presenting cells (like DCs) take up those TAAs. This is followed by antigen 
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processing, DC maturation and migration to the tumor draining lymph node. Here, 
presentation of the processed antigen to T cells takes place, leading to the activation of 
cytotoxic T lymphocytes (CTL) which can travel back to the tumor site via the blood 
circulation system. Having infiltrated the tumor tissue and recognized the cancerous cells, the 
CTL will kill the tumor cells, resulting in a higher number of released cancer antigens and by 
this amplifying the cancer-immunity cycle. 
Nevertheless, cancer cells can develop strategies to block this self-propagating cycle at 
several steps and thus evade the immune system’s surveillance. This process consists of three 
different phases, the so-called elimination, equilibrium and escape, as shown in Figure 
1-15.
133
 
 
Figure 1-15: Three distinct phases of cancer progression and immunoediting. NK: natural killer cell, NKT: 
natural killer T cell, CD8
+
: cytotoxic T lymphocyte, CD4
+
: helper T cell. Reprinted by permission from Springer 
Nature Customer Service Centre GmbH: Springer Nature, Nature Reviews Cancer, “Vaccines for established 
cancer: overcoming the challenges posed by immune evasion” by van der Burg, S. H.; Arens, R.; Ossendorp, F.; 
van Hall, T.; Melief, C. J. M., 16, 219, Copyright 2016.
133
 
In the first step, called elimination, the tumor cells are killed according to the cancer-
immunity cycle described above. Due to resistance arising from genetic mutations in the 
tumor cells, they gain the ability to survive the attacks of the immune system until an 
equilibrium is reached. Even more variations in the mutated cells lead to the cancer cell 
escape from the immune system followed by uncontrolled cancer progression.  
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All these fresh insights principally allow for the development of new, enhanced cancer 
therapies. An extremely promising and already partially applied approach is cancer 
immunotherapy. Here, the goal is to (re-) initiate the cancer-immunity cycle in a way that a 
successful, amplified cancer immune response is achieved without inducing autoimmunity. 
The main concept of cancer immunotherapy is discussed in the following section. 
1.4 Cancer Immunotherapy 
Cancer immunotherapy is seen as the upcoming fourth column in cancer therapy next to the 
conventional methods surgery, chemotherapy and radiation. It was called the ‘breakthrough of 
the year’ by Science
134
 in 2013 and ‘One of the hottest areas in cancer research’ by Nature in 
2018.
135
 And the hype has not stopped yet about this rapidly advancing research field which 
has already covered a long distance. The concept of cancer immunotherapy is almost 130 
years old and dates back to the year 1891 in which the young New Yorker surgeon William 
Coley started to treat malignant tumors partially successfully by injecting bacterial toxins. The 
resulting acute inflammation was supposed to activate the patient’s immunity.
136-137
 Coley’s 
toxins did not find broad acceptance in clinics due to the varying results and efficacies, and 
the severe side effects.
138
 Only time would show that it should take generations of scientists to 
bring cancer immunotherapy to where it is now.  
In 2008, the centenary of Paul Ehrlich’s Nobel Prize gave reason to commemorate the ‘father 
of immunology and chemotherapy’. With his interdisciplinary studies in histological 
stainings, haematology, bacteriology, immunology and many more, he created the foundation 
of chemotherapy and was an outstanding scientist among his great contemporaries, such as 
Emil von Behring and Robert Koch.
139
 His postulate “wir müssen chemisch zielen lernen” 
(“we have to learn how to aim chemically”) combined with his idea of designing the magic 
bullet in the fight against cancer inspired scientists for more than a century in the field of 
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cancer research.
140
 The magic bullet is supposed to consist of an antibody or drug that 
specifically targets toxins or malignant cancer cells without harming the healthy ones; and it 
still describes the requirements for the perfect anticancer drug nowadays.
141
 Ehrlich started his 
search for such a magic bullet in the year 1891 by studying the effect of methylene blue on 
malaria patients with mediocre success.
142
 Several years later he discovered an arsenic 
compound that effectively fought syphilis – a disease with huge impact at that time. Salvarsan 
- the arsenic that saves - was the first successful chemotherapeutic drug and gained Ehrlich 
worldwide reputation.
140, 142
  
Ehrlich was not only called the father of chemotherapy, but legitimately also of immunology. 
His understanding of the role of the immune system and his side-chain theory became pioneer 
work in the world of immunology. In his theory he describes the three central aspects of an 
immune response of the body resulting in antibody production. First, he states that cells 
possess so-called ‘side-chains’, which bind specific toxins with high affinity. Nowadays, 
these ‘side-chains’ are termed receptors, which specifically bind antigens. Second, he 
postulates that this binding of a toxin to a side-chain leads to its ejection into the blood stream 
and the following higher production of the ‘lost’ side-chain on the cell’s surface. This can be 
transferred to the clonal multiplication of a B lymphocyte upon binding the particular antigen 
(receptor). The third and last aspect of his theory lays in the exuberant behavior of the 
resulting side-chain or rather antibody production.
139
 His idea that the immune system might 
be able to control the cancer itself should suffer several throwbacks and failures over the years 
until his heirs were to be able to gain hope again and experience some success.
138
 
1984, Niels Kaj Jerne, Georges J. F. Köhler and César Milstein received the Nobel Prize for 
their theories about the specific composition and control of the immune system, as well as the 
discovery of the production of monoclonal antibodies (Köhler and Milstein invented the 
hybridoma technology) in 1975.
143-144
 This method enabled the first mass production of 
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monoclonal antibodies and hence their first clinical applications in cancer treatment. 
138, 145
 
The introduction of chimaeric antibodies with a mouse component of only 5-10% introduced 
by Greg Winter and his group paved the way for over 80 monoclonal antibodies (mAb) which 
have been granted marketing approval during the last 30 years, and some hundred more in 
current clinical studies.
146
  
In 2018, two scientists were awarded with the Nobel Prize in physiology or medicine for their 
seminal achievements in the field of cancer immunotherapy.
147
 Both scientists pursued the 
approach of a checkpoint blockade therapy which ‘loosens the brakes’ of the immune system 
by blocking the blocker. James P. Allison from the U.S. discovered that the cytotoxic T-
lymphocyte antigen 4 (CTLA-4) regulates T cell proliferation at an early stage of an immune 
response. His idea was to block this checkpoint of the body, resulting in an unsuppressed 
reaction. 24 years after the discovery of CTLA-4, Ipilimumab - an inhibitor of CTLA-4 – was 
FDA-approved and became the first checkpoint inhibitor to reach patients in 2011.
134, 148
 
Tasuku Honjo from Japan was honored for his work on PD-1 (programmed death 1), also a 
negative regulator of the later T cell immune response. Antibodies that specifically block this 
checkpoint were FDA-approved in 2014 (Nivolumab) for melanoma and in 2015 
(Pembrolizumab) for non-small-cell lung cancer (NSCLC).
149-150
  
Despite those game-changing achievements, the great success of immune checkpoint 
inhibitors is still limited to a small percentage of patients and thus leaving a great demand for 
improved immunotherapies. A very promising approach to boost the antitumor T cell 
response is the use of tumor-specific antigens. Besides the above mentioned antibodies aiming 
at immune checkpoints, there is also a large number of monoclonal antibodies used to 
specifically target antigens expressed on cancer cells. Several of these mAbs are already FDA 
approved as stated above.
146, 151
 For example bevacizumab is designed to block the vascular 
endothelial growth factor (VEGF) leading to an anti-angiogenic effect and thus limiting tumor 
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growth and metastatic development. It has marketing approvals under the trade name Avastin 
for the treatment of several cancers, especially in combination with chemotherapy. This is 
common for mAbs as their use in monotherapy is often not satisfactory.
152-153
  
Next to mAb, engineered T cell therapies have shown recent success with the FDA approval 
of two CAR T cell systems.
154-155
 The approach is to collect T cells from the patient’s blood 
and modify them ex vivo to express so-called chimeric antigen receptors (CARs) which are 
specific to tumor-associated antigens. Upon re-injection to the patient, CAR T cells recognize 
the tumor via the targeted antigen and kill it. Despite the promising results, the clinical 
application is hampered by the complex and costly production of CAR T cells.  
Another promising approach in tumor-antigen directed cancer immunotherapy are cancer 
vaccines which are discussed in the following section. 
1.4.1 Cancer vaccines 
The method of vaccination has been successfully used for more than two centuries in the form 
of prophylactic vaccines. In 1796, Edward Jenner was the first to develop a vaccination from 
cowpox to induce immunity against smallpox – a life-threatening disease at that time.
156
 He 
named the method vaccination, deduced from the Latin word vacca for cow. The following 
great success of prophylactic vaccinations has to be attributed to the work of Louis Pasteur.
157
 
His principle “isolate, inactivate and inject” has been followed since to produce bacterial and 
viral vaccines.
158
 Furthermore, he postulated that vaccination could be applied to any 
microbial disease, which was successfully proven in the ultimate eradication of smallpox and 
effective treatments of many other perilous diseases.
159
 In addition, vaccines used for the 
prevention of cancers aetiologically induced by viruses showed also considerable success.
137
 
Efforts to transfer the achievements of immunoprophylaxis to immunotherapy of already 
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existing chronic viral infections and cancer failed for several decades. The striking difference 
in the target of a preventive to that of a therapeutic vaccine lies in the gained ability of 
cancerous cells to evade the immune system via different mechanisms.
160
 Huge efforts are 
being made towards identifying new tumor-associated antigens that can effectively stimulate 
T cell responses without leading to a central tolerance through expressed self-antigens. Some 
common human cancers result from an infection with a virus like the human papillomavirus 
(HPV), Epstein-Barr virus or hepatitis B and C viruses and contain therefore viral antigens, 
which represent a great target for immunotherapy.
159, 161
 Other cancer associated antigens are 
completely unique and have to be identified with more complex methods like SEREX, 
serologic identification by recombinant expression cloning, or mass spectrometry of TAAs 
bound to MHC I (major histocompatibility complex class I) molecules.
159, 162-163
  
 
There are several kinds of cancer vaccines such as gene-based (mainly DNA), protein- or 
peptide-containing vaccines, whole cell cancer ones as well as ex-vivo-loaded dendritic-cell 
vaccines.
164-170
 DNA or mRNA-based vaccines target antigen presenting cells (APCs) to be 
taken up, translated and thus able to induce antigen expression. They were tested in several 
clinical trials but due to immunogenicity and degradation problems, their success is still 
limited. Similar stability issues occur when applying peptide- or protein vaccines. Here, 
fragments which are specifically overexpressed on the tumor are used as antigens. Peptide- 
and protein vaccines were shown to be safe, but struggle to induce a full T cell response due 
to limited uptake by dendritic cells. Another source of antigens used for cancer vaccines can 
be derived from complete tumor cell lysates. They are deduced from the patient’s isolated 
tumor. Whereas TAAs derived from real tumors represent an array of multiple tumor antigens 
and thus significantly enhancing the probability of a successful T cell response, the process to 
produce them from the tumor cell lysates is complex and very cost-intensive. Another 
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elaborate procedure is the production of ex vivo-loaded dendritic cell vaccines. Here, the key 
players for inducing a potent immune response are isolated from the patient’s blood, ex vivo 
activated and loaded with TAAs before being re-injected into the patient. In 2010, the first 
DC-based vaccine Sipuleucel-T (Provenge) was FDA-approved for the use in prostate 
cancer.
171
 Nevertheless, its commercialization is restricted due to the high costs and 
regulations for the production. 
Many of the cancer vaccines described above can be improved by using a delivery system.
170, 
172-173
 This allows for the protection of the respective cargo as well as an enhanced uptake by 
DCs, thus enabling a strong local immune response while preventing autoimmunity. 
Furthermore, co-delivery of multiple antigens as well as of adjuvant and antigen can be 
accomplished. The need for the latter combination is explained in the following. 
Recent insights into the functioning of antigen-presenting cells (APCs) with T cells provide 
useful antigenic target points for an actively attacking therapy. Especially the enhancement of 
antigen-presenting cell (APCs) activation, primarily dendritic cells, has been addressed to 
augment the priming of T cells and therefore the overall efficacy of therapeutic vaccines. 
Dendritic cells play a critical role in the innate immune response as they capture antigens 
immaturely and present them after successful maturation to T-cells via MHC molecules in the 
lymph nodes. DCs are beside B cells and macrophages (the three main subtypes of bone-
marrow derived APCs) the most potent candidates to present antigens.
129, 159, 161
 If the 
maturation of dendritic cells is successful, priming of T cells takes place in lymphoid organs 
via the presentation of processed antigens on MHC complexes on the surface of DCs. This is 
helped through the expression of several cytokines, such as IL-6 and IL-12, IFN-α/β, and 
TNF-α and costimulatory molecules, such as CD80, CD86.
129
 Thus, an effective T cell 
response is induced resulting in activation of CD4
+
 T cells to Th cells (T helper cells) and 
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CD8
+
 cells to CTL (cytotoxic T lymphocytes), which are responsible for killing the cancer 
cells. This cyclic process of T cell activation is severely disturbed when the key players, the 
dendritic cells, are not completely activated. In this case, the maturation of the dendritic cells 
fails, meaning they remain in a so-called steady-state. This in turn leads to a promotion of 
regulatory T cells (Treg), resulting in an opposed antitumor response.
137
  
To avoid such effects, successful DC maturation can be achieved by adding adjuvants to the 
vaccine formulation which induce activation of the so-called pattern recognition receptors 
(PRRs). Those agonists or PRR-ligands can augment the effect of the anti-tumor immune 
response and are therefore fittingly called adjuvants, coming from the Latin word adjuvare 
meaning “to help”.
174-175
 They are responsible for the complete maturation of an APC 
resulting in a successful immune response. One of the most famous groups of PRRs are the 
transmembrane proteins named Toll-like receptors (TLRs).
129, 159, 176
 They belong to the TLR-
interleukin-1 (TIR) receptor superfamily.
177
 There are ten different TLRs known in humans, 
classified by the specific pathogen-associated molecular patterns (PAMP) they respond to. 
TLRs trigger inflammatory responses by activating dendritic cells to coordinate a systemic 
defense against microbial infections.
178
 If those PRR-activating agonists are left out in the 
vaccination formulation, one might achieve T cell tolerance instead of potent T cell 
activation.
129
 In the following, very potent members of the TLR adjuvant family are 
introduced, specifically TLR-7/8 agonists. 
1.4.1.1 Imiquimod/ Resiquimod 
TLR-7/8 agonists represent very powerful adjuvants. Among other TLR agonists, TLR-7 and 
-8 are listed by the National Cancer Institute as agents belonging to the most potent anti-
cancer ones.
177
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Besides TLR-3 and TLR-9, TLR-7 and -8 are present in endosomal compartments. TLR-7 is 
mainly found in B cells and plasmacytoid dendritic cells (pDCs), whereas TLR-8 is expressed 
in monocytes and myeloid dendritic cells (mDCs).
174, 179
 They are specialized in viral 
detection and recognition of nucleic acids in late-endosomes-lysosomes, whereas other TLRs 
located on the cell surface mainly respond to bacterial products of extracellular pathogens 
(Figure 1-16). Agonists of TLR-7 and TLR-8, like single-stranded RNA coming from RNA 
viruses or artificial imidazoquinolines, provoke a Th1-type proinflammatory immune 
response resulting in the production of cytokines like IFN-γ and the activation of cytotoxic T 
lymphocytes (CTL).
178, 180
 
 
Figure 1-16: Location of the innate immune system’s pattern recognition receptors (PRRs). NLR, NOD-like 
receptor; RLR, RIG-like receptor; TLR, Toll-like receptor 
130
  
The class of imidazoquinolines represents a family of small synthetic molecules, bearing a 
structure homologous to adenosine, which can activate TLR-7 and -8. Among others, 
imiquimod and resiquimod (R848) are the most prominent ones. Whereas imiquimod is 
already FDA approved since 2004, under the trade name Aldara, for the treatment of 
superficial basal cell carcinoma, resiquimod still remains in clinical trials.
181-183
 Imiquimod is 
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100-fold less potent than resiquimod at inducing cytokine expression and is only a TLR-7 
agonist, whereas resiquimod can actively stimulate TLR-7 and TLR-8.
174, 182, 184
 Due to the 
facts mentioned above, we chose resiquimod in this work. 
1.4.1.2 Nanoparticle-based TLR-7/8 vaccines 
Due to its small size, resiquimod diffuses quickly away from the injection site leading to a 
systemic distribution. This can cause severe side effects resulting from a systemic immune 
response.
185
 In addition, like all imidazoquinolines, resiquimod shows a poor solubility in 
aqueous media at physiological pH. Therefore, a formulation or encapsulation of resiquimod 
is needed to ensure a localized delivery of the adjuvant after administration. There are 
different types of delivery systems using lipidation, adsorption to alum adjuvants, conjugation 
to polymers or encapsulation in nanoparticles.
174
 The first carrier system and adjuvant in one 
were aluminum salts (Alum). Despite the fact that much knowledge has been gained about the 
mechanisms of the immune system, this ‘old system’ still remains the most widely used one 
in clinics.
186
 The biodegradable polymer PLGA (poly(D,L-lactic-co-glycolic acid)) is also 
intensively studied as efficient drug carrier for vaccine antigens.
177, 187
 A co-delivery of 
adjuvant and antigen with PLGA particles was successfully shown by Ilyinskii et al..
188
 They 
compared covalently and non-covalently attached antigen/adjuvants and could show a strong 
and sustained local immune activation. However, this promising material shows certain 
drawbacks: contradictory to the stated high encapsulation efficiencies in the polymer, the 
actual drug loading is usually quite low. Furthermore, the system does not show a sustained 
release of the loaded cargo but usually presents a burst release – often prior to reaching the 
targeted cells. In the end, the great advantage to have a biodegradable material also presents 
its pitfall due to the acidic degradation products which may harm delivered proteins.
189
 Mottas 
et al. applied small gold nanoparticles functionalized with 1-octanethiol and 11-
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mercaptoundecane sulfonate to accommodate resiquimod in the ligand shell.
190
 With this 
system they were able to show enhanced antitumor efficacy in comparison to the free drug. 
Despite the successful results, it has to be noted that the particle system with an approximate 
size of 5 nm is not taken up by antigen-presenting cells at the site of injection but is drained 
passively to the lymph node. This impairs a controlled uptake and release. A study from 
Lucke et al. uses cathepsin-responsive spider silk nanoparticles to deliver the antigen OVA.
191
 
The authors describe a strong activation of T cell proliferation without an additional adjuvant. 
In contrast to the described organic and metallic nanoparticles, mesoporous silica 
nanoparticles (MSNs) represent one of the most-promising inorganic drug delivery systems. 
They are well-known for their large surface areas allowing high drug loading efficiencies. 
Furthermore, they can be perfectly tuned to accommodate the antigen and adjuvant of choice. 
From a variety of capping systems, the matching one can be chosen to tightly seal the pores 
and open them only upon action of certain stimuli. Additionally, the size and surface 
functionalization can be adjusted to enhance indirect active uptake by antigen-presenting 
cells. Studies investigating the degradation behaviour of mesoporous silica nanoparticles 
show its tunability and prove the decomposition into harmless silicic acid.
32-34, 192-193
 Together 
all these facts suggest that MSNs are promising, biocompatible drug delivery vehicles. 
Chapter 3 of this thesis describes the evaluation of MSNs as appropriate drug delivery vehicle 
for the immunostimulant cargo resiquimod and proving indeed its promising use. In addition, 
in chapter 4 the successful implementation of the advanced multifunctional system as 
optimized carrier for adjuvant R848 is shown. Enhanced uptake of the R848-loaded MSNs by 
DCs and the subsequent effective DC activation is reported. Furthermore, the simultaneous 
delivery of adjuvant and antigen is achieved, leading to an augmented T cell proliferation and 
thereby underlining the potential of MSNs in nanoparticle-based cancer vaccines.   
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2. Characterization 
For the characterization of nanoparticles, many different techniques can be applied. First, to 
determine the particle size, dynamic light scattering (DLS) can be applied. Furthermore, 
transmission electron microscopy and scanning electron microscopy can be used to estimate 
the sizes of the sample, as well as shape and morphology of the particles and pores. To further 
investigate the porous structure and large surface area of the network, N2-sorption 
measurements are conducted. As indirect methods to show that silica nanoparticles possess 
mesopores, used for loading with different cargoes, fluorescence spectroscopy or UV-Vis 
measurements can be consulted – depending on the fluorescence or absorbance of the 
particular guest molecule. Time-based release curves are recorded with fluorescence 
spectroscopy to prove the tight capping and stimuli-responsive release of the (model-) drugs. 
UV-Vis measurements are applied to investigate the catalytic performance of LP-MSN-
Enzyme constructs by means of colorimetric activity assays. Furthermore, to monitor the 
different steps of functionalization, Fourier-Transform Infrared (FTIR) microscopy was 
applied to identify the diverse functional groups. Additionally, zeta potential measurements 
were conducted to evaluate changes in surface charge through incorporated organic moieties. 
Thermogravimetric analysis (TGA) was used to determine the relative amounts of organic 
functionalization of core-shell MSNs. To examine the degree of hydrolysis/functionalization 
and gain information about the chemical bonds, magic angle solid state nuclear magnetic 
resonance (MAS ssNMR) was applied.  
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2.1. Dynamic light scattering (DLS) 
Dynamic Light Scattering (DLS) is used to determine the hydrodynamic diameter or rather 
the Stokes diameter of the nanoparticles. This can be deduced from the obtained diffusion 
coefficient of the measured particles if the solvent’s viscosity is known. Dynamic light 
scattering is also called photon correlation spectroscopy (PCS) or quasi-elastic light scattering 
(QELS).
1
  
The principle of DLS is based on the interaction between electromagnetic radiation and 
particles in a comparable size range. Since the applied laser’s wavelength of 633 nm is in the 
range of visible light, the interference with nanoparticles is very good. Samples are measured 
in suspension. If the refractive index of the suspended sample differs from the one of the 
solvent, stray light is produced. Since the sample suspensions are always prepared under 
dilute conditions, there is a strong Brownian molecular motion of the particles. This motion 
leads to fluctuations of the scattered light intensity. Due to this movement of the individual 
scattering centers, a frequency shift occurs due to the Doppler Effect which can be monitored 
through the autocorrelation function. The fluctuation and the resulting shifts are dependent on 
the size of the particles. Larger particles show a slower Brownian motion in comparison to 
smaller ones. This velocity is defined as the translational diffusion coefficient D which is 
related to the hydrodynamic diameter d(H) of the particles via the Stokes-Einstein equation 
(equation 2.1). 
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𝑑(𝐻) =
𝑘𝑇
3𝜋𝜂𝐷
 
(2.1) 
Stokes-Einstein equation. d(H): hydrodynamic particle diameter, D: translational diffusion coefficient, k: 
Boltzmann’s constant, T: temperature, η: the viscosity of the suspending medium.
2
 
The received diameter represents the diameter of a sphere with the determined translational 
diffusion coefficient. This coefficient is influenced by factors like ionic strength of the 
medium and nature of the particles’ surface which can both lead to an untrue display of the 
diffusion speed. It should be noted that larger particles scatter light significantly more than 
small particles. This means that even small amounts of large particles or agglomerates can 
cause high scattering intensity. As a result, the method is only suitable for relatively 
monodisperse and uncontaminated (e.g. by dust), non-agglomerated samples. If all those 
considerations are taken into account, DLS is a very powerful and commonly used method to 
investigate the hydrodynamic size of particles between 1 and 1000 nm. 
2.2. Zeta potential 
To determine the outer surface charge of nanoparticles zeta potential measurements can be 
applied. Furthermore, the colloidal stability of the finely dispersed solid nanoparticles in 
solution can be assessed. Due to dissociation of surface groups or adsorption of solvent 
molecules, particles are usually (slightly) charged in aqueous solution. This net charge leads 
to a surrounding of oppositely charged solvent molecules creating an electrostatic potential 
between the two phases. One distinguishes between a layer of tightly bound counter ions 
(Figure 2-1: positively charged, shown in red), called Stern layer, and a layer with loosely 
bound counter charges (Slipping plane). The ordered layers are so closely connected to the 
surrounded particle that they follow its Brownian movement. The rest of the very disordered 
surrounding ions remains at the same place in the bulk solvent. The potential at the boundary 
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distinguishing between those tight layers and the rest of the solvent molecules is called zeta-
potential (also described with the Greek letter ζ).
3
  
 
Figure 2-1: Schematic representation of a negatively charged particle surrounded by positively charged solvent 
ions and the description of the resulting layers.
4
 
The existence of the electrical potential allows interactions with an applied external electric 
field. Depending on the induced direction of motion, one distinguishes four main 
electrokinetic effects: electrophoresis, electroosmosis, streaming potential and sedimentation 
potential. While the latter arises by the sedimentation of charged particles, a streaming 
potential is generated by letting a liquid stream by a charged surface. Electroosmosis 
describes the motion of a liquid induced through an applied electric field relative to a 
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stationary charged surface. The zeta potential can be related to the electrophoretic mobility 
(UE). This is measured in electrophoresis by applying an electric field and monitoring the 
velocity of the charged particle to the electrode of opposite charge relative to the medium. 
The speed of movement depends on the dielectric constant (ε), the viscosity (η) of the 
medium, the strength of the applied field and the zeta potential itself. The relation between 
these dimensions is given by the Henry equation:  
𝑈𝐸 =  
2 𝜀 𝜁 𝑓(𝜅𝑎)
3 𝜂
 
(2.2) 
Henry equation: UE, electrophoretic mobility; ε, dielectric constant of the medium; η, viscosity of the medium; ζ, 
zeta potential; f (κa) Henry function with κ Debye length and a particle radius. 
The Debye length κ in the Henry function describes the size of the electrical double layer. The 
Henry function can be approximated to 1.5 with the Smoluchowski model – suited for 
particles larger than 200 nm and a polar medium – or to 1.0 with the Hückel approximation 
for small particles in a non-polar medium.  
2.3. Nitrogen sorption 
Gas adsorption measurements are widely used for different porous materials to obtain their 
respective surface area and pore size distributions.
5
 Nitrogen is commonly applied as 
adsorptive at 77 K and is especially recommended for mesoporous samples.
5-6
 Due to the only 
weak van-der-Waals interactions between the adsorbent and adsorptive, the process is 
classified as physisorption. Conventionally, certain amounts of nitrogen are successively 
introduced into the system, which is then allowed to reach an equilibrium state. By plotting 
the applied nitrogen amounts (calculated in volume) versus the monitored equilibrium relative 
pressures, one obtains isotherms. In Figure 2-2 the extended overview of different isotherm 
types classified by the IUPAC is shown.
7
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Figure 2-2: Different isotherm types classified by the IUPAC. Adapted from Thommes et al., IUPAC Technical 
Report, 2015, © IUPAC.
7
 
The division of the isotherms is made with regard to the material’s pore size and structure as 
well as its interactions with the adsorptive. During the desorption process hysteresis can 
occur. This is the case when more energy is needed to remove the gaseous adsorptive from the 
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solid adsorbent. It can occur due to network or pore blocking effects in pores wider than 4 nm. 
For the physisorption in mesoporous materials three different stages can be classified: (i) 
Formation of a monolayer of adsorbed nitrogen molecules which all have contact to the 
surface of the adsorbent, (ii) multilayer adsorption on top of monolayers, (iii) capillary 
condensation.
7
 The most common model to describe isotherms under consideration of 
multilayer adsorption is the Brunauer-Emmet-Teller-, short BET-model.
8
 Though it extends 
the Langmuir theory from monolayer to multilayer adsorption, it still remains a very 
simplified model. Nevertheless, it is still the most commonly one to calculate the specific 
surface area from the gained measurement data. For this, the monolayer capacity nm has to be 
derived from a ‘BET plot’ following the BET equation: 
𝑝/𝑝0
𝑛(1 − 𝑝/𝑝0)
=
1
𝑛𝑚𝐶
+
𝐶 − 1
𝑛𝑚𝐶
(𝑝/𝑝0) 
(2.3) 
BET equation. 𝑛: specific amount adsorbed at relative pressure p/p0; 𝑛m: specific monolayer capacity; C: BET 
constant.
7-8
 
The gained value of the monolayer capacity can then be used to calculate the ‘BET area’. For 
this, the average area of each adsorbed nitrogen molecule in a close-packed monolayer at 
77 K is usually assumed to be am(N2) = 0.162 nm
2
. 
𝐴(𝐵𝐸𝑇) = 𝑛𝑚
𝑎 ∙ 𝐿 ∙ 𝑎𝑚 
(2.4) 
Calculation of BET area with 𝑛𝑚
𝑎  monolayer capacity, L Avogadro constant and 𝑎𝑚 average area occupied by 
adsorptive molecule.
5
 
To assess mesoporosity and the pore size distribution, the phenomena capillary condensation, 
the third step of physisorption in mesopores, is monitored. Here, a transition from liquid to 
vapour phase occurs in the confined space of the capillary leading to a pore filling by 
immediate meniscus formation. In former days the Kelvin equation has been used to 
determine the pore radius. This simple model has been further developed to consider the 
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multilayer film formation. The modified equation is used by many models, the most used one 
is the mesopore size analysis of Barret, Joyner and Halenda (BJH).
9
 
ln (𝑝/𝑝0) = −
2𝛾𝑉𝑚
𝑅𝑇(𝑟𝑝 − 𝑡𝑐)
 
(2.5) 
Modified Kelvin equation for cylindrical pores. p/p
0
: relative pressure , γ: surface tension, Vm: molar liquid 
volume, R: gas constant, T: temperature, rp: pore radius, tc: thickness of adsorbed multilayer film.
7
 
Due to the assumptions made in the BJH model like control of meniscus curvature by rigid 
cylindrical pores, homogenous film formation, and no consideration of vapour-liquid and 
liquid-liquid interactions, medium pore sizes are often significantly underestimated. To avoid 
these limitations, more advanced methods like Monte Carlo and DFT simulations have 
evolved. They can describe the behaviour of fluids in confined pores at a molecular level with 
the help of statistical mechanics. Non-local density functional theory (NLDFT) based 
methods give reasonably realistic results for several pore shapes and different 
adsorptive/adsorbent pairs.  
2.4. Thermogravimetric Analysis (TGA) 
Thermogravimetry (TG) or Thermogravimetric Analysis (TGA) determines the mass change 
of a sample as a function of temperature or time.
10
 These changes may be caused by thermal 
decomposition or combustion, as well as a chemical reactions or the like. In a thermobalance, 
the measurement of the mass of a sample crucible takes place simultaneously with that of a 
reference. This provides several signals during the heating process. In addition to the normal 
TGA signal, the mass change, information on temperature change (differential thermal 
analysis (DTA)) and heat change (differential scanning calorimetry DSC) are also obtained. 
This allows conclusions about the thermal stability of the sample as well as relative amounts 
of incorporated organic moieties. 
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2.5. Molecular Spectroscopy 
Spectroscopy describes several analytical methods which study the interaction of 
electromagnetic radiation with matter.
11-12
 From the resulting spectra, important information 
about molecular structure and chemical characteristics can be derived. Methods like 
ultraviolet-visible- (UV-Vis-), infrared- (IR-) and Raman, as well as fluorescence and nuclear 
magnetic resonance (NMR) spectroscopy all belong to the methods of molecular spectroscopy 
and are introduced in the following. 
Electromagnetic radiation is characterized by its wavenumber λ or rather its frequency ν, 
which are related through the velocity of light constant c: 
𝜈 ∙ 𝜆 = 𝑐 
(2.6) 
 
A light quantum, a photon, possesses the following energy with h representing the Planck’s 
constant: 
𝐸 = ℎ ∙ 𝜈 
(2.7) 
 
Molecules can absorb light with appropriate frequency and are thus excited to higher energy 
levels. Succeeding spontaneous or stimulated emission brings the molecule back to its former 
(usually ground) energy level. 
Interaction between electromagnetic radiation and matter leads to different energy absorption 
and emission processes, depending on the radiation’s frequency. The complete 
electromagnetic spectrum is shown in Figure 2-3.  
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Figure 2-3: Overview of the complete electromagnetic spectrum.
13
 
Methods using light in the ultra-violet, visible, infrared or radio wave region are discussed in 
the following. 
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2.5.1. UV-Vis Spectroscopy 
The role of UV-Vis spectroscopy or rather spectrophotometry is important in qualitative and 
quantitative drug analysis, and it is commonly used in trace analysis, for example to 
determine the alcohol level in the blood.
14-15
 Here, a sample usually in suspension is irradiated 
by UV or visible light. By absorption of electromagnetic radiation in this range electrons, 
generally valence electrons in the outer orbitals of the molecules, are excited to higher distinct 
energy levels. These observed absorption bands show a distinct position, intensity, from and 
fine structure and are associated with defined transitions. Due to the fact that they are 
commonly accompanied by rotational and vibrational transitions, the arising lines in the 
spectrum are commonly broadened and the fine structure overlayed. The measured absorption 
is defined by the following law, introduced by Bouguer, Lambert and Beer: 
𝐴 = 𝑙𝑜𝑔
𝐼0
𝐼
= 𝜀 ∙ 𝑐 ∙ 𝑑 
(2.8) 
Law of Bouguer, Lambert and Beer. 
Here, dimensionless absorption A, also called absorbance or extinction, is defined through the 
ratio between intensity of incident beam I0 and emergent one I. d describes the path length of 
the sample cell, c the applied concentration of the sample solutions and ε the molar absorption 
coefficient. The law can be applied for diluted solutions under the use of a monochromatic 
light source.
14
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2.5.2. IR- and Raman Spectroscopy 
The complementary techniques mid-infrared (IR) and Raman spectroscopy belong both to the 
vibrational spectroscopy and are used to elucidate molecular structures.
16
 In the field of 
infrared radiation, molecular vibrations and rotations are excited. These can be measured 
either directly as absorption in an IR spectrum or indirectly as scattered radiation in a Raman 
spectrum. 
The IR region is differentiated between the near, middle and far infrared (NIR, MIR, FIR).
17
 
In the mid-infrared (MIR) region the absorption of vibrations by covalently bound molecules 
as well as certain group frequencies of functional, organic groups can be detected, which 
makes IR spectroscopy a powerful analytical method. The common range of an IR spectrum 
lays between 4000 and 400 cm
-1
. A molecule vibration is IR-active if the molecule’s dipole 
moment changes during the vibration. 
To be capable to absorb the energy of incident radiation, the resonance condition has to be 
fulfilled. This means the energy between two distinct vibrational states, given through the 
quantum mechanical conditions, has to correspond to the energy of the incident photon. This 
energy absorption process leads to a change in vibrational energy level which results in a 
characteristic absorption spectrum. Successive Fourier transformation of the gained 
interferogram gives rise to a characteristic wavenumber-dependent spectrum with information 
about molecular structure and dynamics.  
Whereas IR spectroscopy involves transitions between different vibrational states, Raman 
spectroscopy consists of a two-photon dependent scattering process.
16
 Here, the sample is 
irradiated with monochromatic light. Subsequent, different scattering processes can be 
observed. The main part is comprised of elastic Rayleigh scattering and a small part shows 
inelastic Raman scattering. The latter can be further divided into Stokes- and Anti-Stokes 
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scattering, depending on the previous state of the excited molecule (if it has been in the 
ground state or an excited vibrational state before). The different two-photon processes are 
depicted in Figure 2-4. The Boltzmann distribution describes that a higher number of 
molecules is present in the ground state under ambient conditions. Therefore, the intensity of 
the Stokes lines is significantly higher than that of the Anti-Stokes Scattering.  
 
Figure 2-4: Schematic representation of elastic Rayleigh and inelastic (Anti-) Stokes Raman Scattering. The 
corresponding shifts in frequency relative to the laser frequency νL are respectively shown.
16
 
A molecule is Raman active if an external electric field can deform the electron cloud 
surrounding the molecule, meaning to induce a change of molecular polarizability α. The 
respective shifts in frequency observed as Anti-Stokes or Stokes shifts are characteristic for 
each molecule and can give information about the molecular structure. 
For molecules with a symmetry center the so-called mutual exclusion rule is valid meaning 
vibrations are IR-active but Raman-inactive and vice versa. It has to be noted that vibrations 
can also be inactive in both methods. If the symmetry center is missing, each vibration has to 
be assessed on its own whether it is IR and or Raman active.  
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2.5.3. Fluorescence Spectroscopy 
Fluorescence spectroscopy represents a powerful and very sensitive tool in biochemical, 
biophysical and biomedical fields.
18
 Luminescence describes the emission of light from 
electronically excited states of a material. It can be formally divided into two categories: 
fluorescence and phosphorescence. Upon light absorption, a fluorophore is excited to higher 
vibrational energy levels, commonly of the multiplicity S1 or S2. This uptake is followed by 
rapid vibrational relaxation to the lowest of the S1 energy levels. From here a fast, spin-
allowed emission back to the ground state via fluorescence can occur. Phosphorescence, on 
the other hand, describes the spin-forbidden and therefore slow emission of light following 
intersystem crossing from an excited triplet state. Here, average lifetimes of milliseconds to 
seconds can be observed. The distinction between fluorescence and phosphorescence can be 
seen in a Jablonski diagram shown in Figure 2-5. 
As observed in the Jablonski diagram, the energy of emission through fluorescence is always 
smaller than the absorbed one. This energy loss between excitation and emission is called the 
Stokes shift and is caused through several effects like the mentioned vibrational relaxation as 
well as solvent, complexation or energy transfer effects.
14, 18
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Figure 2-5: Jablonski diagram. Vertical lines represent singlet (Sn) and triplet (Tn) states. VR: vibrational 
relaxation, IC: internal conversion, ISC: intersystem crossing.
19
  
The structure of a fluorescence spectrometer consists of a radiation source such as a xenon 
lamp (which has a high intensity in the wavelength range used), monochromators, the sample 
space and subsequent photomultiplier detectors. Finally, the data are converted into a 
spectrum by means of software. Besides excitation and emission spectra, time-based 
fluorescence measurements can be conducted. 
2.5.4. Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy is a very sensitive method to elucidate 
chemical structures of organic molecules. To enable the use of NMR measurements, the 
respective nuclei must have a magnetic dipole moment µ ≠ 0.14, 20  
This magnetic moment is defined as the product of the nuclear spin and the magnetogyric 
ratio γ. The latter is an empirical constant, specific for each kind of nuclei, which describes in 
part the isotope’s sensitivity towards NMR spectroscopy.
20
 By applying an external magnetic 
field the degenerated energy levels of the nucleus are split. Due to the thermal Boltzmann 
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distribution, very strong magnetic fields have to be used to generate a significant difference in 
spin state population. The energy difference between the states directly correlates with the 
strength of the magnetic field. Irradiating the sample with electromagnetic radiation in the 
radio wave region leads to an energy absorption connected with a successive transition to the 
spin state with higher energy. The following relaxation occurs either as spin-lattice or spin-
spin relaxation. The first process occurs via energy transfer to the surrounding medium in 
form of heat within the longitudinal relaxation time T1 and leads to relaxation from the high 
energy level to the low energy level. In addition, the transversal relaxation time T2 describes 
the time period of the transversal magnetization’s relaxation induced by perturbation through 
other spinning particles and their magnetic fields. Neighbour molecules as well as 
corresponding electron densities have an impact of the resonance frequency as well as the 
energy transfer and relaxation behaviour of the respective nuclei. Monitoring these processes 
allows great insight into the chemical molecular structure.  
Conducting the NMR experiments with liquids allows dipole-dipole interactions and 
quadrupole effects to be averaged out due to the mobility of the nuclei. In the solid state they 
can cause severe line broadening. In addition, anisotropic effects enhance the broadening of 
the lines in solids as well as they lead to a more complex line structure. Additionally, spin-
lattice relaxation times of nuclei like 
13
C are extremely long. To avoid these effects in solid-
state NMR, the Magic Angle Spinning (MAS) method can be applied. Here the sample is 
rotated with high velocity in the magic angle of 54.736° relative to the magnetic field, which 
avoids the above mentioned line broadening effects. To circumvent the long relaxation times 
cross polarization (CP) can be applied. Here, a polarisation transfer from the surrounding 
protons to the 
13
C nucleus takes place, which shortens the relaxation times dramatically and 
enhances the 
13
C signal.  
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2.6. Electron Microscopy 
Electron microscopy is one of the most powerful methods to investigate and depict nanometer 
sized objects. By use of charged particles (electrons) one can achieve a 1000 fold higher 
resolution limit in comparison to standard light microscopes. Electron microscopy is a very 
general description and can be divided into four big subgroups. They are distinguished by 
their combination of the two different measurement modes, namely scanning- or static image, 
with the two different detection modes (reflection and transmission). The four resulting 
combinations are called transmission electron microscopy (TEM), reflection electron 
microscopy (REM), scanning electron microscopy (SEM) and scanning transmission electron 
microscopy (STEM). All of them except for REM are applied in practical work. The three 
main parts of an electron microscope are the electron source, the electromagnetic lenses (in 
this case especially the objective is crucial for the performance of the instrument) and a 
detecting and computing system for the resulting images.
21
 
2.6.1. Scanning Electron Microscopy (SEM) 
SEM is especially used for the investigation of (rough) surfaces and their topographies. It can 
depict various surfaces of massive samples immediately with depth of sharpness if the 
samples are stable in the high vacuum and electroconductive. The latter can be overcome for 
nonconductive samples by coating them. For measurements highly accelerated electrons are 
focussed via lenses onto the samples and the resulting interactions monitored. Besides 
backscattered electrons, which possess almost the same energy as the incident beam, 
secondary electrons can be recorded. These secondary electrons possess a much smaller 
energy than the incident ones and are recorded with a different detector. Other products of the 
interactions between the incident electron beam and the sample are X-rays, Bremsstrahlung 
and so called Auger electrons. Due to those interactions, the whole scanning electron 
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microscope has to be under vacuum, to enable free movement of the charged particles. As 
shown in Figure 2-6 the electron beam is focussed with different lenses onto the sample. 
Scanning coils are responsible to guide the beam to scan the sample line by line.
21-22
  
 
Figure 2-6: Schematic setup of a Scanning Electron Microscope. 
2.6.2. Transmission Electron Microscopy (TEM) 
The resolution limit of TEM is tenfold higher than the one of SEM. The main field of 
application is the investigation of very thin metal foils as well as biological thin sections. 
While SEM follows originally more the concept of a television set, TEM originates rather 
from a common light microscope. In comparison to SEM with its scanning mode and 
resulting raster image, a fixed beam is used in transmission electron microscopy leading to a 
2. Characterization  
73 
 
static image. Furthermore, not the reflected but the transmitted electrons are being detected. 
To this, a relatively big part of the sample is illuminated with the help of condenser lenses and 
a magnified image of the sample’s refraction pattern is recorded with an optical system 
underneath the sample holder. In TEM measurements, acceleration voltages between 100 and 
400 kV are being used, whereas in SEM only 10 to 40 kV. 
 
Figure 2-7: Schematic setup of TEM and STEM. Elbaum, M.; Wolf, S. G.; Houben, L., Cryo-scanning 
transmission electron tomography of biological cells. MRS Bull. 2016, 41 (7), 542-548, reproduced with 
permission.
23
 
2.6.3. Scanning Transmission Electron Microscopy (STEM) 
This electron microscopy technique combines the scanning of a sample in a high-vacuum 
apparatus with the detection of transmitted electrons via various detectors. The array of the 
detectors can be seen Figure 2-7. ADF stands for annular dark field detector and collects only 
the scattered electrons with a ring shaped detector, whereas the bright field detector BF 
records not or only very little scattered electrons.
22
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CHAPTER 3 
 
 
Immune response to functionalized mesoporous silica 
nanoparticles for targeted drug delivery 
 
 
 
 
 
 
 
 
 
 
 
 
The following results have been achieved in a cooperation: Simon Heidegger, Alexandra 
Schmidt, Thomas Bein and Carole Bourquin designed the concept of the project and 
interpreted the results. Dorothée Gößl and Stefan Niedermayer designed, synthesized and 
characterized the mesoporous silica nanoparticles. Simon Heidegger performed and analyzed 
the in vitro experiments with primary cells. Stefan Endres and Christian Argyo gave 
methodological support and advice. The study was guided by Thomas Bein and Carole 
Bourquin and is the groundwork for the experiments described in Chapter 4.
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targeted drug delivery 
 
This chapter was published as: 
Simon Heidegger, Dorothée Gößl, Alexandra Schmidt, Stefan Niedermayer, Christian Argyo, 
Stefan Endres, Thomas Bein, Carole Bourquin, Nanoscale 2016, 8, 938–948. Reproduced 
with permission from The Royal Society of Chemistry. 
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Abstract 
Multifunctional mesoporous silica nanoparticles (MSN) have attracted substantial attention 
with regard to their high potential for targeted drug delivery. For future clinical applications it 
is crucial to address safety concerns and understand the potential immunotoxicity of these 
nanoparticles. In this study, we assess the biocompatibility and functionality of 
multifunctional MSN in freshly isolated, primary murine immune cells. We show that the 
functionalized silica nanoparticles are rapidly and efficiently taken up into the endosomal 
compartment by specialized antigen-presenting cells such as dendritic cells. The silica 
nanoparticles showed a favorable toxicity profile and did not affect the viability of primary 
immune cells from the spleen in relevant concentrations. Cargo-free MSN induced only very 
low immune responses in primary cells as determined by surface expression of activation 
markers and release of pro-inflammatory cytokines such as Interleukin-6, -12 and -1β. In 
contrast, when surface-functionalized MSN with a pH-responsive polymer capping were 
loaded with an immune-activating drug, the synthetic Toll-like receptor 7 agonist R848, a 
strong immune response was provoked. We thus demonstrate that MSN represent an efficient 
drug delivery vehicle to primary immune cells that is both non-toxic and non-inflammagenic, 
which is a prerequisite for the use of these particles in biomedical applications. 
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3.1. Introduction 
In biomedical research applications, rationally designed nanoparticles are engineered for 
targeted delivery of various drugs or vaccines.
1
 With spatio-temporally controlled release of 
their therapeutic cargo, such nanoparticles have the potential to increase drug efficacy while 
minimizing undesired off-target effects. However, due to their nanoscale size, chemical 
composition and surface reactivity, nanoparticles can be potentially detected by and interact 
with the host immune response.
2
 While in certain applications (e.g. vaccine delivery) an 
immunostimulatory function may be desirable,
3
 uncontrolled systemic immune activation will 
limit their therapeutic use. Thus, the profound understanding of a nanomaterial’s interaction 
with the immune system and its possible stimulatory and suppressive actions are a critical 
prerequisite for any clinical application. 
 
Specialized antigen-presenting cells (APC) of the innate immune system, such as dendritic 
cells (DC), constantly sample their surroundings, taking up cell debris and foreign materials. 
These cells are equipped with a variety of pattern-recognition receptors that allow for the 
detection of invading pathogens or signs of cell stress and damage.  Ligation of these 
receptors results in maturation of APCs associated with expression of costimulatory 
molecules (such as CD80 and CD86), the release of proinflammatory cytokines and 
eventually the initiation of a subsequent adaptive immune response.
4
 DCs have been shown to 
efficiently engulf various kinds of nanoparticles both in vitro and in vivo,
5, 6
 but the 
consequences with regard to subsequent immune responses remain poorly understood.  
 
Previous work of some of us has been focused on the development of core-shell colloidal 
mesoporous silica nanoparticles.
7, 8
 Due to their different molecular functionalization in the 
core and the shell, the MSN can be equipped with internal functionality for controlled host-
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guest interactions, a system for accurate cargo release upon external stimuli, as well as 
targeting ligands towards the required type of cell. A broad variety of different triggered-
release capping systems were presented in the past years, based on external stimuli,
9-11
 or 
triggered by intracellular events.
12-14
 We recently reported a multifunctional system based on 
a pH-responsive polymer (poly(2-vinylpyridine), MSN-PVP) that allows for the facile 
delivery of membrane-permeable cargos into cancer cells.
15
 With the possibility to integrate 
almost any functionality of interest, as well as the efficient synthesis, this system holds 
promise for wide-ranging biological and medical applications. In general, the special 
properties of MSN have been successfully implemented for experimental targeted anti-cancer 
therapies and vaccines.
16, 17
 Thereby, MSN-based adjuvants have been shown to elicit potent 
anti-tumor and anti-microbial immune responses.
18, 19
 A recent report demonstrated that 
injectable mesoporous silica rods can form macroporous structures that provide a cellular 
microenvironment for host immune cells in vivo, thus modulating their function and 
increasing vaccine efficacy.
20
 
 
In this study, we investigate the immune-modulatory properties of MSN in primary murine 
splenocytes. We show that MSN themselves provoke only a marginal immune response but 
when loaded with a synthetic immune activator can function as an efficient delivery tool for 
potent immune activation. 
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3.2. Results 
MSN particle characteristics 
As reported previously,
15
 the template-free MSN-NH2 show a wormlike pore structure with an 
average pore size of 3.8 nm and feature a large surface area (1097 m
2
/g) which is typical for 
MSN (Figure 3-1and Table 3-1).  
Table 3-1 Key features of pH-responsive MSN-PVP 
Sample Particle size
a
 
[nm] 
BET surface area 
[m
2
/g] 
Pore size
b
 
[nm] 
Relative mass loss
c
 
[%] 
MSN-NH2 160 1097 3.8 15 
MSN-PVP 550 617 3.4 62 
 
a Particle size refers to the peak value derived from dynamic light scattering (DLS). b Non-linear density functional theory 
(NLDFT) pore size refers to the peak value of the pore size distribution. c Relative mass loss obtained by thermogravimetric 
analysis (TGA). All curves were normalized to 150 °C.15 
 
The covalent modification of MSN-NH2 with a boc-protected poly(2-vinylpyridine) and the 
following de-protection was monitored with several characterization methods; the accessible 
pore size as determined by nitrogen sorption measurements is barely affected by the surface 
modification with the pH-responsive polymer, whereas the decrease of the specific surface 
area is relatively large. This can be explained by the addition of non-porous polymer to the 
outer surface and the blocking of some pores by frozen polymer on the surface layer of the 
MSN. Dynamic light scattering (DLS) measurements in aqueous media revealed an average 
particle size of 160 nm for MSN-NH2 and 550 nm for MSN-PVP. The polymer-modified 
sample shows some aggregation behaviour in water due to the hydrophobicity at pH 7, 
indicated by the apparent size increase to 550 nm. However, transmission electron 
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microscopy (TEM) revealed that the polymer-functionalized sample MSN-PVP still features a 
narrow particle size distribution, which makes them excellent candidates as drug delivery 
vehicles. 
 
Figure 3-1 Characteristics and structure of mesoporous silica nanoparticles. (A) Transmission electron 
micrograph of a template-extracted MSN-NH2, exhibiting a worm-like structure. (B) Schematic illustration of 
the pH-responsive nanocarrier system (MSN-PVP) employed in this work at a pH value of 5 (open state). The 
inorganic-organic hybrid material consists of a mesoporous silica core (grey) and a covalently attached pH-
responsive polymer (poly(2-vinylpyridine), blue). (C) Nitrogen sorption isotherms of the samples MSN-NH2 
(black), MSN-PVP-open (red) and MSN-PVP-closed (blue). These data have already been presented in ref. 15. 
(D) Calculated NLDFT pore size distributions for the samples MSN-NH2 (black) and MSN-PVP-open (red); 
data of the red curve are shifted by a value of 1.0 along the y-axis for clarity. 
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Efficient uptake of mesoporous silica nanoparticles by specialized antigen-presenting 
cells  
To test whether MSN-NH2 can serve as a delivery tool in primary immune cells, freshly 
isolated mouse splenocytes that harbor a variety of different immune cells were cultured in 
the presence of fluorescently-labeled MSN (MSN-FITC) overnight. The uptake of labeled 
MSN-FITC by different cell types was analyzed by flow cytometry. Cells of the innate 
immune system, that includes macrophages and dendritic cells, showed high uptake of MSN-
FITC, as measured by fluorescence signal-positive cells (Figure 3-2A). As such, dendritic 
cells, which are highly specialized in antigen uptake, processing and presentation, were more 
efficient in uptake than macrophages. In contrast, T and B cells, which are the effector cells of 
the adaptive immune system, showed only trace fluorescence signal positivity. The 
intracellular uptake of MSN-FITC was clearly concentration-dependent (Figure 3-2B). 
Fluorescent microscopy showed a speckled distribution pattern of fluorescent signals within 
dendritic cells, suggesting uptake of labeled MSN into distinct intracellular compartments but 
not into the cytosol or nucleus (Figure 3-2C). Indeed, counter-staining with a fluorescent 
marker for lyso-/endosomes showed co-localization with the fluorescein-labeled MSN. In 
summary, MSN show rapid and efficient uptake into the endosomal compartment of 
specialized antigen-presenting cells such as dendritic cells but not into adaptive immune cells. 
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Figure 3-2 Mesoporous silica nanoparticles are efficiently taken up by antigen-presenting cells. (A, B) Freshly 
isolated, total splenocytes were incubated for 18 h with different concentrations of fluorescein-labeled MSN 
(MSN-FITC). The uptake of fluorescence signals by different cell populations was determined by flow 
cytometry. (A) Representative histograms are gated on the indicated cell subset. The numbers give the 
percentage of fluorescein highly positive-stained cells. (B) Diagrams show the mean percentage of fluorescein-
positive cells of triplicate samples ± s.e.m. An asterisk indicates comparison with unstimulated cells. (C) 
Complete splenocytes were incubated for 3 h with 0.1 µg mL
-1
 MSN-FITC. Cell endosomes were stained with 
LysoTracker
TM
 and intracellular MSN localization was determined by fluorescence microscopy. All results are 
representative of at least two independent experiments. No stim., no stimulation. 
MSN-NH2 are non-toxic and do not affect the viability of splenocytes, unless used in very 
high concentrations  
We next sought to determine the cytotoxicity of MSN for primary cells. For this purpose, 
freshly isolated splenocytes were cultured in the presence of increasing concentrations of 
MSN-NH2 and 18 hours later, we performed Annexin V / propidium iodide (PI) analysis by 
flow cytometry. Annexin V binds to phosphatidylserins, which in apoptotic cells are 
translocated from the inner to the outer leaflet of the plasma membrane, and are thus exposed 
to the external cellular environment.
23
 PI is a small molecule that intercalates into double-
stranded DNA and becomes fluorescent upon intercalation. PI can only reach nuclear DNA 
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when the cell’s integrity is severely compromised during late apoptosis and cell death. The 
gating strategy for early and late apoptotic cells is depicted in the representative dot blot 
(Figure 3-3A). MSN-NH2 showed a favorable (low) toxicity profile in primary cells and 
induced marked apoptosis only when used in very high concentrations of 200 µg mL
-1
. The 
common cytotoxic chemotherapeutic drug oxaliplatin was used as a positive control.  
 
Figure 3-3 MSN-NH2 are non-toxic and do not affect the viability of splenocytes, unless used in very high 
concentrations. Complete splenocytes were incubated for 18 h with different concentrations of MSN-NH2. (A) 
Cell integrity and viability of splenocytes as determined by propidium iodide (PI) exclusion and Annexin V 
staining was analyzed by flow cytometry. The dot blot shows the gating strategy of viable (PI
-
 Annexin V
-
), 
early (PI
-
, Annexin V
+
) and late apoptotic (PI
+
, Annexin V
+
) cells. (B) DNA fragmentation was assessed by 
TUNEL assay. The histogram shows the gating strategy for TUNEL
+
 cells. All data give the mean percentage of 
apoptotic cells of triplicate samples ± s.e.m. The mean base-line level of apoptosis in the untreated control group 
was set as zero %. An asterisk indicates comparison to untreated cells. Results are representative of at least two 
independent experiments. 
To confirm these data, we also performed terminal deoxynucleotidyltransferase dUTP nick 
end labeling (TUNEL). During the late phase of apoptosis endonucleases degrade the higher 
order chromatin structure into small DNA pieces. With the TUNEL assay these DNA 
fragments can be identified through addition of bromolated deoxyuridine triphosphates (Br-
dUTP) to the 3'-hydroxyl (OH) termini of double- and single-stranded DNA by the 
endogenous enzyme terminal deoxynucleotidyl transferase (TdT) and subsequent staining 
with an FITC-labeled anti-BrdU antibody. The TUNEL analysis confirmed that MSN-NH2 
are non-toxic to primary murine splenocytes over a wide concentration range (Figure 3-3B). 
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Mesoporous silica nanoparticles induce only very low immunological responses in 
primary myeloid immune cells  
As a next step, we focused on the immunological response of mammalian primary immune 
cells to cargo-free MSN. For the implementation of any nanoparticle constructs as molecular 
delivery system, it is essential to fully understand their immune-modulatory potential in order 
to tightly control the initiation of immune responses according to the therapeutic goal. Thus, 
freshly isolated splenocytes were cultured in the presence of MSN-NH2. After 24 hours, 
surface expression of the B7 family member CD80, a co-stimulatory molecule and activation 
marker, was examined on different antigen-presenting cells by flow cytometry with specific 
fluorochrome-coupled antibodies. Additionally, the concentration of the secreted pro-
inflammatory cytokines IL-6 and IL-12p70 in the culture supernatant of stimulated cells was 
quantified by enzyme-linked immunosorbent assay (ELISA). Synthetic unmethylated CpG 
sequence-containing oligonucleotides (CpG-ODN) that resemble bacterial DNA were used as 
a positive control. CpG-ODN bind to the endosomal Toll-like receptor (TLR) 9, thereby 
initiating a full-blown immune response.
24
 In comparison to CpG-ODN, MSN-NH2 induced 
only low levels of CD80 expression on monocytes and dendritic cells, indicating that the 
cargo-free nanoparticles barely activate immune responses (Figure 3-4A). The secretion 
profile of pro-inflammatory cytokines confirmed these findings, as cells cultured with MSN-
NH2 released only low amounts of IL-6 and IL-12p70 (Figure 3-4B). Crystalline silica (found 
in nature as sand or quartz) have been shown to activate a cytosolic multi-protein complex 
called the NALP3 inflammasome resulting in the release of bioactive IL-1β, a very potent 
pro-inflammatory cytokine.
25
 In contrast, MSN-NH2 only induced trace levels of IL-1β 
(Figure 3-4C).  
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Figure 3-4 Mesoporous silica nanoparticles induce only very low immunological responses in primary myeloid 
immune cells. Complete splenocytes were incubated for 18 h with different concentrations of MSN-NH2. (A) 
The surface expression of the co-stimulatory molecule CD80 on myeloid antigen-presenting cells was analyzed 
by flow cytometry. Data give the mean fluorescence intensity (MFI) of the indicated marker on triplicate 
samples ± s.e.m. The amounts of the pro-inflammatory cytokines (B) IL-6, IL-12p70 and (C) IL-1β in the cell 
culture supernatant were determined by ELISA. Data give the mean values of triplicate samples ± s.e.m. An 
asterisk indicates comparison to unstimulated cells. All results are representative of at least two independent 
experiments. 
To exclude that adsorption of the analyzed cytokines to the cationic surface of MSN-NH2, 
could influence the cytokine measurements, we incubated defined concentrations of 
recombinant cytokines with either non-functionalized (bare) MSN or MSN-NH2 for 18h in 
cell culture medium. The presence of MSN did not alter the concentration of any of the 
cytokines tested (Figure S 3-1A). In line with these findings, we found that MSN without 
surface functionalization did not induce the release of proinflammatory cytokines when 
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incubated with primary murine splenocytes (Figure S 3-1B). In summary, these data 
demonstrate that MSN-NH2 only mildly activate primary murine APCs. 
Bystander lymphoid cells are not stimulated by mesoporous silica nanoparticles  
 
Figure 3-5 Mesoporous silica nanoparticles do not result in activation of bystander lymphoid cells. Complete 
splenocytes were incubated for 18 h with different concentrations of MSN-NH2. Expression of the activation 
marker CD69 on effector (A) B lymphocytes and (B) T lymphocytes was analyzed by flow cytometry. The 
representative histogram is gated on B220
+
 B cells and illustrates CD69 expression (black dotted line, 
unstimulated cells; red line, 1 μg mL−1 MSN; blue line, CpG-DNA). Data in the graphs give the mean values of 
triplicate samples ± s.e.m. An asterisk indicates comparison to unstimulated cells. All results are representative 
of at least two independent experiments. 
T and B lymphocytes are the effector cells of the adaptive immune system. We have shown 
that these cell types do not efficiently take up MSN-FITC and are thus unlikely to directly 
recognize these nanoparticles (Figure 3-2A,B). However, T and B cells may react to low 
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levels of pro-inflammatory cytokines released by antigen-presenting cells in response to 
MSN. In order to investigate the immunostimulatory effect of MSN on such bystander 
lymphocytes, complete splenocytes (containing both antigen-presenting cells and 
lymphocytes) were cultured in the presence of MSN-NH2 and expression of the 
transmembrane C-type lectin CD69, an early activation marker on B and T cells, was 
analyzed by flow cytometry. We found that neither B nor T cells showed upregulation of the 
activation marker CD69 (Figure 3-5), indicating that the low-level cytokine release by 
antigen-presenting cells in response to MSN-NH2 is not sufficient for activation of bystander 
lymphocytes.  
In summary, our findings show that MSN-NH2 are rapidly taken up into specialized antigen-
presenting cells but are non-toxic and only weakly immunostimulatory to primary murine 
immune cells. 
Functionalized mesoporous silica nanoparticles are an efficient delivery tool for the 
synthetic immunostimulatory TLR7 ligand R848 
To test whether MSN can principally function as delivery tool in primary immune cells, MSN 
coated with a pH-responsive polymer (MSN-PVP) were loaded with R848. A defined amount 
of the drug was adsorbed at low pH values into the mesopores of MSN-PVP, followed by the 
subsequent closure of the polymer coat on the mesoporous nanoparticles at pH 7. Following 
internalization and shuttling into the endosome, the local acidic environment allows for re-
opening of the mesopores and release of the cargo. The low molecular weight, synthetic 
imidazoquinoline compound R848 (also called resiquimod) induces potent immune responses 
upon uptake and ligation to endosomal TLR7.
26
 Indeed, we found that both unbound 
(molecules suspended in liquid) as well as MSN-PVP-encapsulated R848 induced activation 
3. Immune response to functionalized mesoporous silica nanoparticles for targeted drug 
delivery  
89 
 
of dendritic cells with potent upregulation of CD80 and release of pro-inflammatory IL-6 
(Figure 3-6A and B). 
 
Figure 3-6 Mesoporous Mesoporous silica nanoparticles are an efficient delivery tool for the synthetic 
immunostimulatory TLR7 ligand R848. Complete splenocytes were incubated for 18 h either with the small 
molecule immunostimulant R848, cargo-free, or R848-loaded MSN-PVP, respectively. (A) The surface 
expression of the co-stimulatory molecule CD80 on dendritic cells was analyzed by flow cytometry. (B) The 
level of Interleukin-6 in the cell culture supernatant was determined by ELISA. Expression of the activation 
marker CD69 on effector (C) B lymphocytes and (D) T lymphocytes was analyzed by flow cytometry. Data give 
the mean values of triplicate samples ± s.e.m. An asterisk indicates comparison to unstimulated cells. All results 
are representative of two independent experiments 
Such R848-mediated dendritic cell activation was associated with strong upregulation of the 
activation marker CD69 on co-cultured lymphocytes (Figure 3-6C and D). This activation 
affected both B cells and bystander T cells that do not express functional TLR7. These data 
show that MSN-PVP can be used as a drug delivery tool in primary immune cells. A 
therapeutic approach to use the targeted release of MSN cargo in the endosome of immune 
cells in order to target endosomal receptors such as TLR7 with stimuli-responsive capping 
mechanisms in cancer immunotherapy will be the subject of future studies.   
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3.3. Discussion 
Despite intense research in the field of nanomedicine, fundamental knowledge about the 
interaction of nanomaterials with the cellular components of the host immune system remains 
scarce. We demonstrate in this work that MSN-NH2 particles are rapidly and efficiently taken 
up by specialized antigen-presenting cells (APCs) such as dendritic cells and macrophages 
and are delivered into endo-/lysosomes. Efficient uptake of MSN via endocytosis into non-
immune cells, in particular different types of tumor cell lines, has been observed previously.
27-
29
 For example, for HeLa cervical adenocarcinoma cells, Mou and co-workers reported a size-
dependent endosomal uptake of MSN, favouring a size range of 50 - 120 nm.
30
 In contrast to 
tumor cells, APCs are specialized to scavenge their environment by taking up and sampling 
cell debris and foreign material, and are also equipped with a variety of germ-line encoded 
immune receptors to identify invading microorganisms. Many of these receptors, especially 
several members of the family of Toll-like receptors (TLR), are localized in the endosome and 
upon ligation of pathogenic material lead to innate immune stimulation. However, our results 
demonstrate that the uptake of cargo-free MSN-NH2 into APCs did not result in immune 
activation, as dendritic cells and macrophages showed only mild upregulation of the 
co-stimulatory molecule CD80 and released only low levels of pro-inflammatory cytokines. 
Similarly, Lee et al. showed that incubation of a macrophage cell line or peritoneal 
macrophages with MSN resulted in only trace release of cytokines and that short-term in vivo 
application of MSN in mice did not lead to contact hypersensitivity.
31
 However, treatment of 
mice with MSN over a time course of several weeks resulted in histological changes in liver 
and spleen.
32
 We note that such findings are expected to be very dependent on the size, 
surface functionalization and zeta potential of the particles and thus cannot be generalized for 
different types of MSN. Generally, the impact of repetitive treatments with MSN must be 
carefully evaluated before long-term clinical applications are conducted. 
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Crystalline silica have been shown to potently activate the NLRP3 inflammasome, a cytosolic 
multiprotein complex, triggering the release of the bioactive form of the potent pro-
inflammatory cytokine IL-1β.
33
 Similar to crystalline silica, non-functionalized, amorphous 
silica nanoparticles can activate the inflammasome, leading to significant IL-1β secretion.
34
 In 
contrast, here we demonstrate that the molecularly functionalized MSN-NH2 particles do not 
induce relevant levels of IL-1β release from primary murine splenocytes. Initial reports 
suggested that phagocytosis of crystalline silica  with a median particle size of 5 µm results in 
presumably osmotic swelling and damage of the lysosome, leading to activation of the 
NALP3 inflammasome, which is triggered by lysosomal rupture and content release, not the 
crystal structure itself.
33
 While others linked the formation of reactive oxygen species during 
an oxidative stress situation to NLRP3 activation,
35
 the exact molecular mechanism and 
prerequisite for inflammasome activation remains to be determined. We propose that due to 
their size and molecularly functionalized surface structure, spherical MSN-NH2 in comparison 
to silica crystals do not induce lysosomal damage and subsequent inflammasome-mediated 
IL-1β release. Generally, besides the physicochemical properties of particle size and surface 
chemistry, the biological activity of MSN has also been attributed to shape features such as 
aspect ratio and morphology.
36
 
MSN have attracted much interest for their potential as drug delivery vehicles to control 
various cell functions by the stimuli-responsive delivery of bioactive cargos.
37-39
 An ideal 
drug delivery vehicle based on MSN may be composed of a multifunctional silica core able to 
specifically control the interaction with diverse active cargo components. The cargo 
molecules (e.g. pharmaceutically active drugs) are adsorbed in the mesopores of the 
nanoparticles, yielding an effective shielding from external degradation in biological fluids.
40, 
41
 Such multi-functional MSN have been successfully evaluated as antigen carriers and 
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adjuvants for vaccine delivery.
17
 Thereby, MSN have shown intrinsic adjuvant activity under 
certain conditions, thus potentiating antigen-specific T-cell immune responses.
42, 43
 
Interestingly, MSN have been described to enhance MHC class I-restricted presentation of 
antigens by human dendritic cells.
44
 This process called cross-presentation is a vital 
prerequisite for the induction of adaptive T-cell immunity against exogenous antigens such as 
tumor proteins. We found that the functionalized MSN-NH2 without protein or adjuvant cargo 
do not interact with or activate T- and B-lymphocytes in vitro. These findings underline the 
important role of dendritic cells at the interface of innate and adaptive immunity. Importantly, 
the lack of unspecific lymphocyte priming by the MSN carrier system is a promising requisite 
for future in vivo applications in order to use the high specificity of molecular 
immunostimulants either on the surface of the MSN or delivered as cargo from its pore 
system.  
Generally, the application of immunostimulatory adjuvants or vaccines via MSN harbors the 
risk of undesired systemic inflammatory responses upon the uptake of cargo-loaded MSN and 
subsequent cargo release. These dangerous adverse events can possibly be circumvented by 
context-dependent, spatiotemporally controlled cargo release. We and other groups pursue a 
promising approach that takes advantage of internal triggers such as an intracellular change in 
pH
45, 46
 The efficient pH-responsive closing and opening mechanism of a reversible polymer 
cap system has been previously demonstrated by time-based fluorescence release 
experiments; fluorescent dyes were used in these studies.
15, 47
 In this work, the synthetic TLR7 
agonist R848 (resiquimod) was used as active cargo. R848-loaded MSN-PVP particles 
induced strong stimulation of dendritic cells with potent release of pro-inflammatory 
cytokines as well as activation of bystander lymphocytes. As a defined ligand for endosomal 
TLR7/8, R848 was presumably released after pH-dependent reopening of the mesopores in 
the endosome. Whether such spatially controlled release can augment the efficacy and 
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regulation of the subsequent immune response is the focus of ongoing research. Similarly, 
temporally defined release of the MSN-PVP cargo also appears attractive, as the kinetics of 
receptor sensitivity strongly influence the outcome of R848-based cancer immunotherapy.
48
 
3.4. Conclusion 
In summary, we demonstrate in this study that MSN-NH2 nanoparticles are non-toxic to 
primary murine leukocytes and provoke only trace immune activation. In addition, surface 
functionalized MSN-PVP can serve as a pH-triggered drug delivery tool for the synthetic 
TLR7/8 ligand R848 to induce potent immune activation in responder cells. The controlled 
release of their immunomodulatory cargo by otherwise non-immunogenic MSN is a 
promising tool in future therapies in order to achieve localized immune activation (e.g. in the 
tumor microenvironment) while preventing undesired, systemic adverse effects. 
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3.5. Experimental Part 
Materials. All reagents were purchased from commercial suppliers. Tetraethyl orthosilicate 
(TEOS, Sigma-Aldrich, >98%), cetyltrimethylammonium chloride (CTAC, Fluka, 25wt% in 
H2O), triethanolamine (TEA, Sigma-Aldrich, 98%), (3-aminopropyl)-triethoxysilane (APTES, 
Fluka, 95%), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC, Sigma-
Aldrich, 97%), ammonium nitrate (Sigma-Aldrich, 99%), conc. hydrochloric acid (Sigma-
Aldrich, >95%, 37 wt%), α-amino-ω-carboxy terminated poly(2-vinylpyridine) (NH2-PVP-
COOH, Polymer Source, Mn = 10.000, PDI = 1.08), Boc anhydride (Aldrich, 95%), N-
hydroxysulfosuccinimide sodium salt (sulfo-NHS, Sigma-Aldrich, 98%), ethanol (EtOH, 
Sigma-Aldrich, >99.5%), tetrahydrofuran (THF, anhydrous, Sigma-Aldrich, ≥99.9%), 
trifluoroacetic acid (TFA, Acros Organics, 99%), magnesium sulfate (MgSO4, anhydrous, 
Sigma-Aldrich, ≥99.5%), triethylamine (Sigma-Aldrich, ≥99%), fluorescein isothiocyanate 
(FITC, Fluka, >90%), saline-sodium citrate buffer concentrate (SSC-buffer (20x), Sigma-
Aldrich), citric acid buffer solution (citric acid/HCl/NaCl buffer, pH 2, Sigma-Aldrich), TLR7 
agonist R848 (Invivogen, Toulouse). All chemicals were used as received without further 
purification. Doubly distilled water from a Millipore system (Milli-Q Academic A10) was 
used for all synthesis and purification steps. 
Preparation of colloidal mesoporous silica nanoparticles without functionalization. 
Unfunctionalized (bare) MSN were prepared as previously reported.
21
 Briefly, a mixture of 
triethanolamine (TEA) and tetraethyl orthosilicate (TEOS) was heated at 90 °C under static 
conditions, resulting in solution A. In the meantime, a second solution consisting of 
cetyltrimethylammonium chloride (CTAC) and bi-distilled water was prepared and heated to 
60 °C, before it was added to solution A. The resulting mixture was stirred (500 rpm) at 
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ambient temperature overnight yielding MSN without functionalization. Afterwards, the 
organic template was removed via a two-step extraction.  
Preparation of shell-functionalized colloidal mesoporous silica nanoparticles. Polymer-
capped mesoporous silica nanoparticles (MSN-PVP) were synthesized as described 
previously.
7,
 
15
 In brief, colloidal MSN with an amino-functionality (MSN-NH2) were 
prepared by a delayed co-condensation approach with cetyltrimethylammonium chloride 
(CTAC) as structure directing agent and tetraethylorthosilicate (TEOS) as primary silica 
source.
7
 In order to introduce the outer shell functionalization, 3-aminotriethoxysilane 
(APTES) was added during the condensation process. The synthesis was followed by a facile 
extraction of the organic template from the mesopores. Then, 50 mg of the template-extracted 
MSN-NH2 were subsequently reacted with a boc-protected bi-functional polymer (COOH-
PVP-NHboc) dissolved in THF in an EDC-assisted amidation reaction. The reaction was 
followed by the deprotection of the polymer with trifluoroacetic acid, yielding the sample 
MSN-PVP.
15
 
Fluorescein labeling of the MSN. Fluorescein isothiocyanate (FITC)-labeling of MSN-NH2 
was performed following a described procedure.
22
 In brief, 50 mg of MSN-NH2 dispersed in 
ethanol (25 mL) were added to an ethanolic solution of FITC (25 mL, containing 7.4 mg 
FITC, 0.19 mmol). The suspension was stirred at ambient temperature in the dark for 24 h. 
The resulting sample MSN-FITC was collected by centrifugation (19.000 rpm, 43.146 RCF, 
20 min) and washed three times with ethanol (25 mL each) by subsequent centrifugation and 
redispersion. After the final centrifugation step the particles were resuspended in absolute 
ethanol. For cell experiments, 1 mg of the labeled MSN were centrifuged and resuspended in 
1 mL phosphate-buffered saline (PBS).  
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MSN loading with the synthetic TLR7 agonist R848. 1 mg MSN-PVP were dispersed in 
240 µL of sterile water. To open the pores and enable the uptake of the respective drug 
molecule, 50 µL of citrate buffer (pH 2) was added, followed by the addition of 10 µL R848 
of the stock solution (1 mg/mL), yielding an overall drug concentration of 10 µg/300 µL in 
the solution. The particles were stirred overnight, centrifuged, and re-dispersed in 700 µL 
SSC buffer (pH 7) to enable the closure mechanism of the pH-responsible polymer. The 
resulting particles were washed extensively with SSC buffer (pH 7) and finally redispersed in 
1 mL SSC. For incubation with primary cells, MSN were centrifuged and redissolved in 
complete RPMI medium (see below).  
Characterization of MSN. Centrifugation was performed using a Sorvall Evolution RC 
equipped with a SS-34 rotor or an Eppendorf centrifuge 5418 for small volumes. All samples 
were investigated with an FEI Titan 80-300 transmission electron microscope operating at 
300 kV with a high-angle annular dark field detector. A droplet of the diluted MSN solution 
in absolute ethanol was dried on a carbon-coated copper grid. Nitrogen sorption 
measurements were performed on a Quantachrome Instruments NOVA 4000e. All samples 
(15 mg each) were heated to 60 °C for 12 h in vacuum (10 mTorr) to outgas the samples 
before nitrogen sorption was measured at 77 K. Pore size and pore volume were calculated by 
a NLDFT equilibrium model of N2 on silica, based on the desorption branch of the isotherms. 
In order to remove the contribution of the interparticle textural porosity, pore volumes were 
calculated only up to a pore size of 8 nm. A BET model was applied in the range of 0.05 – 
0.20 p/p0 to evaluate the specific surface area of the samples. Dynamic light scattering (DLS) 
measurements were performed on a Malvern Zetasizer-Nano instrument equipped with a 
4 mW He-Ne laser (633 nm) and an avalanche photodiode. The hydrodynamic radius of the 
particles was determined by dynamic light scattering in ethanolic or aqueous suspension. For 
this purpose, 100 µL of an ethanolic suspension of MSN particles (ca. 10 mg/mL) was diluted 
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with 3 mL of ethanol or water prior to the measurement. Zeta potential measurements of the 
samples were performed on a Malvern Zetasizer-Nano instrument equipped with a 4 mW He-
Ne laser (633 nm) and an avalanche photodiode. Zeta potential measurements were performed 
using the add-on Zetasizer titration system (MPT-2) based on diluted NaOH and HCl as 
titrants. For this purpose, 1 mg of the particles was diluted in 10 mL bi-distilled water. 
Thermogravimetric analysis was performed on a Netzsch STA 440 C TG/DSC with a heating 
rate of 10 K / min in a stream of synthetic air of about 25 mL/min. The mass was normalized 
to 100% at 150 °C for all samples to take into account solvent desorption.  
Mice. Female C57Bl/6 mice were purchased from Harlan-Winkelmann. Mice were at 6-8 
weeks of age at the time of the experiment. Animal studies were approved by the local 
regulatory agency (Regierung von Oberbayern, Munich, Germany). 
Media, reagents and cell culture. Single cell suspensions from spleens were obtained as 
follows: Spleens were mechanically disrupted and the tissue was subsequently filtered 
through a 100 µm cell strainer (BD Biosciences, Heidelberg, Germany). Erythrocytes were 
lysed with ammonium chloride buffer (BD Biosciences). Cell yield and viability were 
assessed by trypan blue exclusion and a Neubauer counting chamber. Splenocytes were then 
cultured in complete RPMI (Roswell Park Memorial Institute) 1640 medium (10% fetal calf 
serum (FCS), 2 mM L-glutamine, 100 µg/mL streptomycin and 1 IU/mL penicillin) at 37 °C 
in 10% CO2. In some conditions, CpG 1826 (unmethylated CpG sequence-containing 
oligonucleotides, a TLR9 agonist, 3 µg/mL, from Invivogen, Toulouse, France) was added to 
the culture. For maximal IL-1β release, DCs were primed with lipopolysaccharide (LPS, a 
TLR4 agonist, 20 ng/ml, from Invivogen) overnight and ATP (5 mM, from Sigma-Aldrich) 
was added to the culture 2 hours prior to the analysis. For exposure to nanoparticles, 
splenocytes were seeded in complete RMPI at a density of 1.0 x 10
6
 / mL in 96-well tissue 
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culture plates. Silica nanoparticles were added in complete RPMI medium at the indicated 
concentration. After 18 - 24 hours, cells and culture supernatant were analyzed.  
Quantification of cytokines. Cell supernatants were analyzed for cytokine secretion by 
ELISA (R&D Systems or eBioscience) according to the manufacturers’ protocol. 
Flow cytometry and apoptosis assay. Cell suspensions were stained in PBS with 1% FCS.  
Fluorochrome-coupled antibodies against the surface antigens B220, CD3, CD4, CD8, 
CD11b, CD11c, CD69, CD80, F4/80 and appropriate isotype controls were purchased from 
BioLegend. Data were acquired on a FACSCanto II (BD Biosciences) and analyzed using 
FlowJo software (Tree Star, Ashland, OR). The Annexin V-FITC Apoptosis Detection KIT 1 
(BD Biosciences) was used for detection of apoptotic cells. Following surface staining and 2 
washing steps, single-cell suspensions were resuspended in the provided buffer, incubated 
with Annexin V - FITC and propidium iodide (PI) and subsequently analyzed by flow 
cytometry. Terminal deoxynucleotidyltransferase dUTP nick end labeling (TUNEL staining) 
was done with the APO-BRDU™ Kit (BD Pharmingen) according to the manufacturer’s 
protocol. The chemotherapeutic drug oxaliplatin (30 µg/ml) was used as a positive control for 
cell death induction. 
Confocal Microscopy. Splenocytes were incubated for 4 hours with fluorescein-tagged NPs, 
washed and re-suspended in culture medium. 75 nM LysoTrackerⓇ (Invitrogen) and 3  µg/mL 
Hoechst dye (Invitrogen) were used for lysosomal and nuclear staining. Stained cells were 
visualized using a confocal laser scanning microscope (TCS SP5II, Leica). 
Statistics. All data are presented as mean ± S.E.M. Statistical significance of single 
experimental findings was assessed with the independent two-tailed Student’s t-test. For 
multiple statistical comparison of a data set the one-way ANOVA test with Bonferroni 
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post-test was used. Significance was set at p-values p < 0.05, p < 0.01 and p < 0.001 and was 
then indicated with an asterisk (*, ** and ***). All statistical calculations were performed 
using Graphpad Prism (GraphPad Software).   
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3.7. Appendix 
 
Figure S 3-1 Cytokines are not adsorbed to the cationic surface of MSN-NH2. (A) MSN-NH2 and 
unfunctionalized (bare) MSN were incubated with defined concentrations of recombinant cytokines. After 18 h, 
the concentration of the indicated cytokines in the culture medium was analyzed by ELISA. (B) Complete 
splenocytes were incubated for 18 h with different concentrations of MSN-NH2 or bare MSN. The amounts of 
the pro-inflammatory cytokines IL-1β, IL6 and IL12p70 in the cell culture supernatant were determined by 
ELISA. Data give the mean value of triplicate samples ± s.e.m. All results are representative of two independent 
experimenta.  
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CHAPTER 4 
 
 
Mesoporous silica nanoparticles as pH-responsive drug carrier 
for R848 
 
 
 
 
The following chapter is a joint project: The nanoparticle synthesis was performed and 
optimized by Dorothée Dollenmayer, Natasha Ustyanovska, Stefan Datz and Olga 
Zhuzhgova. Characterization and optimization of the carrier system as well as in cuvette 
stability, loading and release and quantification measurements were performed and interpreted 
by Dorothée Dollenmayer. Thomas Bein and Hanna Engelke guided the studies. The live cell 
imaging experiment was performed by Daniel Hauser. The in vivo biodistribution and toxicity 
studies as well as the in vitro toxicity, uptake, immune activation and T cell proliferation 
studies were performed and interpreted by Julia Wagner. Carole Bourquin guided the studies. 
This project will also be part of the doctoral thesis of Julia Wagner. 
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Abstract 
Nanoparticle-based cancer immunotherapies aim to improve the safety and efficacy of small-
molecule immune-stimulants through targeted and local delivery to specialized antigen-
presenting cells (APCs). Multifunctional mesoporous silica nanoparticles (MSNs), with their 
large surface areas, their tunable particle and pore sizes and their spatially-controlled 
functionalization, represent a safe and non-inflammagenic carrier system for these immune-
modulatory molecules. In this study, we demonstrated the potential of MSNs as a pH-
responsive drug carrier system for the immune-stimulant R848 (resiquimod), a synthetic Toll-
like receptor 7 and 8 agonist. Equipped with a unique biotin-avidin-cap, the tailor-made 
nanoparticles showed efficient stimuli-response release of their R848 cargo if the 
environmental pH dropped to 5.5 or below. We showed that the MSNs were rapidly taken up 
by APCs into the acidic environment of the lysosome and, upon subcutaneous injection into 
mice, mainly accumulated in migratory dendritic cells (DCs) in the draining lymph node. 
Particles loaded with R848 potently activated DCs as observed by the upregulation of co-
stimulatory molecules and the release of pro-inflammatory cytokines. Furthermore, 
simultaneous delivery of the model antigen OVA and the adjuvant R848 resulted in an 
augmented antigen-specific T cell response. In sum, we were able to demonstrate that MSNs 
represent an optimal tool for targeted delivery of the immune-modulator R848 to antigen-
presenting cells and hold considerable promise as a cancer vaccine carrier in future therapies. 
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4.1. Introduction 
In recent years, cancer immunotherapies have revolutionized the field of cancer research.
1
 
The novel idea behind immunotherapies is to harness the power of the immune system to fight 
the cancerous cells instead of targeting the tumor directly. For a successful anti-tumor 
response, antigen-presenting cells (APC) such as dendritic cells (DCs) need to take up tumor 
antigens, undergo maturation and migrate to the tumor-draining lymph node. Upon 
recognizing the antigen presented by the APCs, cytotoxic T cells are activated and proliferate 
before traveling back to the tumor site to kill the cancerous cells.
2
 However, tumor cells can 
evade their immune destruction by suppressing and controlling immune cells. Thus, a major 
success in cancer immunotherapy was the development of immune checkpoint inhibitors such 
as ipilimumab and nivolumab – antibodies which block the inhibitory interaction between 
tumor and T cells and thus unleash the killing ability of cytotoxic T cells.
3
 These antibodies 
help just a small percentage of patients, however, and the demand for different cancer 
immunotherapy strategies still remains high. One such strategy involves boosting the antigen-
presenting cells in order to increase the activation of cytotoxic T cells by targeting the pattern 
recognition receptors (PRRs) of APCs. These receptors normally sense pathogen-associated 
molecular patterns (PAMPs) upon infection and promote the maturation of the APCs. Among 
the most studied receptors is the family of the Toll-like receptors (TLR), and several TLR 
agonists are being investigated for their use in cancer immunotherapy.
4
 The TLR-7/8 agonist 
imiquimod has already been successfully used for the topical treatment of basal cell 
carcinoma after its FDA-approval in 2004.
5
 Besides imiquimod, resiquimod or R848 also 
belongs to the group of imidazoquinolines and was shown to be one hundred times more 
potent.
6-7
 However, systemic applications of TLR7/8 agonists remain clinically problematic 
due to their toxicity at the dose required for them to be effective.
8-10
 
4. Mesoporous silica nanoparticles as pH-responsive drug carrier for R848  
107 
 
Therefore, improved delivery systems are urgently needed to achieve a more localized and 
targeted immune response and thus to enhance the safety and efficacy of these immune-
activating drugs. The use of nanoparticles as delivery systems has already shown great 
promise in pre-clinical and clinical studies. By using DC-targeted nanoparticles that carry 
adjuvants, several studies were able to demonstrate an increase in CD8
+
 cytotoxic T cells in 
the tumor microenvironment as well as subsequent tumor shrinkage.
11-14
 Several of these 
studies used the nanoparticles as a platform for cancer vaccination, meaning that they 
delivered not only an immune-activator such as TLR7/8 ligands to the cells, but also a tumor-
specific antigen. 
The most promising nanoparticulate delivery platforms to date include liposomes, polymers, 
gold nanoparticles and mesoporous silica nanoparticles. Liposomes represent a well-studied 
delivery system with several FDA-approved formulations for chemotherapeutic delivery. 
They are thus also well-studied for cancer vaccination.
15-16
 However, liposomal formulations 
show a poor control of drug release kinetics. This may lead either to a burst release, often 
prior to reaching the target, or an impaired release, depending on the hydrophobicity or 
hydrophilicity of the drug.
17
 Another intensively studied material is poly(D,L-lactic-co-
glycolic acid) (PLGA) nanoparticles.
18-21
 For example, Ilyinskii et al. could show that 
polymeric PLGA nanoparticles loaded with the immune-stimulant resiquimod and the antigen 
OVA could induce a strong and sustained local immune activation.
22
 Although PLGA are 
FDA-approved, it is known that their biodegradation leads to acidic products, like glycolic 
and lactic acid, which may degrade peptides and proteins and thus may limit their delivery. 
This limitation is amplified by the fact that the polymeric particles can only accommodate 
hydrophobic or lipophilic drugs, whereas many potent antigens and adjuvants are 
hydrophilic.
17
 In addition, the clinical efficiency of these particles shows poor results, 
probably due to the formation of a protein corona in vivo which decreases colloidal stability of 
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the particles and accelerates their clearance by macrophages.
23
 Besides these organic 
platforms, metallic ones such as gold nanoparticles (AuNPs) are also being investigated for 
their use in cancer immunotherapy. AuNPs exhibit a versatile surface chemistry and a high 
affinity with dendritic cells. In a previous study, we could show that small functionalized gold 
nanoparticles could successfully load the TLR7/8 ligand resiquimod in their ligand shell, and 
we observed enhanced antitumor efficacy with the loaded particles compared to the free 
drug.
24
 Despite those encouraging results, the clinical application of gold nanoparticles is 
hampered by their high affinity to nucleic acids and related toxicity issues.
25-26
 The long-term 
accumulation of AuNPs in the body also raises additional safety concerns.
27
 
Mesoporous silica nanoparticles (MSNs) represent one of the most promising inorganic drug 
delivery systems. Their size and pore structure can easily be tuned, yielding colloidally stable 
MSNs with narrow pore size distributions. Moreover, they possess very large surface areas 
and pore volumes and thus show high cargo loading efficiencies. They can be functionalized 
with spatial control, thus enabling perfectly tailored host-guest relations inside the pores as 
well as a matching external surface allowing for optimized particle-cell interactions.
28
 With 
respect to the above-mentioned safety concerns, MSNs show a tuneable degradation 
behaviour resulting in harmless silicic acid and related molecules.
29-31
 Furthermore, we were 
able to show in a previous study that these MSNs hold promise as an ideal drug vehicle for 
immune-modulatory cargo.
32
  
 
In this project, we present spatially segregated core-shell mesoporous silica nanoparticles 
(MSNs) as a tight pH-responsive drug carrier system for the immune-stimulant resiquimod. 
We show that loaded R848 is successfully delivered to antigen-presenting cells, resulting in 
potent APC maturation. We also show that co-loading R848 and the antigen OVA on the 
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particles results in augmented T cell activation. This suggests that MSNs hold great potential 
as a cancer vaccine carrier. 
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4.2. Results 
Synthesis and characterization of MSN-Avidin particles 
Core-shell functionalized MSNs were prepared via a modified site-specific co-condensation 
approach with cetyltrimethylammonium chloride (CTAC) as organic template and 
tetraethylorthosilicate as primary silica source.
35
  
 
Figure 4-1. Synthesis schemes of different functionalization steps to construct avidin-capped MSNs. Particle 
represents co-condensed core-shell MSNs. Green core: phenyl functionality. Blue intermediate layer: Pure 
TEOS. Red external surface: Carboxylic moieties. (A) EDC coupling reaction of acetal linker to carboxylic 
functionalized MSNs. (B) Covalent attachment of biotin to residual amine groups of acetal linker via EDC-
assisted amidation reaction. (C) Avidin (green) capping of pores (grey) via formation of strong avidin-biotin 
complex (scheme from Schlossbauer et al.
37
). 
The core of the particles was functionalized with phenyl groups to accommodate hydrophobic 
R848 and the external surface was functionalized with carboxylic groups, allowing for 
successive modifications to attach a stimuli-dependent capping system, consisting of a pH-
responsive acetal linker and a biotin-avidin complex as bulky gatekeeper.  
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In the first step of subsequent core-shell MSN modification, shown in Figure 4-1 A, the pH-
responsive acetal linker (AK) is covalently bound to the carboxylic-functionalized periphery 
of the particles via an EDC-assisted amidation reaction. This step is followed by a second 
EDC-coupling between the residual amine-group of the attached acetal linker and the COOH-
group of biotin (Figure 4-1 B). Capping of the pores is achieved through non-covalent 
attachment of avidin through formation of the biotin-avidin complex. This interaction is the 
strongest known non-covalent link between a protein and its ligand and shows a dissociation 
constant of Kd = 10
-15
 M.
38
 Avidin possesses four binding sites for biotin, therefore, it is 
added in great excess to avoid any cross-coupling reaction between two or more different 
particles. With its dimensions of 5 x 5 x 4 nm
3
, avidin is big enough to completely block the 
3.2 nm pore.
39
 The concept is shown in Figure 4-1 C.
37
 
The transmission electron microscope (TEM) image of the template-free core-shell MSNs 
shows spherical particles with sizes of around 70 nm and a wormlike pore structure (Figure 
4-2A). Dynamic light scattering measurements (DLS) reveal colloidally stable particles with a 
narrow particle size distribution (Figure 4-2 B). Particle sizes obtained with this method show 
a mean value of 146 nm (hydrodynamic diameter) for the core-shell MSNs MSN-Phin-
COOHout. Functionalization with acetal linker and biotin shows only a moderate increase in 
size up to a mean value of 183 nm. DLS measurements of avidin-capped particles in aqueous 
solutions demonstrate a shift to higher sizes of around 280 nm. This can be explained by the 
attachment of the bulky protein as well as a small agglomeration effect. The difference in the 
sizes measured by TEM and DLS can be partially attributed to the larger hydrodynamic radius 
of the particles measured in solution and determined with DLS. Some additional 
agglomeration effect may also contribute to the increased size in DLS. Additionally, in a 
former paper by Cauda et al. it was shown that DLS leads to a systematic overestimation of 
size compared to techniques like TEM, SEM and FCS.
40
 Sorption measurements reveal an 
Results 
112 
 
average pore size of around 3.2 nm and large surface areas (1006 m
2
/g for MSN-Phin-
COOHout) which are typical for MSNs (Figure 4-2 C). The respective values for the 
functionalized samples are shown in Figure 4-2 D.  
All samples, except MSN-Phin-Avidinout, exhibit a type IV isotherm which is typical for 
mesoporous materials. The avidin capped sample shows a type II isotherm which is assigned 
to non-porous materials and proves the successful pore closure mechanism. The Brunauer-
Emmet-Teller (BET) surface areas were calculated from the respective isotherms in the range 
p/p0 = 0.05-0.2 and are summarized in the table shown in Figure 4-2 D. The samples MSN-
Phin-COOHout, AKout, Biotinout all feature a very large specific surface area which is 
characteristic for MSNs. The decrease of BET surface area in the sample MSN-Phin-AKout to 
824 m
2
/g may be attributed to some crosslinking events through the bifunctional acetal linker. 
Additionally, electrostatic interactions between the residual amine-group of the attached 
linker and unfunctionalized carboxyl groups of the MSNs might occur. This may lead to 
minor pore blocking, apparent in the smaller BET surface area. To minimize those effects, the 
acetal linker was used in great excess in the amidation reaction. In contrast, the specific 
surface area of the sample MSN-Phin-Biotinout is with 1025 m
2
/g even higher than the BET 
area of MSN-Phin-COOHout. This effect comes supposedly from the attachment of additional 
biotin molecules to the free amine group of the linker which enlarges the overall surface area 
slightly. On the other hand, the very low specific surface area of MSN-Phin-Avidinout with 
32 m
2
/g proves the efficient pore sealing upon addition of the bulky gatekeeper avidin. The 
mean pore size of the samples MSN-Phin-COOHout was calculated to be 3.2 nm which is 
significantly smaller than the 4 nm pores which are commonly achieved with this synthesis 
route under use of smaller organosilane amounts.
35
 It is stated in literature that in contrast to 
hydrophilic organic moieties, hydrophobic organosilanes are capable of aligning with the 
organic tails of the template instead of disturbing the micelle structure.
41
 This results in 
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smaller particle sizes and also shows a pore shrinking effect in comparison to incorporation of 
other organosilanes.
35, 42-43
  
 
Figure 4-2. Characterization of functionalized MSNs. (A) TEM image of core-shell MSN-Phin-COOHout. (B) 
DLS measurements of samples MSN-Phin-COOHout (black) MSN-Phin-AKout (cyan), MSN-Phin-Biotinout 
(purple), MSN-Phin-Avidinout (pink). (C) BET isotherm and pore size distribution (inset) for clarity reasons only 
shown for sample MSN-Phin-COOHout (black) and MSN-Phin-Avidinout (pink). (D) Table summarizing results of 
N2-sorption measurements and isoelectric points (IEPs) of corresponding zetal potential measurements shown in 
(E). (E) Titration curves of zeta potential measurements of all four samples. (F) IR spectra of all four samples 
(for clarity reasons respectively shifted by a factor of 0.25). 
Concluding, the successful incorporation of a large phenyl-content is indicated by the 
calculated smaller pore sizes. Modifications of the particle’s external surface with acetal 
linker and biotin have no impact on the pore size. Therefore, the pore size distributions 
derived from NLDFT calculations for the samples MSN-Phin-AKout and MSN-Phin-Biotinout 
also show a mean pore size of 3.2 nm. This proves the spatial control over the selective 
functionalization of the external surface with little or no effect on the pore accessibility. The 
corresponding pore volumes show a slight decrease after functionalization with the acetal 
linker and biotin, respectively. This further proves the assumption of minor pore blocking 
events through crosslinking reactions as described above. All results from nitrogen sorption 
measurements are summarized in Figure 4-2 D.  
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Zeta potential measurements can be applied to monitor the different functionalization steps 
(Figure 4-2 E). MSN-Phin-COOHout shows an isoelectric point of 3.4 and a zeta potential of 
almost – 50 mV. This negative zeta potential confirms the successful implementation of 
TEPSA, including the ring opening of the succinic anhydride of the organosilane and the 
resulting two adjacent carboxyl groups. After attachment of the acetal linker, the IEP is 
shifted by almost 1.5 because of the residual amine end groups of the linker which are 
positively charged at acidic pH. MSN-Phin-Biotinout possesses an IEP of pH 5.5. This can be 
explained with the urea containing motif in biotin. Through the possible resonance forms at 
least one of the two nitrogen atoms is protonated at slightly acidic pH. Adding avidin to the 
particles results in a zeta potential of around + 20 mV and a tremendous shift in isoelectric 
point to a pH value of 9.01. This can be attributed to the large number of N-termini present in 
the protein cap. 
The different surface functionalization steps, including the capping with avidin protein, are 
also apparent in IR spectra, as shown in Figure 4-2 F. The silica framework vibrations are 
visible in all spectra in the region between 1240 and 1000 cm
-1
. Furthermore, the phenyl core 
of the MSNs is indicated in all samples by a peak at 1431 cm
-1
 (C=C stretching vibrations) 
and at 3077 cm
-1
 and 3059 cm
-1
, respectively, which indicate the aromatic C-H stretching 
vibrations of the phenyl ring. Sample MSN-Phin-COOHout shows additional peaks at 1740 and 
1720 cm
-1
 belonging to the COOH stretching vibrations of saturated dicarboxylic acids. This 
proves the successful in situ ring opening of the succinic anhydride silane TEPSA. Addition 
of acetal linker via amidation reaction results in a new vibration band at 1599 cm
-1
, which can 
be attributed to the deformation vibration of free amines, present at the unbound site of the 
difunctional linker. After biotinylation via EDC amidation, a new C=O stretching vibration 
band arises at 1658 cm
-1
 belonging to the biotin group. This peak is obscured upon avidin 
addition by the Amide I and II stretching vibrations, occurring at 1660 cm
-1
 (Amide I: C=O 
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stretching vibration) and 1640 cm
-1
 (Amide II: N-H deformation stretching vibration and C-N 
stretching vibration). 
Besides the already mentioned characterization methods, thermogravimetric analysis (TGA) 
can be used to investigate the successful functionalizations and the avidin capping step. To 
exclude the effect of physisorbed water in the samples, all TGA/DSC curves were normalized 
to 100% at 130 °C. Incorporation of a large phenyl content can be observed with a mass loss 
of 28% in the sample MSN-Phin-COOHout (Figure 4-3 A). 13% thereof can be attributed to the 
decomposition of ethoxy groups as well as to silanol condensation which can be seen in the 
comparison to unfunctionalized particles (Figure S 4-1, Equation S 1). Most aliphatic groups 
decompose in the temperature range between 130-300 °C. This is shown in Figure 4-3 B in 
the first endothermic signal at around 300 °C which can be attributed to the decomposition of 
external carboxylic groups in sample MSN-Phin-COOHout (black DSC curve).  
 
Figure 4-3. Additional characterization of successful functionalization process. (A) TGA measurement for 
sample MSN-Phin-COOHout (black) and MSN-Phin-Avidinout (pink) (heating rate: 10 K / min, flow rate of 
synthetic air: 25 mL/min). Spectra are normalized to 100% at 130 °C (B) Corresponding DSC curves of MSN-
Phin-COOHout (black) MSN-Phin-AKout (cyan), MSN-Phin-Biotinout (purple), MSN-Phin-Avidinout (pink). (C) 
Emission spectra after fluram assay of the samples MSN-Phin-COOHout, -AKout, -Biotinout. 
Furthermore, the decomposition of the AK linker can be observed in the cyan curve at 400 °C. 
The high thermal stability of the phenyl ring can be detected in all samples with a combustion 
temperature at 600 °C. This enhanced thermal stability is also observed in the biotinylated 
sample. Addition of the enzyme avidin to the MSNs leads to an even higher thermal stability, 
initiating the weight loss only at 800 °C. This may be attributed to a carbonization effect 
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which can occur during the measurement. Here, a relatively fast heating ramp is applied 
which can lead to the mentioned carbonization effect of the highly organic protein due to a 
lack of sufficient oxygen. The ‘delayed’ decomposition then results in an exothermic signal as 
can be seen in Figure 4-3 B.  
Finally, we confirmed successful functionalization by monitoring the presence of free amine 
groups in a fluram assay. Here, the dye fluorescamine, short fluram, reacts with primary 
amines to form pyrrolinone type moieties, resulting in fluorescence activity of the molecule.
44
 
As can be seen in Figure 4-3 C, fluram does not show any fluorescence when added to a 
solution of MSN-Phin-COOHout (black curve), whereas a tremendous increase in fluorescent 
counts can be seen after successful addition of the acetal linker (MSN-Phin-AKout, cyan 
curve). This can be explained with the free residual primary amine groups of the AK linker 
and proves its successful one-sided attachment to the particles. Subsequent biotinylation 
shows again a very low fluorescence of the dye. Amine groups present in the biotin structure 
cannot react with fluram as they are secondary instead of primary amines. The slightly higher 
amount of detected fluorescence in comparison to the carboxylated MSNs indicates a minor 
deviation from a complete biotin addition to all available acetal linker molecules.  
All in all, we could show that core-shell MSNs were successfully modified with a pH-
responsive acetal linker, followed by biotinylation and thus enabling pore closing via 
formation of a strong biotin-avidin complex. 
Comparison of two capping systems – PVP versus Avidin 
Previous work in our laboratory described a pH-sensitive MSN architecture with a PVP 
capping system.
45
 In a further study, we investigated the properties of amine- and PVP-
functionalized MSNs regarding their toxicity and immune-modulatory profile.
32
 It was 
demonstrated that MSNs represent a safe, non-toxic carrier system which activates the 
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immune system only to a very small extent. Furthermore, it was shown that functionalization 
with the pH-responsive PVP polymer as gatekeeper and successive loading and release with 
immune-stimulating resiquimod could represent a promising platform for future immune 
therapies. 
Due to the fact that the PVP system showed a slightly impaired release of the cargo at lower 
pH due to pore blocking by polymer, the PVP cap was compared to a biotin-avidin system. 
Here, the bulky gatekeeper is attached to the MSN periphery via a pH-responsive cleavable 
acteal linker. Upon acidification of the environment, the linker is hydrolyzed and the complete 
cap irreversibly detached. 
First, time-based fluorescence measurements in cuvette were performed to compare the 
(loading and) release efficiencies of both systems. For this purpose the loaded samples were 
put into a special teflon cap, which was successively sealed with a dialysis membrane and put 
on top of a cuvette filled with the respective buffer. Both samples open up with different pH-
dependent mechanisms in MES buffer (pH 5.5). This enables released R848 to diffuse 
through the membrane and to be detected in the cuvette by measuring its fluorescence. The 
time-based release of both samples is shown in Figure 4-4 B. Both systems show a tight 
capping with very little premature release. At pH 5.5 the MSN-Avidin system exhibits a 
strong release of R848, whereas MSN-PVP releases only a minor amount in comparison. 
For a more functional, physiological comparison of the two capping systems, a cell-based 
assay was performed. To this end, the different R848-loaded nanocarriers were investigated in 
their ability to activate antigen-presenting cells (APCs). APCs such as dendritic cells 
represent key players of the innate immune system and are potent inducers of an adaptive 
immune response when activated. Therefore, bone marrow derived dendritic cells (BMDCs) 
were incubated with the two different R848-loaded MSN particles. It is known that R848 is an 
Results 
118 
 
efficient activator of dendritic cells and leads to upregulation of co-stimulatory molecules on 
their surface as well as to production of pro-inflammatory cytokines.
46
 As shown in Figure 
4-4, BMDCs produced the pro-inflammatory cytokine interleukin-6 (IL-6) and upregulated 
the co-stimulatory molecule CD80 upon incubation with MSN-R848-Avidin. However, 
MSN-R848-PVP failed to properly induce dendritic cell activation as seen by barely 
detectable IL-6 production and absence of CD80 upregulation with the concentrations used.  
 
 
Figure 4-4. MSN-Avidin is superior to MSN-PVP as R848 carrier. Two different capping systems, PVP and 
Avidin (A), were compared in their ability to release R848 from the mesopores and thus activate dendritic cells. 
(B) The in cuvette time-based fluorescent release of R848 from MSN-Avidin or MSN-PVP was measured at pH 
7 (DPBS buffer) and pH 5.5 (MES buffer). (C) BMDCs were incubated with increasing concentrations of the 
indicated MSN particles. Lipopolysaccharide (LPS, 100 ng/mL) and R848 (200 ng/mL) were included as 
positive controls. The secretion of the cytokine IL-6 was assessed by ELISA. (D) The cell surface expression of 
the co-stimulatory molecule CD80 was determined by flow cytometry. In the graph shown the MSN 
concentration is 50 µg/mL. The mean fluorescence intensity (MFI) in live cells is expressed relative to the 
unstimulated control. 
In conclusion, the Avidin cap is far superior to the PVP cap as R848 release is significantly 
increased.  
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Optimization of the carrier system MSN-Avidin 
Choosing the matching functionalization of the nanocarrier  
Having found the optimal capping system on the outside of the particles, we next optimized 
the interior of the particles in regard of the drug’s hydrophobicity. To enable hydrophobic 
interactions between the cargo and the pores, we chose hydrophobic phenyl moieties for the 
inside. We could show that an exchange of phenyl groups to amine groups inside the pore 
almost completely prevented loading of the drug due to electrostatic repulsion. This 
underlines that the interior of the particles has a pronounced effect on drug loading efficiency 
(Figure 4-5). A second step was to identify the best buffer for the loading process of 
resiquimod (R848). R848 is mainly uncharged at physiological pH due to a pKa of about 6.7 
of its imidiazo group. The protonation of the group at lower pH leads to a better solubility in 
aqueous solution and therefore a better loading performance. Nevertheless, buffers below pH 
6.0 cannot be used with the chosen capping system due to the beginning hydrolysis of the 
acetal linker.
47
 To enable hydrophobic interaction between R848 and the phenyl moieties 
inside the pores, a buffer with antichaotropic or rather kosmotropic ions was chosen. 
According to the Hofmeister series ions are divided into kosmotropic or chaotropic depending 
on their ability to (de-) stabilize biopolymers. Kosmotropic ions are commonly being used to 
either precipitate biomolecules or enhance their adsorption onto hydrophobic chromatography 
matrices.
48-51
 The hydrophobic effect is described as the repulsion between a nonpolar 
compound and a polar environment such as water.
52
 If a hydrophobic compound is dissolved 
in aqueous solution, a forced hydration shell of highly ordered water molecules is built around 
it which is combined with a loss of entropy. If there are more hydrophobic molecules present, 
they will agglomerate quickly due to an increase of entropy. By adding salts to water, one 
changes the conditions to either favor hydrophobic interactions or to disrupt the structure of 
the surrounding water molecules and therefore decrease the hydrophobic interactions.
53
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Sodium citrate is a kosmotropic salt which, at high concentrations, enhances the hydrophobic 
interactions. Sodium chloride is quite in the middle of the Hofmeister series, showing neither 
a strong salting in nor a salting out effect. The combination of both salts can be found in the 
highly concentrated Saline Sodium Citrate (SSC) 20x buffer. As can be seen in Figure 4-5, 
SSC buffer leads to the best loading result of the phenyl functionalized MSNs.  
 
Figure 4-5. Loading in SSC20x buffer (pH 7.0) with phenyl functionalized MSNs shows the highest R848 
uptake in pores. (A) Absorption spectrum of supernatants after R848 loading in 1 M MES buffer (pH 5.5). Red 
curve shows resiquimod stock solution in MES buffer; blue curve shows supernatant after loading of resiquimod 
into MSN-NH2,in–CNout, black curve shows supernatant for MSN-Phin–CNout. Corresponding spectrum of 
supernatants after R848 loading in 0.1 M Citric Acid Phosphate Buffer (pH 4) (B), after R848 loading in HBSS 
buffer (pH 7.8) (C), after R848 loading in SSC20x (pH 7) (D). 
Experimentally the loading efficiency in each buffer was assessed by washing the particles 
once with the respective buffer and then incubating them with the same amount of the R848 
stock solution, prepared in the respective buffer. After 24 h at room temperature the particles 
were centrifuged and the supernatant measured with UV-Vis (nanodrop). To only focus on the 
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inside of the particles, the outside was functionalized with a neutral nitrile group, which 
should not interact with the cargo during the loading. As mentioned above, buffers with lower 
pH show a moderate loading behavior (Figure 4-5 A: MES buffer pH 5.5, 1 M), even at 
smaller concentrations (Figure 4-5 B: Citric Acid Phosphate (CAP) buffer pH 4, 0.1 M) due to 
the protonation of the imidazo group, whereas HBSS (Hank’s Balanced Salt Solution) buffer 
with a pH of 7.8 (Figure 4-5 C) shows no loading of R848 into the pores of both samples. All 
in all, SSC buffer with salt concentrations of 3.0 M NaCl und 0.3 M sodium citrate and a pH 
value of 7.0 showed the highest loading efficiency for both samples, and especially for the 
MSN-Phin–CNout (Figure 4-5 D).  
In conclusion, the optimized R848 delivery vehicle consists of phenyl functionalized MSNs 
with a pH-responsive acetal linker in combination with a biotin-avidin complex as capping 
system. 
Testing the optimized nanocarrier in long-term cuvette experiments 
To avoid prematurely released R848 that leads to systemic distribution, the particles must be 
tightly sealed at physiological pH and show long-term stability. To test this, we performed a 
time-based release study in two different buffers at pH 7.0 and pH 5.5, respectively. 
Subsequently, we measured both samples in parallel with a multi-cuvette holder at 37 °C for 
60 hours. To prove that the sample at pH 7.0 (blue curve Figure 4-6) was tightly sealed and 
did not lose its ability to open up at lower pH, we performed a buffer change experiment. For 
this, the membrane sealed cap with R848-loaded MSNs re-dispersed in SSC20x buffer was 
transferred after measuring for 60 hours at 37 °C to a cuvette with fresh MES buffer (pH 5.5). 
After two to three hours, the SSC buffer in the cap was completely exchanged with MES 
buffer. The resulting hydrolysis of the acetal linker could be measured with increasing 
amounts of detected R848 (dark pink curve). 
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Figure 4-6. Buffer change experiment proves long-term stability of MSN-R848-Avidin at physiological pH. 
Time-based fluorescent release of resiquimod is measured simultaneously at pH 5.5 (MES buffer, pink curve) 
and pH 7.0 (SSC buffer, blue curve) and 37 °C. After 60 h a buffer change experiment takes place, as shown in 
the pictures: Starting from the left blue box, the cap containing tightly closed MSNs at pH 7.0 is moved to a 
cuvette filled with fresh MES buffer (pH 5.5). This cuvette shown in the dark pink box on the right is put back to 
measure the time-based release at pH 5.5 (MES buffer, dark pink curve). 
Concluding, the MSN-R848-Avidin system proved long-term stability and efficient release. 
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Uptake of MSN into lysosomes of antigen-presenting cells 
For the success of our pH-responsive drug-carrier system, it is important that the particles are 
efficiently taken up by antigen-presenting cells and accumulate in the acidic environment of 
the lysosome to ensure targeted drug-release. To investigate if our MSN-Avidin particles 
indeed end up in the lysosome of antigen-presenting cells, fluorescently labeled MSNs were 
added to a macrophage cell line (J774A.1) and analyzed by live cell imaging. To be able to 
see co-localization, we stained the lysosomes with LysoTracker. Uptake of MSNs into the 
cells was already visible 20 min after addition of the nanoparticles. After 30-40 min, a clear 
co-localization between the blue-stained lysosomes and the red-labelled MSNs was apparent, 
recognizable by the pinkish color where lysosomes and MSNs overlap (Figure 4-7 A). 
In order to examine the uptake of MSNs in primary cells, freshly isolated lymph node cells 
and splenocytes were incubated with different concentrations of Atto633-labelled MSNs. As 
shown in Figure 4-7 B (and Suppl. Figure S 4-3), the particles were readily taken up by DCs 
(characterized as CD19
-
CD3
-
CD11c
+
 cells) in a concentration-dependent manner. This uptake 
was so efficient that at higher MSN concentrations a total of 80% of all dendritic cells were 
MSN
+
. 
Besides the uptake, it is also important to assess whether the pH-responsive MSNs are safe to 
use as drug-carrier systems. Therefore, their cytotoxicity was examined on freshly isolated 
lymph node cells and splenocytes in vitro with the help of a Zombie dye. Zombie dyes react 
with primary amine groups on proteins. Therefore, the staining appears brighter in dead cells 
as the dye can enter through the disrupted cell membrane and label cytoplasmic proteins. For 
up to 100 µg/mL of our MSNs, we could not observe any toxic effect on these cells (Figure 
4-7 C and Suppl. Figure S 4-3), and this was also true for J774A.1 macrophages and BMDCs 
(data not shown). 
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Figure 4-7. MSNs are taken up into the lysosome of antigen-presenting cells. (A) J774A.1 macrophages were 
stained with LysoTracker (blue) and MSN-Atto633 (red) were added to the cells at time point 0 min. Images 
were taken every 10 min. (B, C) Mouse lymph node cells were incubated with increasing concentrations of 
MSN-Atto633 for 24 h and analyzed by flow cytometry. Dead cells were excluded with the help of a Zombie 
dye and the dendritic cell population was characterized by CD19
-
CD3
-
CD11c
+
 cells. The graphs show the mean 
and SD of minimum three independent experiments. 
All in all, our MSNs did not show any cytotoxicity in the concentration range used and were 
readily taken up by antigen-presenting cells of the immune system.
32
 Therefore, our system 
fulfills all the basic requirements for a promising drug delivery vehicle. 
Successful activation of dendritic cells with MSN-R848 
Dendritic cells are among the most potent antigen-presenting cells and patrol the body in 
search for pathogens or aberrant cells. Upon encounter with one of these, DCs will mature and 
become activated. This will result in the expression of high levels of MHC-peptide complex 
and co-stimulatory molecules as well as secretion of pro-inflammatory cytokines, all of which 
are pre-requisites for a successful induction of adaptive immune responses. 
To evaluate the optimized R848 loading and release efficiencies of our avidin-system, we 
investigated their effect on the activation of APCs. To this end, we incubated BMDCs with 
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different concentrations of R848-loaded MSN and compared their response to the effect of a 
corresponding amount of free R848 and unloaded MSN. MSN-R848 induced secretion of 
high amounts of IL-6 and IL-12p40 (Figure 4-8 A) and led to upregulation of the co-stimulatory 
molecules CD80 and CD86 and of the MHC I complex (Figure 4-8 B). The unloaded MSN did 
not show any cell activating properties. Importantly, the supernatant coming from the spun 
down MSN-R848 induced only very low levels of IL-6 production in BMDCs. This indicates 
that the particles were quite stable even in cell culture conditions and only released 
vanishingly small amounts of R848 pre-maturely. 
Figure 4-8. R848-loaded MSN successfully activate dendritic cells. BMDCs were incubated with increasing 
concentrations of MSN-R848. The amount of MSN-R848 was calculated with the help of R848-release 
measurements and an equimolar amount of loaded or free R848 was used. (A) The secretion of the cytokines IL-
6 and IL-12p40 was measured in the cell culture supernatants by ELISA. (B) The cell surface expression of the 
MHC I complex and of the co-stimulatory molecules CD80 and CD86 was assessed by flow cytometry. The 
mean fluorescence intensity (MFI) in live cells is expressed relative to the unstimulated control. (C) BMDCs 
were incubated with supernatants (SN) coming from different MSN batches for 24 h. The amount of SN 
corresponded to the same amount of MSN that would be necessary to reach 50 ng/mL R848. The IL-6 
production was measured in the cell culture supernatants by ELISA. The graphs show the mean and SD of 
minimum four independent experiments. 
 
In conclusion, we developed a system that can efficiently deliver the immune-stimulant R848 
to antigen-presenting cells and induce a robust immune response – measured by the 
upregulation of cytokine production, expression of costimulatory molecules and MHC I 
complex in dendritic cells.  
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Co-loaded MSN-R848-OVA particles enhance T cell proliferation  
Potent activation of dendritic cells is important to induce a powerful cytotoxic T cell response. 
T cells are part of the adaptive immune system and can directly kill infected or cancerous 
cells when activated. Activation of T cells happens when they recognize a specific antigen 
presented by the MHC complex on APCs with proper co-stimulation. These antigen-specific 
T cells will then proliferate to fight the cells that express the recognized antigen. Cancer 
vaccines take advantage of this phenomenon by using a tumor-specific antigen in combination 
with an adjuvant to induce a strong T cell response. In order to improve our delivery system 
and induce a more directed, specific immune response, we attached the model antigen 
ovalbumin to the capping system avidin. Here, we used the peptide SIINFEKL (OVA peptide) 
instead of the whole protein, because the peptide usually results in a higher selectivity due to a 
limited number of possible epitopes. From now on, the short-form “OVA” stands for the 
OVA peptide.  
To study how our new MSN-R848-OVA system performs in inducing activation and 
proliferation of T cells, we co-cultured BMDCs, stimulated with R848- and/or OVA-loaded 
particles, with OVA-specific T cells. To follow proliferation, T cells were labelled with the 
fluorescent dye CFSE (5-(and 6)-carboxyfluorescein diacetate succinimidyl ester). CFSE 
passively diffuses into cells and covalently links to intracellular molecules which leads to its 
dilution with each cell division. Therefore, lower presence of CFSE means that the T cells 
proliferated. As shown in Figure 4-9 A, over 80% of the T cells proliferated when incubated 
with MSN-R848-OVA-stimulated BMDCs. Importantly, this was considerably more than 
with “MSN-R848 plus free OVA” or with “free R848 and free OVA”. Furthermore, activation 
of T cells - measured by the upregulation of CD25 – was also most pronounced when 
incubated with MSN-R848-OVA stimulated BMDCs. 
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Figure 4-9. MSN-R848-OVA particles induce T cell proliferation and activation in vitro. BMDCs were exposed 
to different combinations of R848- and/or OVA peptide-loaded MSN. The amount of MSN-R848 used was 
equimolar to 50 ng/mL R848; free OVA peptide was used at a concentration of 10 ng/mL. After 24 h, OVA-
specific, CFSE-labeled CD8+ T cells were added to the BMDCs and co-cultured for another 2-3 days. (A) 
Proliferation of T cells was determined by analysis of CFSE expression (CFSElow) with flow cytometry. (B) 
Activation of T cells was assessed by the surface expression of CD25. The MFI in live CD8+ T cells is 
expressed relative to the unstimulated control. The graphs show the mean and SD of two independent 
experiments. 
 
In conclusion, MSN-R848-OVA stimulated dendritic cells induced a potent cytotoxic T cell 
response and seem to be promising vaccine carriers. 
Biodistribution of MSN-Avidin in mice 
After proving the potential of pH-responsive MSN in vitro, we investigated their safety and 
biodistribution in vivo. C57BL/6 mice were injected sc. with fluorescent Atto633-labelled 
MSN or PBS and left for 14 days with daily assessment of weight and behaviour. In this time 
period, the mice did not show any toxicity signs and gained weight comparable to the control 
group (Suppl. Figure S 4 4). 
For the biodistribution evaluation, mice were analyzed one day after MSN-Atto633 injection 
(Figure 4 10 A). The ipsilateral inguinal and axillary as well as the contralateral inguinal 
lymph nodes (LNs) and the spleen were investigated for MSN-Atto633+ cells by flow 
cytometry (Figure 4 10 B). Unsurprisingly, we found the highest amount of MSN+ cells in the 
ipsilateral inguinal lymph node (iLN), which is the draining lymph node for the injection site 
(Figure 4 10 C). Few mice also showed MSN+ cells in the ipsilateral axillary LN. However, 
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these mice had less MSN+ cells in the iLN, which led us to the conclusion that a slight 
variation in the injection site could have turned the axillary LN to the first draining LN 
 
Figure 4-10. MSNs are mainly found in the draining lymph node in migratory DCs. (A) 1 mg of Atto633-labeled 
MSNs were subcutaneously injected into the right hind limb of mice and analyzed after 24 h. (B) Ipsilateral and 
contralateral lymph nodes and spleens were analyzed by flow cytometry (the scheme was adapted from Dunn, 
T.B. 1954).
54
 (C) The amount of MSN-Atto633
+
 cells in the different organs was compared to the control group 
(PBS). (D) The uptake of MSN-Atto633 was analysed in different cell populations: B cells (CD45
+
CD3
-
CD19
+
), 
resident DCs (CD45
+
CD3
-
CD19
-
CD11c
+
MHCII
low
), migratory DCs (CD45
+
CD3
-
CD19
-
CD11c
+
MHCII
high
). The 
graphs show the results of three independent experiments. 
 
In all mice, we consistently found that the contralateral lymph node and the spleen did not 
show any MSN-Atto633+ cells after 24 h. Further analyzing the different cell populations in 
these organs, we could see that mainly migratory DCs (CD19-CD3-CD11c+MHCIIhigh) in 
the ipsilateral iLN took up the MSNs (Figure 4 10 D). As the avidin-capped MSNs with a 
particle size of around 280 nm are too large to be drained with the interstitial flow to 
lymphoid organs from the injection site, it came as no surprise to find them predominantly in 
migratory dendritic cells. Thus, MSNs are taken up by patrolling dendritic cells and brought 
to the next draining lymphoid organ, in our case mostly the ipsilateral inguinal lymph node. 
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4.3. Discussion and Conclusion 
In this study, we developed a tight pH-responsive drug delivery system for the TLR7/8 ligand 
R848 that induced potent immune activation. By comparing a reversibly working polymer 
capping system that opens and closes upon pH-dependent (de-) protonation of the PVP group 
with an avidin closure mechanism triggered by the hydrolysis of the acetal linker at lower pH, 
we were able to show that irreversible detachment of the bulky protein gatekeeper leads to 
enhanced drug release. Furthermore, we demonstrated that correctly tailoring the 
multifunctional MSNs enables augmented loading of the hydrophobic drug R848. For this 
purpose, we performed a delayed co-condensation approach, developed in our group, to 
introduce phenyl groups solely into the pores.
42
 It was proven before that this synthesis 
procedure allows spatial control over incorporated organic moieties.
35
 Delayed 
functionalization of the exterior surface in the same synthesis procedure with carboxylic 
groups allowed for further modification with a pH-responsive acetal linker and the respective 
biotin-avidin capping system. The pH-dependent hydrolysis of the linker, already shown in 
literature, enables stimuli-responsive opening of the pores.
47
 This stimulus is of particular 
interest in the project described here due to the fact that MSN are taken up into dendritic cells. 
This uptake occurs as energy-dependent endocytosis because of the nanoparticles’ size of 
280 nm as also shown by Vallhov et al..
55
 The pH in the endosome drops to a value of pH 5.5 
when it fuses with the lysosome. It thereby triggers the cleavage of the applied acetal linker, 
inducing the pore opening and therefore also drug release through complete detachment of the 
bulky biotin-avidin complex.
56
 Besides closing the drug loaded pores tightly, capping of the 
MSNs with the protein avidin also leads to improved particle-cell interactions. As shown by 
van Rijt et al., avidin coating of the MSNs leads to enhanced biocompatibility.
57
 Compared to 
amine-functionalized MSNs which were shown to exhibit a strong protein corona formation, 
avidin coating of the particles minimizes this effect and the subsequent clearance by 
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macrophages.
58
 Furthermore, Zhang et al. reported that anionic vaccines were not taken up by 
APCs due to the repulsion of negatively charged particles and negatively charged 
phospholipid bilayers of the cell membranes.
59
 The dramatic change in surface charge after 
addition of avidin to the MSNs, as seen by a shift in zeta potential from – 50 mV (MSN-Phin–
COOHout) to + 20 mV (MSN-Phin–Avidinout), enables an attractive and not repulsive particle-
dendritic cell interaction and thus facilitates the uptake by APCs. Successful uptake of avidin-
coated MSNs in antigen-presenting cells in vitro was already observed within 30 min, proving 
the positive influence of the protein capping system. Furthermore, we could show that our 
MSN system was also preferably taken up by APCs in vivo. After subcutaneous injection of 
the particles into mice, they were mainly found in migratory dendritic cells in the draining 
LN. As the size of the MSNs prevents them from draining freely to the closest lymphoid 
organs, an entrapment of MSNs, consisting of all MSNs that were not yet taken up by cells 
under the skin could still be observed after 24 h. This depot effect could be beneficial in a 
clinical setting with loaded particles. It would ensure the continuous uptake of the particles by 
migratory dendritic cells, which would lead to a prolonged immune cell activation in the 
lymph node beyond 24 h. Yet the balance between a stronger, continuous immune response 
and the induction of immune tolerance will have to be closely investigated in future 
experiments. 
When OVA peptide and R848 were co-loaded into the MSNs, we could demonstrate that 
potent T cell activation and proliferation was induced. As previously shown, simultaneous 
delivery of both adjuvant and antigen to the same cell increases the potency of a vaccine.
60
 
This phenomenon is also apparent with our MSN-R848-OVA particles and underlines the 
great potential of MSNs as combined carrier system for both adjuvant and antigen. In this 
work, we used only the OVA peptide as a model antigen. However, the system is easily 
adaptable and other antigens could be attached to avidin. This means that even several 
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different tumor-specific antigens could be loaded onto the MSNs to achieve a stronger anti-
tumor effect.
61-65
 Furthermore, the MSNs could also accommodate patient-specific tumor-
antigens to generate a “personalized” MSN vaccine carrier system. The adjustability of the 
pore size of mesoporous silica particles also enables loading of larger antigen proteins. This 
was shown by Cha et al., who successfully delivered the complete OVA protein in 
combination with a TLR-9 adjuvant in extra-large pore MSNs.
66
 It has to be noted that 
antigen and adjuvant were both loaded via electrostatic interactions into randomly amine-
functionalized particles without additional capping system. This may cause premature release 
and therefore systemic activation or enhanced protein corona formation and thus rapid 
clearance of the particles before they reach dendritic cells. Our spatially controlled synthesis 
of core-shell MSN with a multifunctional capping system can overcome these problems. 
In sum, we were able to demonstrate that MSNs hold considerable promise as a carrier system 
for the immune-stimulant R848. They display significant adjustability and flexibility which 
allows for simultaneous delivery of adjuvant and antigen and the specific generation of an 
enhanced T cell response. Our tight pH-responsive system thus shows great potential as a 
successful cancer vaccine in future therapies, enabling advantageous local immune activation 
while preventing adverse systemic events.  
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4.4. Experimental Part 
Materials. All reagents were purchased from commercial suppliers. Tetraethyl orthosilicate 
(TEOS, Sigma-Aldrich, >98%), cetyltrimethylammonium chloride (CTAC, Fluka, 25wt% in 
H2O), triethanolamine (TEA, Sigma-Aldrich, 98%), triethoxyphenylsilane (PhTES, Sigma-
Aldrich, 98%), 3-(triethoxysilyl)propylsuccinic anhydride (TEPSA, ABCR, 60-70%), 3,9-
bis(3-aminopropyl)-2,4,8,10-tetraoxaspiro[5.5]undecane (AK linker, TCI, ≥ 98%), biotin 
(Sigma-Aldrich, ≥99%), avidin, egg white (Merck Millipore, ≥10 units/mg protein), (3-
aminopropyl)-triethoxysilane (APTES, Fluka, 95%), N-(3-dimethylaminopropyl)-N-
ethylcarbodiimide hydrochloride (EDC, Sigma-Aldrich, 97%), ammonium nitrate (Sigma-
Aldrich, 99%), conc. hydrochloric acid (Sigma-Aldrich, >95%, 37 wt%), α-amino-ω-carboxy 
terminated poly(2-vinylpyridine) (NH2-PVP-COOH, Polymer Source, Mn = 10.000, PDI = 
1.08), Boc anhydride (Aldrich, 95%), N-hydroxysulfosuccinimide sodium salt (sulfo-NHS, 
Sigma-Aldrich, 98%), ethanol (EtOH, Sigma-Aldrich, >99.5%), tetrahydrofuran (THF, 
anhydrous, Sigma-Aldrich, ≥99.9%), trifluoroacetic acid (TFA, Acros Organics, 99%), 
magnesium sulfate (MgSO4, anhydrous, Sigma-Aldrich, ≥99.5%), triethylamine (Sigma-
Aldrich, ≥99%), saline-sodium citrate buffer concentrate (SSC-buffer (20x), Sigma-Aldrich), 
2-morpholinoethanesulfonic acid hydrate (MES hydrate, Sigma-Aldrich, ≥99,5%), 
fluorescamine (Fluram, Sigma-Aldrich, ≥99%), TLR-7/8 agonist resiquimod (R848, Enzo, 
≥98%), OVA 257-264 peptide (chicken egg albumin, Invivogen, ≥95%), 2-iminothiolane 
hydrochloride (Sigma-Aldrich, ≥98%), alpha-maleimido-24(ethylene glycol)-omega-
propionic acid succinimidyl ester (mal-dPEG(24)-NHS, Iris Biotech GmbH). All chemicals 
were used as received without further purification. Doubly distilled water from a Millipore 
system (Milli-Q Academic A10) was used for all synthesis and purification steps. 
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Preparation of MES buffer (0.1 M, pH 5.5). 2-(N-Morpholino)ethanesulfonic acid (MES, 
9.76 g) was dissolved in 500 mL water. The pH was adjusted to 5.5 using sodium hydroxide 
(1 M). 
Synthesis procedures. 
Polymer-capped MSNs (MSN-PVP) were synthesized and loaded with R848 as previously 
described.
33,
 
32, 34
  
Preparation of core-shell-functionalized colloidal mesoporous silica nanoparticles 
(MSN-Phin-COOHout). Core-shell functionalized MSNs were synthesized according to a 
slightly modified synthesis approach as previously reported.
35
 In detail, a mixture of tetraethyl 
orthosilicate (TEOS, 1.62 g, 7.79 mmol) and triethoxyphenylsilane (PhTES, 0.45 g, 
1.86 mmol) was added as a layer on top of triethanolamine (TEA, 14.3 g, 95.6 mmol) and 
heated without stirring at 90 °C for 20 min in a polypropylene reactor. Subsequently, a 
solution of cetyltrimethylammonium chloride (CTAC, 2.41 mL, 1.83 mmol, 25 wt% in H2O) 
and ammonium fluoride (NH4F, 100 mg, 2.7 mmol) in water (21.7 g, 1.21 mmol) preheated to 
60 °C was quickly added and the reaction mixture vigorously stirred (700 rpm, 20 min) while 
cooling down to room temperature. Afterwards, four equal portions of TEOS (192.2 mg in 
total, 0.922 mmol) were added every 3 min and the reaction mixture was allowed to stir for 
another 30 min at room temperature. In the end, TEOS (38.3 mg, 184 µmol) and 3-
(triethoxysilyl)propylsuccinic anhydride (TEPSA, 56.2 mg, 184 µmol) were added and the 
resulting mixture allowed to stir overnight at room temperature. In the following, MSNs were 
collected by centrifugation (43,146 rcf, 20 min) and re-dispersed in absolute ethanol. 
Subsequent template extraction of the MSNs was performed in 100 mL ethanolic solution, 
containing ammonium nitrate (NH4NO3, 2 g), under reflux heating at 90 °C for 45 min. After 
centrifugation (7179 rcf, 15 min) and re-dispersion in ethanol, the described extraction was 
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performed a second time. Finally, the MSNs were collected by centrifugation (7179 rcf, 
15 min) and washed with 100 mL absolute ethanol, resulting in the sample MSN-Phin–
COOHout. 
AK linker attachment (MSN-Phin–AKout). 50 mg MSN-Phin–COOHout were collected by 
centrifugation (7179 rcf, 15 min) and re-dispersed in 70 mL of a 1:1 = EtOH:HBSS buffer 
solution. Subsequently, N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride 
(EDC, 20 µL, 114.4 µmol) was added under vigorous stirring of the particle solution. 
10 minutes later, N-hydroxysulfosuccinimide sodium salt (sulfo-NHS, 2.6 mg, 12 µmol) was 
added and the reaction mixture allowed to stir five more minutes at room temperature. 
Afterwards, the acetal linker 3,9-bis(3-aminopropyl)-2,4,8,10-tetraoxaspiro[5.5]undecane 
(AK linker, 917 µL (55 mg, 0.20 mmol) from stock solution with c = 60 mg/mL in 1:1-
EtOH:HBSS-mixture) was added dropwise to the solution and the resulting mixture was 
allowed to stir overnight (700 rpm, room temperature). Particles were collected by 
centrifugation (7179 rcf, 15 min) and washed twice with absolute ethanol (50 mL). 
Biotin functionalization (MSN-Phin–Biotinout). Biotin (6 mg, 24.6 µmol) was dissolved in a 
DMSO/EtOH mixture (500 µL DMSO, 2.5 mL EtOH). Subsequently, EDC (6 µL, 34.3 µmol) 
was added under vigorous stirring, followed by sulfo-NHS (0.78 mg, 3.6 µmol). Then, 30 mg 
of MSN-Phin–AKout, re-dispersed in 40 mL ethanol, was added dropwise to the solution. The 
reaction mixture was allowed to react overnight (700 rpm, room temperature). Particles were 
collected by centrifugation (7179 rcf, 15 min) and washed likewise twice with absolute 
ethanol (50 mL). 
Avidin coating (MSN-Phin-Avidinout). 2 mg MSN-R848-Biotin was centrifuged (5500 rcf, 
4 min, 15 °C) and re-dispersed in 400 µL avidin solution (c=10 mg/mL). The reaction mixture 
was allowed to react under dark and static conditions at room temperature overnight. The 
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resulting particles (MSN-Phin-Avidinout) were extensively washed with SSC20x buffer (pH 
7.0) and centrifuged (5500 rcf, 4 min., 15 °C) until no absorption was detected in the 
supernatant. 
Attachment of OVA peptide to avidin cap (MSN-Phin-OVAout). A solution with 1 mg of 
the R848-loaded MSN-Avidin was centrifuged (5500 rcf, 4 min., 15 °C) and the solid was 
redispersed in 500 µL DPBS buffer. In the meantime, 2-iminothiolane hydrochloride (0.4 mg, 
2.9 µmol) was added to a solution of 50 µL of OVA peptide (c = (OVA-Stock) = 1 mg/mL in 
bi-distilled water) in 450 µL DPBS buffer. The mixture was allowed to react for 1 h at room 
temperature under static conditions. Afterwards, the hetero-bifunctional PEG-linker 
mal-PEG(24)-NHS (0.6 mg, 430 µmol) was added and the reaction mixture allowed to react 
another hour at room temperature without stirring. The activated OVA-PEG-linker was 
successively added to the MSN solution and the mixture was allowed to react one more hour 
(static conditions). Subsequently, the OVA-functionalized particles were washed three times 
with DPBS buffer (5500 rcf, 4 min., 15 °C).  
Labeling of MSNs with covalently attached Atto-dyes. 1 mg of MSN-SHin-Biotinout was 
redispersed in 1 mL ethanol and 5 µL Atto633-maleimide (or alternatively Atto488-mal) was 
added. The reaction mixture was allowed to react overnight at room temperature in the dark 
under static conditions. Subsequently, the labeled particles were washed three times with 
ethanol (1 mL EtOH, 14000 rpm, 5 min, RT) and one time with SSC20x buffer before avidin 
was added to the solution (as described above). Labeled particles were used for uptake and 
biodistribution studies. 
Characterization of MSNs. Centrifugation was performed using a Sigma 3-30KS equipped 
with a fixed-angle rotor 12310 or an Eppendorf centrifuge (5430 for volumes up to 50 mL or 
5418 for small volumes). Samples were investigated with a Tecnai G2 20 S-Twin 
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transmission electron microscope operated at 200 kV with a bright field detector. A droplet of 
the diluted MSN solution in absolute ethanol was dried on a carbon-coated copper grid at 
room temperature for several hours. Nitrogen sorption measurements were performed on a 
Quantachrome Instruments NOVA 4000e. In general, samples (15 mg each) were heated to 
60 °C for 12 h in vacuum (10 mTorr) to outgas them before nitrogen sorption measurements. 
MSN-Phin–Avidinout was the only sample which was outgassed at room temperature for 12 h 
in vacuum (10 mTorr). Subsequent nitrogen sorption measurments were performed at 77 K. 
Pore size and pore volume were calculated by a NLDFT equilibrium model of N2 on silica, 
based on the adsorption branch of the isotherms. Pore volumes were calculated only up to a 
pore size of 8 nm to avoid contributions of interparticle textural porosity. The specific surface 
area of the samples was determined with a BET model applied in the range of 0.05 – 
0.20 p/p0. Dynamic light scattering (DLS) measurements were performed on a Malvern 
Zetasizer-Nano instrument equipped with a 4 mW He-Ne laser (633 nm) and an avalanche 
photodiode. To determine the hydrodynamic radius of the particles, 100 µL of an ethanolic 
MSNs suspension (ca. 10 mg/mL) was diluted with 3 mL of ethanol prior to the DLS 
measurement. The sample MSN-Phin–Avidinout was respectively measured in water. Zeta 
potential measurements of the samples were performed on a Malvern Zetasizer-Nano 
instrument equipped with a 4 mW He-Ne laser (633 nm) and an avalanche photodiode using 
the add-on Zetasizer titration system (MPT-2) (based on diluted NaOH and HCl as titrants). 
For this purpose, particles were diluted in 10 mL bi-distilled water to achieve a final MSN 
concentration of 0.1 mg/mL. Thermogravimetric analysis was performed on a Netzsch STA 
440 C TG/DSC with a heating rate of 10 K / min in a stream of synthetic air of about 25 
mL/min. The mass was normalized to 100% at 130 °C for all samples to exclude the influence 
of solvent desorption. A Thermo Scientific Nicolet iN10 IR-microscope was used to record 
infrared spectra of dried sample powders in reflection-absorption mode with a liquid-N2 
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cooled MCT-A detector. UV-Vis measurements with 2 µl of the samples were performed on a 
NanoDrop 2000c spectrometer from Thermo Scientific Fisher. Time-based fluorescence 
release experiments were performed at 37 °C on a PTI spectrofluorometer equipped with a 
xenon short arc lamp (UXL-75XE USHIO) and a photomultiplier detection system (Model 
810/814) with λex = 323 nm and λem = 342 nm. Emission scans of fluorescent samples and 
corresponding calibration curves were measured at room temperature with λex = 323 nm and 
λem = 335-355 nm. 
Fluram assay. 2.5 mg particles from ethanolic solution were washed one time with MeOH 
and subsequently redispersed in 2 mL MeOH. Subsequently, 1 mL of a freshly prepared 
Fluram solution (6.957 mg in 5 mL MeOH, 5 mM) was added and the mixture vigorously 
shaken and vortexed for 2 minutes. Immediately afterwards, samples were measured with 
fluorescence spectroscopy (λex = 420 nm, λem = 440-540 nm). 
Release experiments. 
Drug loading. 2 mg MSN-Phin–Biotinout was washed once with SSC20x buffer, followed by 
re-dispersion in 500 µL R848 stock solution (consisting of 50 µL resiquimod (c=10 mg/mL) 
in 450 µL SSC20x buffer (pH 7.0)), yielding an overall drug concentration of 1 mg/mL in the 
loading solution. The particles were shaken for 1 h (thermoshaker, 600 rpm, room 
temperature), centrifuged, washed 5 times with SSC20x buffer and re-dispersed in 400 µL 
avidin solution (c = 10 mg/mL in SSC20x buffer) to trigger closure of the pores by biotin-
avidin complex formation. The resulting particles (MSN-Phin-Avidinout) were extensively 
washed with SSC20x buffer (pH 7.0) until no absorption was detected in the supernatant. For 
in vivo experiments, MSNs were re-dispersed in SSC20x buffer at a concentration of 
10 mg/mL. 
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Time-based fluorescence release experiments in cuvette. A sample of 1 mg R848-loaded 
MSNs re-dispersed in 1 mL SSC20x buffer was split into two and centrifuged (5500 rcf, 4 
min., 15 °C). One half (0.5 mg MSNs) was re-dispersed again in 200 µL SSC20x buffer (pH 
7.0), the other half in 200 µL MES buffer (pH 5.5). Afterwards, the MSNs (200 µL each) 
were transferred to custom-made caps which were sealed with a dialysis membrane (ROTH 
Visking type 8/32, MWCO 14,000 g/mol) and put on top of a disposable PMMA cuvette (UV 
grade). The cutoff molecular weight of the dialysis membrane is too low for MSNs and the 
detached biotin-avidin complex, meaning only released resiquimod can diffuse through the 
membrane to be measured in the cuvette. The cuvette setup can be seen in Figure 4-6 (buffer 
change experiment). The pH-dependent cargo release was measured at 37 °C for 60 h (λex = 
323 nm, λem = 342 nm).  
Quantification of released resiquimod. To determine the amount of released resiquimod, 
samples were allowed to cool down to room temperature after the time-based release. 
Subsequently, emission scans were performed at 22 °C (λex = 323 nm, λem = 335-355 nm). To 
enable quantification (calibration), emission scans of concentration ranges of resiquimod in 
the respective buffers were measured under the same condition as mentioned above. Results 
were plotted and linearly fitted with Origin Pro 9.0, to be able to calculate the released 
resiquimod amounts.  
Supernatant/Loading control with UV-Vis (Nanodrop). To follow the time-dependent 
loading of resiquimod, supernatants during the loading process were measured with Nanodrop 
(2 µL sample, blank: corresponding buffer). Furthermore, the successful washing procedure 
was monitored by measuring the decreasing absorption of the washing supernatants. 
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Biological assays. 
Uptake of MSN by antigen-presenting cells. J774A.1 macrophages (ATCC, TIB-67) were 
plated at a concentration of 5*10
4
 cells/well on a Lab-Tek chamber plate (Nunc) in high 
glucose (4.5 g/L) DMEM (Biowest) supplemented with 10% FBS (MP Biomedicals), 2 mM 
L-Glutamine (Corning, Fisher Scientific), 1 mM Sodium pyruvate (Gibco) and 0.5% 
Ciprofloxacin (Bayer). After overnight incubation at 37 °C, the cells were stained with 
LysoTracker
TM
 (Blue DND-22, life technologies) for 1 h at a final concentration of 50 nM. 
Atto633-labeled MSNs (20 µg/mL) were then added directly onto the cells. Live cell imaging 
was performed using a confocal microscope (Zeiss LSM 710 Meta) with 63x magnification. 
To assess uptake into primary cells, single cell suspensions from total spleen and lymph nodes 
were used. To obtain single cell suspensions from spleens, the tissue was mechanically 
disrupted and filtered through a 40 µm cell strainer (Corning). Erythrocytes were lysed using 
Pharm Lyse™ buffer (BD Biosciences). To attain single cell suspensions from lymph nodes, 
the tissue was cut and digested in RPMI-1640 (Gibco) supplemented with 2% FBS (MP 
Biomedicals), 1x Penicillin/Streptomycin (Gibco), 10 mM HEPES (Gibco), 2 mM calcium 
chloride (Acros Organics), 3 mg/mL Collagenase IV (Worthington) and 200 U/mL DNAse I 
(Worthington) at 37 °C for 20-30 min on a shaker. After digestion, the suspension was filtered 
through a 40 µm cell strainer (Corning). Splenocytes or lymph node cells were cultured in 
RPMI-1640 (Gibco), 10% FBS (MP Biomedicals), 2 mM L-Glutamine (Gibco), 1x 
Penicillin/Streptomycin (Gibco), 1 mM Sodium pyruvate (Gibco), 1x Non-essential amino 
acids (Gibco), 50 µM 2-mercaptoethanol (Gibco) on a 96-well flat bottom plate (Greiner) at a 
density of 5*10
5
 cells/well. MSN were added at concentrations between 3-200 µg/mL to the 
cells and incubated overnight before analysis by flow cytometry. 
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Dendritic cell activation assay. Bone marrow derived dendritic cells (BMDCs) were 
generated as previously described
36
 with the only difference that cells were split 1 to 2 at day 
3. On day 6 BMDCs were seeded on a 96-well flat bottom plate (Greiner) at a density of 
1*10
5
 cells/well and stimulated with different concentrations of R848-loaded MSN, free R848 
(Enzolive), LPS (Lipopolysaccharide, Invivogen) or supernatants coming from the spun down 
MSN formulations. The amount of MSN-R848 was calculated with the help of R848-release 
measurements and an equimolar amount of loaded or free R848 was used. After 18-24 h, cells 
and culture supernatants were collected and analyzed by flow cytometry and ELISA, 
respectively.  
T cell proliferation assay in vitro. BMDCs were generated as described in the previous 
section and seeded at a density of 1*10
5
 cells/well on a 96-well flat bottom plate. Cells were 
then stimulated with different concentrations of R848- and/or SIINFEKL-loaded MSN for 
24h. SIINFEKL-specific CD8
+
 T cells were isolated from spleens coming from OT-I 
transgenic mice. For purification of CD8
+
 T cells, magnetic-associated cell sorting (MACS) 
with the CD8a
+
 T cell isolation kit (Miltenyi) was performed according to manufacturer’s 
protocol. T cells were stained with 0.5 µM CFSE (5-(and 6)-carboxyfluorescein diacetate 
succinimidyl ester, Biolegend) for 10 min at 37 °C before adding them onto the stimulated 
BMDCs at a density of 1*10
5
 cells/well in very-low endotoxin RPMI-1640 (Biochrom), 10% 
FBS (MP Biomedicals), 2 mM L-Glutamine (Gibco), 1x Penicillin/Streptomycin (Gibco), 1 
mM Sodium pyruvate (Gibco), 1x Non-essential amino acids (Gibco), 50 µM 2-
mercaptoethanol (Gibco). T cell proliferation and activation was analyzed by flow cytometry 
and ELISA after 2-3 days. 
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Quantification of cytokines. Cell supernatants were collected and analyzed for cytokine 
secretion by enzyme-linked immunosorbent assay (IL-6, IL-12p40 ELISA kits, Biolegend) 
according to the manufacturer’s protocol. 
Flow cytometry. Cell suspensions were stained in PBS (Gibco) with 0.5% BSA (Pan 
Biotech), 0.5 mM EDTA (Promega). Fc receptor block (TruStain FCX anti-mouse CD16/32), 
fluorochrome-coupled antibodies against the surface antigens CD3, CD4, CD8, CD11b, 
CD11c, CD19, CD25, CD45, CD80, CD86, MHCI, MHCII and appropriate isotype controls 
were all purchased from Biolegend. To assess cell death, a Zombie dye (Biolegend) was used 
according to manufacturer’s protocol. Cells were acquired on the flow cytometer Novocyte 
(Acea Biosciences) and analyzed using the software FlowJo V10.  
MSN biodistribution in mice. To assess the biodistribution of the particles in different 
organs, mice were injected subcutaneously (sc.) in the right hind limb with 1 mg of Atto633-
labeled MSN in a volume of 100 µl. For the control group 100 µl of PBS was injected. After 
24 h, lymph nodes and spleens were collected and organs were processed as described in 
previous sections to obtain single cell suspensions. The cells were then analyzed by flow 
cytometry. 
Mice. Female C57Bl/6 and OT-I mice (purchased from Charles River, France) were housed 
under specific pathogen-free conditions and were 6-16 weeks of age at the time of the 
experiment. All animal studies were conducted in accordance with local regulations. 
Statistics. All data sets are presented as mean + SD (standard deviation). For multiple 
statistical comparison of a data set the two-way ANOVA test with either Turkey or Sidak 
post-test was used. Significance was set at p-values p < 0.05, p < 0.01, p < 0.001, p < 0.0001 
and was then indicated with an asterisk (*, **, ***and ****). All statistical calculations were 
performed with GraphPad Prism (Version 7).   
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4.6. Appendix 
Comparison of thermogravimetric analysis data of unfunctionalized, phenylin-functionalized 
and phenylin-carboxylout-MSNs shows successful implementation of a relative phenyl content 
of 15% (Figure S 4-1).  
 
Figure S 4-1. TGA measurements of unfunctionalized MSNs (grey curve), only phenyl-functionalized MSNs 
(green curve) and MSN-Phin–COOHout (black curve). 
The additional mass loss of sample MSN-Phin–unout was used to determine the degree of 
phenyl functionalization inside the pores. This was calculated according to Equation S 1 with 
the additional mass loss of 13% for MSN-Phin–unout. The estimated degree was determined to 
be 10.4%, indicating that not all PhTES used in the synthesis was incorporated into the silica 
nanoparticles (theoretical value of organic functionalization: 17%). 
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𝑀𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 (𝑇𝐺𝐴) =
𝑥 ∙ 𝑀𝑤(′𝑝ℎ𝑒𝑛𝑦𝑙′)
𝑥 ∙ 𝑀𝑤(′𝑝ℎ𝑒𝑛𝑦𝑙′) + (100 − 𝑥)𝑀𝑤(𝑆𝑖𝑂2)
 
 
 
Equation S 1. Calculation to determine estimated percentage of incorporated phenyl groups into MSNs. x (%): 
estimated degree of organic functionalization. Mw(‘phenyl’) = 77.1 g/mol. Mw(SiO2) = 60.1 g/mol 
 
Figure S 4-2. Calibration curves of resiquimod in MES and SSC20x buffer. 
Quantification of the released amount of R848 was determined after reaching the saturation 
plateau as shown in Figure 4-6. Subsequently, emission scans of the resulting R848 
concentrations were recorded as well as concentration ranges in the respective buffers. The 
amount of released resiquimod was calculated by applying the respective linear equation 
(Figure S 4-3). 
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Figure S 4-3. Uptake and toxicity of MSN in splenocytes. (A, B) Total mouse splenocytes were incubated with 
increasing concentrations of MSN-Atto633 for 24 h and analyzed by flow cytometry. Dead cells were excluded 
with the help of a Zombie dye and the dendritic cell population was characterized by CD19
-
CD3
-
CD11c
+
 cells. 
The graphs show the mean and SD of a minimum of three independent experiments. 
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Figure S 4-4. Mice injected with MSN gained weight comparable to control group. 1 mg of MSNs were 
subcutaneously injected into the right hind limb of mice and the weight of the mice was measured at indicated 
time points over a period of 14 days. 
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Abstract 
Large-pore mesoporous silica nanoparticles (LP-MSNs) with defined particle size (< 200 nm) 
are promising carrier systems for the cellular delivery of macromolecules. Ideal nanocarriers 
should be adaptable in their surface properties to optimize host-guest interactions; thus, 
surface functionalization of the nanovehicles is highly desirable. In this study, we synthesized 
various monofunctional LP-MSNs by incorporating different organic groups into the silica 
framework via a co-condensation approach. Further, we applied a delayed co-condensation 
strategy to create spatially segregated core-shell bifunctional LP-MSNs. Diverse particle 
morphologies were obtained by adding different organosilanes to the silica precursor solution. 
The effect of organosilanes in the co-condensation process on particle size and pore structure 
formation is also discussed. Surface functional groups were then used for binding stimuli-
responsive linkers. These were finally exploited for copper-free click chemistry for cargo 
conjugation to create a delivery system with controlled cargo release. Model cargo release 
experiments in buffer using these new multifunctional LP-MSNs demonstrate their ability in 
controlled cargo uptake and release and their potential for biomolecule delivery. 
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5.1. Introduction 
Since the discovery of periodically ordered mesoporous silica MCM-41 in 1992,
1-2
 scientists 
have spent great efforts on tailoring physical and chemical properties (i.e., particle size and 
morphology, pore size and structure, surface functionalities, etc.) of mesoporous silica 
materials and have accommodated a variety of cargos in the mesopores for the study of guest-
host interactions.
3-5
 Nanosized mesoporous silica materials (mesoporous silica nanoparticles, 
MSNs) feature several favorable properties, for example, high surface area and pore volume, 
ease of surface functionalization and biocompatibility, which make them suitable nanocarriers 
for biomedical applications.
6-7
 Furthermore, mesoporous silica particles can be used as 
templates to create polymer capsules for targeted drug delivery.
8-9
In the past decade, 
multifunctional MSNs have been developed for controlled release as well as targeted delivery 
of various therapeutics such as anti-cancer drugs, antibiotics, etc. either in vitro or in vivo.
6-7, 
10
 However, most of the drug delivery tasks were achieved using small-pore (≤ 4 nm) MSNs. 
As the development of siRNA and protein therapies has dramatically advanced in recent 
years,
11-13
 the interest in developing MSNs for drug delivery purposes has turned toward 
synthesizing large pores for accommodating sizable biomolecules while simultaneously 
retaining particle sizes smaller than 200 nm for better cellular uptake or an increased EPR 
(enhanced permeability and retention) effect.
14-16
 Numerous research articles regarding the 
synthesis of large-pore MSNs with suitable particle sizes have been published in the past 
years. Recently, Zhang et al. reported a synthesis using cetyltrimethylammonium p-
toluenesulfonate (CTATos) as surfactant in near-neutral precursor solutions, resulting in 
wide-pore stellate MSNs.
17
 The pore size distribution of these stellate MSNs ranging from 10 
– 20 nm and their defined particle size of around 100 nm present an ideal platform for the 
cellular delivery of large-sized biomacromolecules. One significant achievement of this 
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synthesis method is that it can be used for large-scale production. Up to now, most of the 
reports regarding the synthesis of stellate MSNs have focused on the discussion of the pore-
forming mechanism and particle size control. While the functionalization and the influence of 
organosilanes on particle characteristics is well studied for small-pore MSNs, only few studies 
have addressed the functionalization of these stellate MSNs (either by post-synthetic grafting 
or only shell functionalization) for optimized biomedical applications
18-19
 None of them has 
discussed the impact of different organosilanes in the precursor solution on stellate particle 
morphology when undergoing silica co-condensation.  
To engineer MSNs suitable for nanomedicine, molecular surface modification offers several 
advantages: hydrophobicity or hydrophilicity as well as the surface charge can be adjusted 
towards the respective guest molecules, thus ensuring optimal uptake and release properties. 
Furthermore, a site-specific surface decoration with functional groups allows for the 
independent attachment of diverse linker or targeting molecules, thus creating multifunctional 
delivery agents. Postsynthetic grafting and co-condensation are two common methods to 
implant functional groups into the framework of MSNs. Post-synthetic grafting is more 
commonly used for functionalizing large-pore stellate MSNs because grafting does not or 
only negligibly impair the particle morphology or pore structure. However, challenges of 
post-synthetic grafting include (i) achieving site-specific localization of two or more different 
functional groups on the MSN surface and (ii) controlling the degree of functional groups 
incorporated into the silica framework. On the other hand, a co-condensation approach 
provides a facile route to attain a controlled degree and spatially selective functionalization in 
the MSN particles. In addition, the functional groups are more homogeneously distributed 
throughout the pore structure when performing a co-condensation synthesis. However, for this 
approach to result in well-defined MSNs, high concentrations and/or highly charged 
organosilanes are typically not applicable. 
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In this study, we first synthesized various monofunctionalized MSNs via the co-condensation 
approach. We discuss the prominent impact of 3-aminopropyl triethoxysilane (APTES) (when 
used together with tetraethyl orthosilicate (TEOS) as silica precursors) on the final pore 
structure and the particle size of MSNs. We further employed our delayed co-condensation 
strategy
20-21
 to synthesize site-specific (spatially selective) core-shell bi-functional LP-MSNs. 
Aza-dibenzocyclooctyne (DBCO)-derivatives were attached to the inner surface of MSNs to 
enable copper-free click chemistry reactions for the conjugation of azide-terminated cargos. 
In combination with different stimuli-responsive linkers (e.g., redox-sensitive disulfide 
bridged and pH-sensitive acetal linkers) between DBCO moieties and the MSN surface, we 
were able to control the cargo uptake and trigger the release in specific buffer solutions. We 
envision these multifunctional LP-MSNs (Scheme 1) to be promising nanocarriers for 
encapsulation and controlled release of various therapeutics in a spatiotemporal manner. 
 
Scheme 1 Schematic illustration of the multifunctional large-pore MSNs established in this study for different 
applications. 
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5.2. Results and Discussion 
Synthesis of Monofunctional MSNs via a Co-Condensation Method 
We first chose three commonly used organosilanes carrying thiol, phenyl or amino groups for 
the functionalization of MSNs. Thiol and amino groups are frequently used in secondary 
cross-linking reactions while phenyl groups are capable of increasing the hydrophobicity of 
the silica surface. The three different organosilanes 3-mercaptopropyl triethoxysilane 
(MPTES), 3-aminopropyl triethoxysilane (APTES) and phenyltriethoxysilane (PTES) were 
mixed with tetraethyl orthosilicate (TEOS), respectively, and introduced as silica precursors 
in the co-condensation procedure. A fraction between 5 % and 10 % of the total amount of 
silica was substituted by the respective organosilane (see Table 2). Un-functionalized MSNs 
(pure silica, un-MSN) were also synthesized as control group (experimental details are 
described in the section of Materials and Methods).  
According to the TEM micrographs (Figure 5-1a-c), the resulting samples un-MSN, thiol-
functionalized MSNs (MSN-SH) and phenyl-functionalized MSNs (MSN-Ph) all show a 
stellate silica framework with conical pore structure, with MSN-SH and MSN-Ph exhibiting a 
less dense central backbone and a smaller particle size than un-MSN. The SEM images 
(Figure 5-1 e-g) further illustrate the flower-shaped morphologies of these stellate MSNs 
containing irregular pores. In contrast, amino-functionalized MSNs (MSN-NH2) present a 
very different particle morphology (Figure 5-1d, 1h), i.e. a denser silica structure with small 
pores and a large particle size of around 200 nm.  
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Figure 5-1. TEM and SEM micrographs of MSNs functionalized with different organic groups. (a),(e) Un-
functionalized MSNs. (b), (f) Thiol-functionalized MSNs. (c), (g) Phenyl-functionalized MSNs. (d), (h) Amino-
functionalized MSNs. 
N2 sorption (Figure 5-2a-b) analysis indicates high surface areas (around 520 – 890 m
2
/g) and 
wide pore size distributions (3 – 30 nm) in samples un-MSN, MSN-SH and MSN-Ph (for 
detailed information, please see Table 1). In accordance with TEM images, N2 sorption 
analysis shows that both MSN-SH and MSN-Ph have wider pore size distributions and larger 
pore volumes than un-MSN. We note that the pore volume was evaluated at a relative 
pressure of p/p0 = 0.99 and includes a small contribution of textural porosity (inter-particle 
volume) due to the small particle size. The results of the N2 sorption also reveal that the 
MSN-NH2 sample has a low surface area of only 285 m
2
/g, a low pore volume and a narrow 
pore size distribution (3 – 4 nm), correlating with the TEM picture. IR spectroscopy shows the 
typical Si-O-Si asymmetric stretching vibration at 1240 – 1050 cm
-1
 (full range spectra in 
Figure S 5-1a). Additionally, an absorption band at 1629 cm
-1
 of the bending mode of water 
adsorbed on the surface of MSNs clearly appears in un-MSN, MSN-SH and MSN-NH2 
indicating that these MSNs are hydrophilic. The signals of the ring C=C stretching mode at 
1431 cm
-1
 and two aromatic ring C-H stretching modes at 3059 cm
-1
 and 3079 cm
-1
 (indicated 
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by *) can be observed in the MSN-Ph spectrum (Figure 5-2c, blue trace). Sample MSN-NH2 
(Figure 5-2 c, green trace) shows the absorbance of the symmetric NH3
+
 vibration at 1532 cm
-
1
 and of saturated primary amines at 1627 cm
-1
 (indicated by *, this band overlaps with the 
physisorbed water in MSNs).  
 
Figure 5-2. N2 sorption (a) isotherms, (b) pore size distributions and (c) IR spectra of MSNs. The signals of the 
ring C=C stretching mode at 1431 cm-1 and two aromatic ring C-H stretching modes at 3059 cm-1 and 3079 cm-
1 (indicated by *) can be observed in the MSN-Ph spectrum (blue trace). The signal at 1627 cm-1 (indicated by 
*) in the MSN-NH2 spectrum (green trace) indicates the presence of saturated primary amines. For clarity, the 
pore size distribution curves in (b) are shifted along the y-axis by a value of 0.1 and the IR spectra in (c) are 
shifted along the y-axis by 0.05. 
 
Table 5-1. Characterization of MSN samples. 
Sample 
DFT
1
 Pore size 
distribution (nm) 
Pore volume
2
 
(cm
3
/g) 
BET surface 
area (m
2
/g) 
Particle 
size
3
 (nm) 
IEP 
(pH) 
Zeta Potential at 
pH 7 (mV) 
Un-MSN 4.5 - 22 1.6 521 135 ± 53 3.6 -35 
MSN-SH 6.0 - 30 3.2 671 117 ± 52 2.3 -30 
MSN-Ph 3.5 - 22 2.4 885 50 ± 10 3.3 -28 
MSN-NH2 3.0 - 4.5 0.3 285 216 ± 56 5.6 -31 
1 Data were acquired from the adsorption branch of the isotherms. 2 The total pore volume was determined at p/p0 = 0.99. 
3 Un-MSN, 
MSN-SH and MSN-NH2 were measured by DLS, MSN-Ph was analyzed by TEM. 
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The amino groups in this sample also increased the isoelectric point (IEP) of the particles (IEP 
= pH 3.6 for un-MSN; IEP = pH 5.6 for MSN-NH2). Thiol groups of sample MSN-SH can be 
detected by Raman spectroscopy (appendix Figure S 5-1) showing the S-H stretching mode at 
2581 cm
-1
. Thermogravimetric analysis (TGA, appendix Figure S 5-2) also demonstrates the 
inclusion and the different stability of the functional groups. The decomposition of SH, Ph 
and NH2 groups can be observed in a dominant weight change at 341 °C, 631 °C and 302 °C 
in the samples MSN-SH, MSN-Ph and MSN-NH2, respectively. The TGA mass losses and 
estimated degree of organic functionalizations of the samples are listed in Table S1.
 
 
 
Figure 5-3.
 29
Si MAS-NMR spectra (a) un-MSN (direct excitation), (b) un-MSN (cross-polarized), (c) MSN-SH 
(direct excitation), (d) MSN-SH (cross-polarized). Spectra (a)- (c) were fitted with a Voigt function and spectra 
(d) with a Gauss function (fits in color, data in black). The numbers in spectra (a) and (c) represent the calculated 
relative condensation degrees.  
29
Si solid state NMR (ssNMR) measurements prove the successful integration of the organic 
groups (cross-polarized measurements) and show high condensation degrees of all four 
5. Clickable Multifunctional Large-Pore Mesoporous Silica Nanoparticles as Nanocarriers  
159 
 
samples (measured with direct excitation) (Figure 5-3 and Figure S 5-8). All spectra show 
peaks at around -110 ppm (Q
4
) and -101 ppm (Q
3
) [Q
n 
= Si(OSi)n(OH)4-n, n = 2-4], 
corresponding to fully condensed silica and silica with one terminal hydroxyl group, 
respectively. From the directly polarized spectra the relative degrees of condensation 
(percentage of Q
4
 relative to the total area following the formula Q
4
 + Q
3 
= 100%) were 
calculated to be 75% for un-MSN and 88% for MSN-SH (Figure 5-3, as well as 73% for 
MSN-NH2 and 79% for MSN-Ph, Figure S 5-8in the SI). Using indirect polarization via the 
hyperpolarization of 
1
H nuclei and subsequent 
1
H → 
29
Si cross-polarization, geminal 
hydroxyls (Q
2
) at around -92 ppm and T
n
-sites can also be observed in the spectra. Those T
n
-
sites are generated by the incorporated organosiloxanes. Their chemical shifts are commonly 
around 40 ppm higher than the ones for Q
n
-sites.
22-23
  
These results show that organosilanes can be successfully introduced into the silica 
framework of large-pore stellate MSNs via a co-condensation synthesis. MPTES and PTES 
had only a moderate influence on the stellate formation, while APTES strongly modified the 
co-condensation process, resulting in a highly divergent silica structure. Factors that affect 
particle morphology and pore structure such as surfactants, catalyst agents, ratio between 
reactants, temperature, reaction time, stirring rate, etc. are well-studied in the literature. In 
contrast, only few papers have discussed the influence of organosilanes on the MSN 
morphology.
24-25
 
Influence of Organosilanes on Pore Structure Formation 
To investigate the influence of organosilanes on the pore structure formation during co-
condensation, we measured the pH values (at room temperature) of the precursor solutions of 
all samples (Table 2).   
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Table 5-2. pH values of synthetic precursor mixtures. 
Sample Silica precursors
1
 (mol%) 
pH value of 
surfactant solution
2
 
pH value
3
 after 
silane addition 
pH value
4
 after 30 min 
of silane addition 
Un-MSN 100% TEOS 9.68 9.30 9.0 
MSN-SH 90% TEOS + 10% MPTES 9.70 9.28 9.01 
MSN-Ph 90% TEOS + 10% PhTES 9.65 9.31 9.03 
MSN-NH2 95% TEOS + 5% APTES 9.70 10.06 9.43 
1 100 mol% = 9.6 mmol. 2 Surfactant solution: 13.7 g of H2O + 0.263 g of CTATos + 0.047 g of TEA. 
3 All pH values were measured 
after 2 min of silane addition at room temperature. 4 All pH values were measured at room temperature. 
 
The surfactant solution containing CTATos, triethanolamine and water has a pH value of 
about 9.7. Upon addition of TEOS, the pH value dropped to 9.3. After stirring the reaction 
solution for 30 minutes, part of the silicon alkoxides are hydrolyzed and condensed, and the 
pH value dropped further down to 9.0. When 10 mol% of TEOS was replaced by MPTES or 
PTES, these pH values remained nearly unchanged. However, the addition of APTES led to a 
higher pH value (pH 10.06) in the reaction mixture due to the basic property of the amino 
groups. Zhang et al. proposed a mechanism for the large-pore stellate MSN synthesis: they 
propose that at near neutral conditions the counterions Tos
-
 (X
-
) compete with the negatively 
charged silicates (I
-
) for the positively charged surfactant micelles (S
+
). Consequently, more 
Tos
-
 ions are included in the silica structure resulting in less dense silica particles and larger 
pores.
17
 Following this argument we propose that the increasing pH caused by the addition of 
APTES enhances the affinity between negatively charged silicates (I
-
) and positively charged 
surfactant micelles (S
+
) and thus results in expelling the counterion Tos
-
 (X
-
). Accordingly, a 
denser particle structure with smaller pores results. Similar observations were reported in a 
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recently published paper from our group showing that CTATos does not influence the pore 
radius in comparison to the commonly used CTAC template when the synthesis was 
performed at the high pH of about 12.
21
  
In a previous publication,
26
 we demonstrated the possibility to create multiply functionalized 
or even core-shell MSN particles, the latter by performing a time-delayed co-condensation 
with more than one organosilane (e.g., APTES + PTES) at high pH. Here, we applied a 
similar strategy for incorporating either PTES and APTES or PTES and MPTES 
simultaneously in the co-condensation processes to establish dual-functionalized stellate 
particles. According to Figure S 5-3, multiply functionalized MSNs were successfully 
synthesized. The aminogroup-containing dual functionalized MSN-Ph/NH2 particles resemble 
the mono-functionlized MSN-NH2 particles in that both of them consist of a comparably 
dense silica framework with a narrow pore size distribution. The reaction solution of the 
MSN-Ph/NH2 particles still has a high pH value of about 9.92 compared to 10.06 in the 
mono-functionalized MSN-NH2
 
solution, containing only half of the amino concentration, 
likely causing again the dense silica structure. However, the smaller APTES concentration 
now results in almost twice the surface area of MSN-NH2. On the other hand, the mixed 
MSN-Ph/SH particles resemble their mono-functionalized parent samples MSN-Ph and MSN-
SH, with pore size, pore volume and particle size of MSN-Ph/SH falling between those of 
MSN-Ph and MSN-SH. 
Synthesis of Core-Shell Bifunctional Stellate MSNs Using the Delayed Co-Condensation 
Approach 
To synthesize core-shell MSNs having two functional groups precisely localized at either the 
internal or the external surfaces, we applied the delayed co-condensation procedure. 3-
cyanopropyltriethoxysilane (CPTES, 5 mol% of total silane content) was used for co-
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condensation with TEOS to generate a nitrile-containing particle core while MPTES (1 mol% 
of total silane content) and TEOS were used to generate thiol groups on the outer surface. A 
shell of pure TEOS was condensed in-between to create an interlayer between the cyano- and 
mercapto-regions. TEM and SEM micrographs (Figure 5-4 a-b) of the resulting coreCN-shellSH 
particles (MSN-CNin-SHout) show a similar stellate morphology, particle size and pore 
structure as the un-MSNs particles.  
According to N2 sorption analysis, MSN-CNin-SHout particles possess a high surface area of 
573 m
2
/g and a wide pore size distribution of about 2.5 – 12 nm (Figure 5-4 c). The 
incorporated nitrile groups can be seen in the IR spectrum (Figure 5-4d, blue trace) at 2256 
cm
-1
 representing the stretching vibration of aliphatic nitriles. The nitrile groups in MSN-
CNin-SHout could be converted into carboxylic groups by heating the sample in a hydrochloric 
acid solution (appendix Figure S 5-4a). The obtained MSN-COOHin-SHout sample shows 
strong COO
-
 asymmetric stretching vibrations at 1556 cm
-1
 in the IR spectrum (Figure 5-4 d, 
magenta trace). To verify the presence of thiol groups on the outer surface, we applied a thiol-
disulfide exchange reaction. Incubating MSN-CNin-SHout particles with cystamine in 
carbonate-bicarbonate buffer resulted in amino groups being anchored on the outer surface of 
the MSNs. This exchange reaction is evidenced by a dramatic increase in the zeta potential of 
the particles (Figure 5-4e). External mercapto-groups can be exploited for ligand attachment, 
e.g., PEGylation of the particles. PEG anchored to the external surface of MSNs has been 
reported to enhance the particle circulation time in the blood stream as well as to prevent 
particle degradation.
27-28
 To assemble the potential nanocarriers MSN-COOHin-PEGout for 
biomedical application, we attached PEG polymers to the outer surface of the MSN-COOHin-
SHout particles via a mercapto-reactive maleimide-PEG linker (appendix Figure S 5-4b). The 
corresponding weight increase of the PEGylation can be seen in TGA measurements (Figure 
5-4f). 
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Figure 5-4. Characterization of core-shell MSNs. (a) TEM and (b) SEM images of MSN-CNin-SHout particles. (c) 
N2 sorption-based pore size distribution obtained from the adsorption branch and calculated using NLDFT mode. 
(d) IR spectra. Blue: MSN-CNin-SHout, magenta: MSN-COOHin-SHout. (e) Zeta potential of MSN-CNin-SHout 
(blue) and MSN-CNin-NH2out (green). (f) Thermogravimetric analysis of MSN-CNin-SHout (blue), MSN-COOHin-
SHout (magenta) and MSN-COOHin-PEGout (green). 
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Copper-Free Click Chemistry for Cargo Immobilization Using Stimuli-Responsive 
Linkers for Controlled Release 
Several strategies have been described to modify functional groups in MSNs for cargo 
immobilization and controlled release. Recently, we reported on NTA (nitrilotriacetic acid)-
modified MSNs chelating metal ions (Ni
2+
, Zn
2+
 and Ca
2+
) capable of a controlled binding 
and pH dependent release of His-tagged fluorescence nanobodies (chromobodies). These 
constructs enabled the direct transport of nanobodies into living cells for antigen visualization 
in real time.
29
 The MSNs used in the above study were similar to the multifunctional large-
pore stellate MSNs discussed in this report. Here, we present an alternative strategy for ligand 
coupling with the functional groups in these particles. We couple DBCO to the interior 
surface of the MSNs to enable a copper-free click chemistry for guest molecule conjugations. 
DBCO was developed independently by the van Delft group in 2009 and the Popik group in 
2010 to enhance the reaction kinetics of strain-promoted azide-alkyne cycloaddition (also 
referred to as copper-free click chemistry).
30-31
 Copper-free click chemistry mediated by 
DBCO derivatives became popular recently in bio-orthogonal conjugation applications for 
their high selectivity and reactivity toward azide-functionalized molecules under 
physiological conditions.
32-35
 The absence of metal catalysts in the reaction solutions also 
renders this type of click chemistry strategy more favorable for biological applications.  
In our study, two different DBCO derivatives (DBCO-NHS ester and DBCO-S-S-NHS ester) 
were used to functionalize the internal surface of MSN-COOHin-PEGout. After a series of 
surface modifications (Figure 5-5 a), we fabricated two types of DBCO-modified MSNs in 
which MSN-(S-S-DBCO)in-PEGout contains redox-sensitive disulfide bridges between the 
mesopore surface and DBCO groups, while MSN-DBCOin-PEGout contains no stimuli-
responsive linkers. Azide-terminated TAMRA dye was chosen as model cargo to carry out the 
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copper-free click reaction with MSN-(S-S-DBCO)in-PEGout and MSN-DBCOin-PEGout. To 
evaluate the cargo immobilization efficacy of the DBCO-modified MSNs, time-based release 
experiments of the fluorescent TAMRA dye were performed in PBS at 37 °C.  
 
Figure 5-5. (a) Preparation of DBCO-modified MSNs. (b) Time-based release of TAMRA dyes from DBCO-
modified MSNs. Azide-terminated TAMRA dye served as model cargo to be immobilized into DBCO-modified 
MSNs via copper-free click chemistry. After 5 h of release experiment initiation, glutathione (10 mM in the final 
concentration) was introduced to the two samples, respectively. The glutathione-added samples were incubated 
at 37 °C under shaking (500 rmp) for 5 min before the continuous release experiment.   
In brief, 0.5 mg of TAMRA dye-coupled MSNs in 200 µl PBS was loaded into a custom-
made Teflon cap fitting on a fluorescence cuvette. The cap was sealed with a dialysis 
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membrane (MWCO 14,000 g/mol) which was permeable for small dye molecules but not for 
MSNs. The released dye in the fluorescence cuvette (filled with 3 mL PBS) was recorded by a 
spectrofluorometer with λex = 545 nm and λem = 565 nm. According to Figure 5-5 b, the two 
MSN samples showed no spontaneous release and thus an efficient coupling of the TAMRA 
dye to the MSN host during the first 5 h. Upon addition of the reducing agent glutathione at 
this point (GSH, 10 mM in the final solutions) to the particle solutions and incubation of the 
samples at 37 °C shortly for 5 min, the TAMRA dye was quickly released from the MSN-(S-
S-DBCO)in-PEGout sample, whereas no release was observed from the MSN-DBCOin-PEGout 
sample. This result demonstrates that DBCO-modified MSNs are capable of conjugating 
azide-terminated molecules and are able to immobilize them stably within the particle interior. 
By introduction of a stimuli-responsive linker between the silica surface and the cargo 
conjugating moiety, a controlled release of the cargo from MSNs can be achieved. 
As an alternative to the redox-sensitive disulfide bridge, we employed a pH-responsive linker 
between the MSN surface and the dye cargo to allow a stimuli-responsive cargo release. The 
pH-sensitive hydrolysis of the acetal linker 3,9-bis(3-aminopropyl)-2,4,8,10-
tetraoxaspiro[5.5]undecane (called AK linker) was previously reported in the literature.
36-37
 
We modified the MSN-COOHin-PEGout particles by attaching the amino terminus of the AK 
linker to the carboxy groups in the inner particle surface and then conjugated an amino-
reactive NHS-DBCO moiety to the residual amino group of the AK-linker (Figure 5-6 a). 
TAMRA dyes were then again coupled to these MSN-(AKL-DBCO)in-PEGout samples via 
copper-free click chemistry. The dye attachment and pH-sensitive release was studied with 
fluorescence spectroscopy as described above. As illustrated in Figure 5-6 b, TAMRA dyes 
were stably attached in the mesopores of MSN-(AKL-DBCO)in-PEGout without premature 
leakage when kept in a buffer solution at pH 7. However, the subsequent exchange of the 
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medium with a pH 5 buffer triggered the TAMRA dye release due to the AK linker 
hydrolysis.  
 
Figure 5-6. (a) Preparation of DBCO-modified MSNs with pH-responsive acetal linker (AKL). (b) Time-based 
release of TAMRA dyes from AKL-DBCO-modified MSNs. 2 h after release of TAMRA dyes in a pH 7 buffer, 
the sample was collected by centrifugation and re-dispersed in a pH 5 buffer for the following release 
experiment.  
These release experiments demonstrate that DBCO derivatives are efficient elements for 
cargo conjugation on functionalized MSNs. Moreover, the sequential MSN modification with 
DBCO and stimuli-responsive linkers has no significant influence on the pore size distribution 
of our large-pore nanoparticles (Figure S 5-5a). The successful modification with DBCO and 
the stimuli-responsive linker is seen in TGA results, which show an increasing mass loss after 
each reaction step (Figure S 5-5b). Detailed information about DBCO-modified MSNs is 
listed in Figure S 5-5c.  
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Finally, we investigated the intracellular release of MSN-TAMRA in HeLa cells. For the cell 
experiments we chose MSN-S-S-DBCO-TAMRA because the endosomal release can be 
triggered externally via chloroquine shock. The successful cellular uptake of MSN-S-S-
DBCO-TAMRA is shown in the fluorescence microscopy image in Figure 5-7.  
Figure 5-7. Fluorescence microscopy image of MSN-S-S-DBCO-TAMRA (magenta) taken up by HeLa cells 
(membranes in green). The orthogonal views on the side show successful uptake of MSNs. 
No release of TAMRA is visible due to the fact that the releasing agent GSH is mainly present 
in the cytosol and not in the rather oxidizing environment of the endosome, which contains 
the MSNs. A chloroquine shock after 36 h released the particles from the endosome into the 
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cytosol, where GSH induced release of TAMRA from the particles. The resulting spread of 
the released dye within the cell is displayed in Figure 5-8 b. The control particles MSN-S-S-
DBCO-TAMRA without chloroquine shock did not show released dye (Figure 5-8(a)). 
 
Figure 5-8. Fluorescence microscopy images of (a) MSN-S-S-DBCO-TAMRA and (b) MSN-S-S-DBCO-
TAMRA after chloroquine shock; insert: respective transmitted light images. The staining in (b) results from 
TAMRA released from the particle and spreading within the cell. 
5.3. Conclusion 
In summary, we tailored the surface properties of large-pore stellate MSNs via co-
condensation and postsynthetic modification into multifunctional MSNs that render promising 
nanocarriers for potential biomolecule delivery. Various organic functional groups were 
incorporated into the silica framework by co-condensing organosilanes with TEOS. We note 
that the acidity or basicity of an organosilane which might alter the pH value of reaction 
solution (e.g., ATPES) should be used with care because they can modify the large-pore 
stellate particle morphology formation and result in different silica structures. A delayed co-
condensation approach was used to spatially control the localization of functional groups in 
the mesoporous nanoparticle, hence creating a core-shell bi-functional stellate MSN structure. 
In addition, we demonstrated the feasibility of both external and internal MSN surface 
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modification. DBCO derivatives were employed for copper-free click chemistry in 
combination with redox-sensitive disulfide bridged or pH-sensitive acetal linkers in our 
multifunctional MSN system to result in controlled cargo release. The synergy of surface 
adaptability and large pore radius in these stellate silica nanoparticles provides a promising 
outlook for applications in biomolecule delivery. This prospect was also demonstrated in our 
recent paper where similar large-pore stellate MSNs were used for the intracellular delivery of 
chromobodies.
29
  
 
.
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5.4. Experimental Part 
Materials. Tetraethyl orthosilicate (TEOS, Aldrich, ≥ 99%), phenyltriethoxysilane (PTES, 
Aldrich, > 98%), (3-mercaptopropyl)triethoxysilane (MPTES, Aldrich, ≥ 80%), 3-
aminopropyltriethoxysilane (APTES, Aldrich, 99%), Cell Counting Kit-8 (CCK-8, Dojindo), 
3-cyanopropyltriethoxysilane (CPTES, ABCR, 97%), cetyltrimethylammonium p-
toluenesulfonate (CTATos, Sigma), triethanolamine (TEA, Aldrich, 98%), cystamine 
dihydrochloride (Aldrich), ethanol (EtOH, Aldrich, absolute), hydrochloric acid (HCl, 
Aldrich, 37%), methoxypolyethylene glycol maleimide (PEG, MW 5000, Sigma), 
ethylenediamine dihydrochloride (Aldrich), dibenzocyclooctyne-S-S-N-
hydroxysuccinimidylester (DBCO-S-S-NHS ester, Aldrich), dibenzocyclooctyne-N-
hydroxysuccinimidyl ester (DBCO-NHS ester, Aldrich), 3,9-bis(3-aminopropyl)-2,4,8,10-
tetraoxaspiro[5.5]undecane (AK linker, TCI), 5-carboxytetramethylrhodamine azide (5-
TAMRA Azide, Baseclick),  L-glutathione reduced (GSH, Sigma), N-(3-
dimethylaminopropyl)-N-ethylcarbodiimide (EDC, Alfa Aesar, 98%), saline-sodium citrate 
buffer (SSC buffer, Sigma), sodium carbonate (Sigma), sodium bicarbonate (Sigma), 
Dulbecco’s phosphate-buffered saline (PBS, Gibco). Bi-distilled water was obtained from a 
Millipore system (Milli-Q Academic A10).   
MSN Synthesis. Un-functionalized MSNs (un-MSN) were synthesized based on an adapted 
recipe reported in the literature.17 In brief, TEA (0.047 g, 0.32 mmol), CTATos (0.263 g, 
0.58 mmol) and H2O (13.7 g, 0.77 mmol) were mixed in a 100 mL round bottom and stirred 
vigorously (1250 rpm) at 80 °C until the surfactant solution became homogeneous. TEOS 
(2.013 g, 9.6 mmol) was then added to the surfactant solution, and the mixture was 
continuously stirred at 80 °C for 2 h. The molar ratio of the above-mentioned mixture is 
TEOS : CTATos : TEA : H2O = 1 : 0.06 : 0.033 : 80. The as-synthesized particles were 
collected by centrifugation (7197 g, 20 min) and were immediately template extracted (see 
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below). For functionalized MSNs (MSN-R), TEOS and organosilanes (RTES) were mixed in 
molar ratios as described in Table 2 (the total silane content remained at 9.6 mmol) for silica 
co-condensation. All other procedures were the same as in the un-MSN synthesis. 
Core-shell bi-functional (MSN-CNin-SHout) MSNs were synthesized through a delayed co-
condensation approach. TEOS (1.71 g, 8.2 mmol) and CPTES (116 mg, 0.48 mmol; 5 mol%) 
were mixed and added to the surfactant solution (as described in the previous section), and the 
mixture was stirred (1250 rpm) at 80 °C for 1 h. Afterwards, 201 mg of TEOS (0.96 mmol) 
was separated into 4 aliquots and added to the mixture every 3 minutes. The solution was 
further stirred for 1 h at 80 °C. A mixture of TEOS (20.1 mg, 0.096 mmol) and MPTES 
(28.6 mg, 0.096 mmol, 1 mol%) was then added to the solution to generate the outer shell of 
MSNs. The resulting solution was continuously stirred at 80 °C for 1 h. The as-synthesized 
particles were collected by centrifugation (7197 g, 20 min) and were subsequently template 
extracted. 
Template Extraction. To remove the organic surfactant from MSNs, 1 g of the as-
synthesized particles were heated in an ethanolic solution (150 mL) containing 3 g of 
ammonium nitrate at 90 °C under reflux for 1 h, cooled and collected by centrifugation 
(7197 g, 20 min) and extracted by a second reflux at 90 °C using a 2 M HCl/ethanolic 
solution (150 mL) for 1 h. Afterwards, samples were washed in the sequence of EtOH, H2O, 
EtOH (100 mL per wash) and were finally kept in 20 mL of EtOH. Particles were collected by 
centrifugation (7197 g, 20 min) after each template extraction and washing step.  
Buffer Preparation.  
Carbonate-Bicarbonate Buffer, pH 9 
2 mL of 200 mM of sodium carbonate (2.2 g of sodium carbonate was dissolved in 100 mL 
H2O) was slowly added to 23 mL of 200 mM of sodium bicarbonate (1.68 g of sodium 
bicarbonate was dissolved in 100 mL H2O) to adjust the pH value to 9.0. By filling the buffer 
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volume to 50 mL with H2O the final carbonate-bicarbonate concentration of 100 mM was 
obtained. 
0.1 M MES Buffer, pH 4.7 
4-Morpholineethanesulfonic acid (1.95 g, 10 mmol) was dissolved in 100 mL of H2O. 2 M 
NaOH was added dropwise to adjust the pH value to 4.7. 
Modification of Core-Shell Bifunctional MSNs.  
Hydrolysis of MSN-CNin-SHout. 200 mg of MSN-CNin-SHout was dispersed in 20 mL of H2O, 
and 60 mL of HCl (37 %) was added carefully. The sample was heated to reflux (90 °C) for 
3 h and then cooled down in ambient environment. Afterwards 40 mL H2O was added and the 
solution was stirred at RT overnight. 100 mL of H2O was added to further dilute the solution 
before centrifugation (7197 g, 20 min) for particle collection. The resulting MSN-COOHin-
SHout particles were washed with SSC buffer (pH 7), H2O and EtOH (50 mL per wash), and 
were kept in EtOH (10 mL). Centrifugation (7197 g, 20 min) was applied after each washing 
step for particle collection. 
Modification of MSN-CNin-SHout with Cystamine. The thiol groups on the outer shell of MSN-
CNin-SHout could be converted to amino groups by disulfide exchange of MSN-CNin-SHout 
with cystamine. In brief, cystamine dihydrochloride (22.5 mg, 0.1 mmol) was dissolved in 
1 mL of H2O as cystamine coupling solution. 10 mg of MSN-CNin-SHout was dispersed in 
900 µL of H2O and then mixed with 100 µL of 100 mM carbonate-bicarbonate buffer and 
1 mL of cystamine coupling solution. The mixture was stirred at RT for 2 h followed by 
washing steps (twice with H2O and twice with EtOH (5 mL per wash), followed by 
centrifugation (16873 g, 5 min) to remove excess of cystamine and the side product 
2-mercaptoethylamine. The resulting MSN-CNin-NH2out particles were suspended in 5 mL 
EtOH. During the modification processes, particles were collected by centrifugation (16873 g, 
5 min) in 1.5 mL Eppendorf tubes after reaction and each washing step. 
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PEGylation of MSN-COOHin-SHout. 10 mg of MSN-COOHin-SHout and 10 mg of maleimide-
terminated PEG were mixed in 6 mL of SSC buffer in a 10 mL-glass bottle. The mixture was 
stirred at RT overnight. The resulting MSN-COOHin-PEGout particles were washed with 10 
mL of H2O three times to remove excess free PEG molecules and were kept in 10 mL of H2O. 
Centrifugation (16873 g, 5 min) was used to collect the particles after reaction and after each 
washing step. 
Modification of MSN-COOHin-PEGout to MSN-DBCOin-PEGout/MSN-(S-S-DBCO)in-PEGout. 
To modify MSN-COOHin-PEGout with DBCO-S-S-NHS ester or DBCO-NHS ester, 
conversion of MSN-COOHin-PEGout to MSN-NH2in-PEGout was required. Ethylenediamine 
was used to convert COOH groups to NH2 groups, the procedure was following the protocol 
described in the literature.
38
 Briefly, ethylenediamine dihydrochloride (1.33 g, 10 mmol) was 
dissolved in 10 mL of 0.1 M MES buffer (pH 4.7) to generate 1 M ethylenediamine coupling 
buffer in a 30 mL-glass bottle. The amount of 4 mg of MSN-COOHin-PEGout was dispersed in 
the ethylenediamine coupling buffer (10 mL) followed by addition of EDC (20 mg, 
128.8 µmol, 2 mg/ml in the reaction solution) and the mixture was stirred at RT overnight. 
The resulting MSN-NH2in-PEGout particles were collected by centrifugation (16873 g, 5 min) 
and were washed with 4 mL H2O three times to remove residual chemicals. 
DBCO-S-S-NHS ester and DBCO-NHS ester were dissolved in DMSO in the concentration 
of 10 mM to serve as stock solutions, respectively. 2 mg of MSN-NH2in-PEGout particles were 
mixed with 1 mg of DBCO-S-S-NHS ester (170 µl from stock solution) or 1 mg of DBCO-
NHS ester (240 µl from stock solution) in 1 mL PBS. The mixtures were shaken at RT for 3 h 
followed by washing steps (washed with 2 mL H2O, 2 mL EtOH and 2 mL DMSO). 
Centrifugation (16873 g, 5 min) was performed for particle collection after each washing step. 
The resulting MSN-DBCOin-PEGout and MSN-(S-S-DBCO)in-PEGout particles were stored in 
DMSO at the concentration of 1 mg/ml. 
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Conversion of MSN-COOHin-PEGout to MSN-(AKL-DBCO)in-PEGout. A mixture of 4 mg of 
MSN-COOHin-PEGout, 5 mg of AK linker (18 µmol) and 5 µl of EDC (4.3 mg, 28 µmol) were 
dispersed in 1 mL SSC buffer in a 10 mL-glass bottle and were stirred at room temperature 
overnight. The resulting MSN-AKLin-PEGout particles were collected by centrifugation 
(16873 g, 5 min), washed with 10 mL SSC buffer and dispersed in 4 mL EtOH. 2 mg of 
MSN-AKLin-PEGout particles in 1 mL EtOH were mixed with 1 mg of DBCO-NHS ester 
(240 µl from stock solution) in a 1.5 mL- Eppendorf tube and the sample was shaken at RT 
for 2 h. The resulting MSN-(AKL-DBCO)in-PEGout particles were washed with 2 mL EtOH 
three times and stored in DMSO at the concentration of 1 mg/ml. 
MSN Characterization. For transmission electron microscopy (TEM), samples were 
prepared by drying a diluted MSN suspension (in ethanol) on a carbon-coated copper grid at 
room temperature for several hours. The measurement was performed at 200 kV on a Jeol 
JEM-2010 instrument with a CCD detection system. Scanning electron microscopy (SEM) 
was performed at 30 kV on a Helios NanoLab G3 UC instrument (FEI, USA) equipped with a 
TLD detector. Diluted MSN suspensions (in ethanol) were dried on a carbon-coated copper 
grid at room temperature for several hours. Nitrogen sorption analyses were performed on a 
Quantachrome Instrument NOVA 4000e at 77 K. Sample outgassing was performed at 120 °C 
under vacuum (10 mTorr) 16 h before measurement. Pore size distribution curves were 
calculated by non-local density functional theory (NLDFT) procedures provided by 
Quantachrome based on the adsorption branch of N2 on silica. A Thermo Scientific Nicolet 
iN10 IR-microscope was used to record infrared spectra of dried sample powders in 
reflection-absorption mode with a liquid-N2 cooled MCT-A detector. Raman spectroscopy 
was performed on a Bruker Equinox 55 with a Nd:YAG laser having a wavelength of 
1064 nm at a laser power of 100 mW and 3000 scans. Dynamic light scattering (DLS) and 
zeta potential measurements were performed on a Malvern Zetasizer-Nano instrument 
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equipped with a 4 mW He-Ne laser (633 nm) and an avalanche photodiode. DLS 
measurements were directly recorded in diluted suspensions of the particles at a concentration 
of 1 mg/ml in ethanol. Zeta potential measurements were performed with an add-on Zetasizer 
titration system (MPT-2) based on diluted NaOH and HCl as titrants, and the samples were 
prepared by adding 1 mg of the particles to 10 mL bi-distilled water. Thermogravimetric 
analyses (TGA) of the powder samples (20 mg) were recorded on a Netzsch STA 440 C 
TG/DSC with a heating rate of 10 °C/min up to 900 °C in a stream of synthetic air of about 
25 mL/min. Solid state NMR measurements (cross-polarized 
13
C and 
29
Si and direct 
29
Si 
excitation) were performed on a Bruker Avance III-500 spectrometer (11,74 Tesla) in a 4 mm 
(respectively 2.5 mm) ZrO2 rotor with a spinning rate of 10 kHz (respectively 20 kHz). The 
resulting spectra were fitted with a Gauss or a Voigt function with Origin Pro 9.0. The 
preparation of all cell experiments took place in a Hera-Safe cell culture unit and Hera Cell 
incubators from Heraeus. Fluorescence microscopy was performed with a Zeiss Observer SD 
spinning disk confocal microscope using a Yokogawa CSU-X1 spinning disc unit and an oil 
objective (63x magnification) and BP 525/50 (WGA488) and LP 690 (TAMRA) emission 
filters. A 488 nm and a 564 nm laser was used for excitation. CCK-8 assays were performed 
with a microplate reader (SPARK 10M, Tecan Austria GmbH) and evaluated with Excel 
2010. 
Release experiments. MSNs modified with DBCO-functional groups in the inner surface 
(MSN-DBCOin-PEGout / MSN-(S-S-DBCO)in-PEGout / MSN-(AKL-DBCO)in-PEGout) were 
used in the release experiments. 5-TAMRA azide was used as model cargo to carry out the 
copper-free click chemistry conjugation with DBCO modified MSNs. For dye loading, 0.5 mg 
of MSNs and 200 µg of 5-TAMRA azide (5 mg/ml in DMSO) were mixed in 1 mL PBS in an 
1.5 mL-Eppendorf tube. The samples were incubated at 37 °C under shaking. After 2 h, 
TAMRA dye conjugated MSN samples were washed with 1 mL PBS three times to remove 
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free dyes in the solution. Centrifugation (16873 g, 5 min) was applied after each washing step 
for particle collection. MSN-TAMRA particles were re-dispersed in 200 µl PBS. 
Cuvette release experiments. To show the successful release of the bound cargo, the MSN-
TAMRA particles were transferred to a custom made Teflon cap fitting on a fluorescence 
cuvette. The cap was sealed with a dialysis membrane (ROTH Visking type 8/32, MWCO 
14,000 g/mol) and placed on the top of a fluorescence cuvette filled with 3 mL PBS. Time-
based fluorescence release experiments were performed at 37 °C on a PTI spectrofluorometer 
equipped with a xenon short arc lamp (UXL-75XE USHIO) and a photomultiplier detection 
system (Model 810/814). The excitation wavelength was set to λ = 545 nm and the emission 
fluorescence intensity was recorded at λ = 565 nm. All slits were adjusted to 2.0 mm. To 
trigger the stimuli-responsive dye release, 22 µl of 100 mM GSH in PBS was added to 
MSN-DBCO-TAMRA and MSN-S-S-DBCO-TAMRA samples (each sample contains 200 µl 
volume), respectively to achieve a final GSH concentration of 10 mM. The samples were 
incubated at 37 °C under shaking (500 rpm) for 5 min. The MSN-AKL-DBCO-TAMRA 
sample was transferred to an Eppendorf tube and the particles were collected by 
centrifugation (16873 g, 5 min). Afterwards, the sample was re-dispersed in 200 µl of acetate 
buffer (pH 5) and was transferred back to the Teflon cap for the release experiment. All 
samples were sealed with the dialysis membranes and the release setups were reassembled. 
The fluorescence cuvettes for MSN-DBCO-TAMRA and MSN-S-S-DBCO-TAMRA samples 
were filled up with PBS containing 10 mM of GSH, while the fluorescence cuvette for MSN-
AKL-DBCO-TAMRA sample was filled with acetate buffer (pH 5). Fluorescence spectra 
(λex = 545 nm, λem = 565 nm) were recorded continuously overnight. Quantification of the 
released dye was performed with the help of a calibration curve (Figure S 5-7). 
Cell experiments. HeLa cells were cultured in DMEM supplemented with 10% FBS and 1% 
PenStrep at 37°C/5% CO2. For fluorescence microscopy experiments 5000 HeLa cells in 
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300 µl DMEM were seeded in ibiTreat 8-well slides (ibidi). One day after seeding 2 µg of 
MSN-S-S-DBCO-TAMRA were added and incubated overnight. Chloroquine shock was 
performed 36 h after incubation by replacing the medium with medium containing 500 µM 
chloroquine. After 10 min chloroquine was removed by replacing the medium with normal 
DMEM. Release was imaged 6 h after chloroquine treatment. For uptake images WGA488 
was added immediately before imaging. A wash with DMEM after one minute of incubation 
removed unbound WGA.  
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5.6.  Appendix 
 
Figure S 5-1. (a) Full range infrared spectra of MSNs. All curves are shifted along the y-axis by 0.1 units for 
clarity. (b) Raman spectrum of MSN-
power of 100 mW and 3000 scans. 
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Figure S 5-2. Thermogravimetric analysis of MSNs functionalized with different organic groups. 
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Table S 5-1. TGA mass losses and the estimated degree of organic functionalizations of the functionalized 
MSNs. 
Sample Formulation of 
functional group (R) 
Molecular weight of 
functional group (MWR) 
TGA mass loss
a
 
(%) 
Estimated degree of organic 
functionalization
b
 (%) 
MSN-SH C3H6SH 75.2 18.6 15.4 
MSN-Ph C6H5 77.1 13.1 10.5 
MSN-NH2 C3H6NH2 58.1 15.0 15.4 
a
 Calculated based on the mass differences between 150 °C and 900 °C. 
b
 Calculated based on the formulation:   
  ,x (%) = degree of organic functional groups. 
 
 
 
 
Appendix 
184 
 
 
Figure S 5-3. Characterization of (a) MSN-Ph/NH2 and (b) MSN-Ph/SH. From left to right: TEM images, N2 
sorption isotherms and NLDFT pore size distributions obtained from adsorption branches. 
 
Table S 5-2. Synthesis and characterization information of MSN-Ph/NH2 and MSN-Ph/SH. 
Sample Precursors 
DFT Pore size 
distribution (nm) 
Pore volume 
(cm3/g) 
BET surface 
area (m2/g) 
Particle size 
(nm) 
pH value after 
silane addition 
MSN-
Ph/NH2 
95 mol% TEOS 
2.5 mol% PTES 
2.5 mol% 
APTES 
2.5-5.0 0.9 496 190 ± 54 9.92 
MSN-Ph/SH 
90 mol% TEOS 
5 mol% PTES 
5 mol% MPTES 
3.5-22 2.6 712 73 ± 15 9.33 
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Figure S 5-4. Surface modification of core-shell MSNs. (a) Hydrolysis of MSN-CNin-SHout particles in acidic 
condition at 90 °C. (b) PEGylation of MSN-COOHin-SHout. 
 
 
Figure S 5-5. Characterization of core-shell MSNs. (a) NLDFT pore size distribution of core-shell MSNs 
calculated from adsorption branches of N2 sorption isotherms. (b) Thermogravimetric analysis. (c) Summary of 
the core-shell MSNs characterization. The TGA mass loss was calculated based on the mass differences between 
100 °C and 900 °C. 
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Figure S 5-6. Cytotoxicity of MSNs. CCK-8 assay for cytotoxicity studies of unfunctionalized and PEGylated 
core-shell MSNs after 24 h incubation on HeLa cells.  
The CCK-8 (Cell Counting Kit 8) was used to determine the cytotoxicity of the here used 
large-pore MSNs. HeLa cells were seeded on a 96-well microplate (5 x 10
3
 cells per well) in 
DMEM (100 µL well
-1
) and incubated at 37 °C and 5% CO2. 24h after cell seeding, 10 µL of 
MSNs (with various particle concentrations) were added to each well. The control group 
consisted of 10 µL water and was used as reference (100%). The cells were incubated with 
MSNs for 24 h. Afterwards 10 µL of CCK-8 solution were added to each well of the plate and 
after incubating the plate for another 4 h, the absorbance at 450 nm was measured in a 
microplate reader (SPARK 10M, Tecan Austria GmbH) with 600 nm as reference 
wavelength. Experiments were performed in triplicates. Error bars show the standard 
deviations. 
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Figure S 5-7. Calibration curve of TAMRA dye for quantification of released amount. Different molar 
concentrations of TAMRA dye are measured with a fluorescence spectrometer and fitted linearly. As expected, 
TAMRA does not show a pH-dependent fluorescence. 
To make sure that the successful click reaction is not hindered due to lack of TAMRA supply, 
we used TAMRA dye in excess. The supernatants were measured before and after the click 
reaction to determine the percentage of loaded dye. For MSN-AKL-DBCO-TAMRA 2% of 
the dye was loaded into the pores (100% correlates to 200 µg TAMRA dye used in the 
solution for the click reaction). After hydrolysis of the AK-linker, 60% of TAMRA dye were 
released. In the pores of MSN-S-S-DBCO-TAMRA, 10% of the provided dye was loaded and 
57% thereof was released after reductive cleavage of the disulfide-bridges. 
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Figure S 5-8. 
29
Si MAS-NMR spectra (a) MSN-NH2 (direct excitation), (b) MSN-NH2 (cross-polarized), (c) 
MSN-Ph (direct excitation), (d) MSN-Ph (cross-polarized). 
 
 
 
Figure S 5-9. 13C MAS-NMR spectra (a) MSN-CNin-SHout (blue), (b) MSN-COOHin-SHout (magenta) and (c) 
MSN-COOHin-PEGout (green). Hydrolysis of the cyano-groups (indicated with C-N at 118 ppm, blue spectrum) 
results in the resonance of carboxyl groups (COOH) appearing at 180 ppm (magenta and green spectra). 
Successful attachment of the PEG linker can be seen by C-O resonances appearing at 70 ppm (green spectrum). 
The asterisked peaks denote residual surfactants. The other resonances are assigned to functionalized silanes of 
the MSNs. 
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Abstract 
Various bio-applications of mesoporous materials (e.g., the immobilization of enzymes or the 
delivery of biomolecules such as siRNA) require large pores for the successful adsorption of 
the rather large molecules of interest and protecting the fragile cargo from external forces 
such as degradation. We describe the facile synthesis of functionalized mesoporous silica 
nanoparticles with large pores (LP-MSNs) providing high loading capacity for the 
immobilization of two differently-sized enzymes. The synthesis procedure yields 
homogeneous core-shell particles of about 100 nm in size with large mesopores (about 7 nm 
in diameter) and an azide-functionality inside the pores. The LP-MSNs were synthesized 
employing a co-condensation approach with the rather large micellar template 
cetyltrimethylammonium p-toluenesulfonate (CTATos). Due to the azide functionality, the 
LP-MSNs are suitable for bio orthogonal click chemistry reactions within the porous network. 
Two different acetylene-functionalized enzymes (sp-carbonic anhydrase (CA) and sp 
horseradish peroxidase (HRP)) were immobilized in the pores of the obtained LP-MSNs by a 
copper-catalyzed 1,3 dipolar cycloaddition reaction. The covalent attachment of the enzymes 
within the mesopores allowed us to investigate the catalytic performance of the enzyme-silica 
systems. The enzymes are stable after bioconjugation with the silica support and show high 
catalytic activity over several cycles for the colorimetric reaction of guaiacol (2-
methoxyphenol) in case of LP-MSN-HRP and the hydrolysis of 4-nitrophenyl acetate (NPA) 
by LP-MSN-CA. 
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6.1. Introduction 
Ordered mesoporous silica materials have attracted increasing attention due to the ability to 
tailor the structural and textural features including particle size, pore size, pore volume and 
surface area.
1-6
 With the possibility to introduce various functionalities into the mesoporous 
framework, these materials have turned into interesting candidates for various 
biotechnological applications.
4, 7-10
 However, such applications often involve fairly large 
molecules of more than 5 nm in size that may not fit into the pores of established silica 
nanoparticles (ca. 4 nm). Additionally, the active molecules need to be immobilized while 
preserving their function.  
Considerable efforts have been made in the past years regarding the control of mesostructural 
diversity, compositional flexibility and morphology during the synthesis of mesoporous silica 
nanoparticles (MSNs).
3, 11-13
 In recent years the synthesis of well-defined large-pore 
mesoporous systems with small particle sizes (in the size-range of 100 – 200 nm) for the 
encapsulation of large biomolecules (i.e. enzymes or siRNA) has been addressed.
14-17
 
Recently, the group of Zhang published a synthesis route for wide-pore stellate MSNs via the 
use of cetyltrimethylammonium p-toluenesulfonate (CTATos) as template in a near-neutral 
precursor solution.
18
 The resulting stellate particles show a pore size distribution between 10 
to 20 nm and a defined particle size of around 100 nm. With those properties they represent 
an ideal delivery vehicle for the cellular transport of large-sized biomolecules.
19
  
Here, we describe a delayed co-condensation approach to create spatially segregated core-
shell phenyl- and azide-functionalized large-pore MSNs (LP-MSNs), which serve as a 
versatile platform for the immobilization of enzymes. Due to their large pores, our 
functionalized LP-MSNs can be loaded with large bioactive molecules and thus are promising 
candidates for numerous bio-applications, including biocatalysis.  
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A promising way to introduce enzymes as biocatalysts in industrial applications is their 
immobilization onto inorganic mesoporous supports.
2, 20-22
 Organo-functionalized 
nanostructured mesoporous silica materials have attracted great attention among the available 
inorganic host systems as they offer outstanding properties for the immobilization and 
encapsulation of biomolecules.
2, 23-24
 As the pores of LP-MSNs match the size of enzymes, 
such silica materials are excellent candidates for enzyme immobilization,
25
 yet their potential 
in this field still needs to be explored. Previous studies on established mesoporous silica 
materials (e.g. SBA-15) revealed that enzyme confinement within such hosts can increase the 
stability and reduce denaturation by protein unfolding, one major issue in industrial 
applications of biocatalysts.
26
 However, as a consequence of immobilization onto the solid 
support, a decrease of the enzymatic activity relative to the free enzyme is often observed in 
such systems.
27-28
 Strong interactions between enzymes and the host materials can be 
controlled by complementary organo-functionalization of the porous network, resulting in 
different catalytic activity and loading capacities.
29-31
 As the functionalization of the 
mesoporous framework can be easily modified, the organo-moieties can be adjusted to the 
requirements of the respective enzyme and the preferred attachment reaction. 
Furthermore, the application of mesoporous silica supports allows for the adjustment of pore- 
and particle size, structural arrangement and surface properties to optimize loading capacity 
and enzyme activity.
8, 32-33
 Lee et al. have reviewed different methods of covalent enzyme 
immobilization onto mesoporous silica supports.
34
 Here, we use the flexibility of silica 
functionalization for loading active enzymes and our newly developed MSNs with large pores 
to immobilize enzymes while retaining their activity. Additionally, we make use of the 
demonstrated reusability of immobilized horseradish peroxidase in SBA-16 to be able to 
study the catalytic behaviour and improved stability over more than one cycle.
35
 Previous 
Introduction 
194 
 
studies describe the immobilization of horseradish peroxidase (HRP) onto the surface of 
mesoporous silica nanoparticles via physical adsorption or covalent binding by using the 
crosslinker glutaraldehyde.
36-37
 Due to the fact that glutaraldehyde is toxic and rather unstable 
in air,
38
 here we use a modified azide-alkyne click chemistry approach established by 
Schlossbauer et al. to immobilize enzymes into the LP-MSNs.
39-40
 This method is 
biocompatible and avoids unfavorable pore blocking. The same immobilization technique is 
also used to covalently bind an essential metalloenzyme, namely carbonic anhydrase, to the 
pore walls of the mesoporous silica nanoparticles. The immobilization of enzymes in general 
enables their already mentioned reusability and furthermore their long-term use in 
bioreactors.
41
  
Two different enzymes, namely the lyase carbonic anhydrase (CA) and the peroxidase 
horseradish peroxidase (HRP), were chosen for this study and were immobilized with an 
efficient method into the newly developed azide-functionalized LP-MSNs. A novel co-
condensation synthesis approach was developed to generate organo-functionalized MSNs 
with large pores suitable for biocompatible coupling methods.  To study the catalytic activity 
of the immobilized enzymes, two suitable activity assays were performed. In the case of 
carbonic anhydrase, the catalyzed hydrolysis of the substrate 4-nitrophenol acetate was 
studied by following the increasing absorbance of yellow 4-nitrophenol at 400 nm over time. 
For immobilized horseradish peroxidase, the catalyzed oxidation of guaiacol (2-
methoxyphenol) was recorded at a wavelength of 470 nm over time. It was shown that the 
immobilized enzymes exhibited high stability and remained highly active after covalent 
immobilization in the LP-MSNs. 
In this work we combine a simple support synthesis with a very efficient immobilization 
technique to obtain an active, stable and reusable enzyme-silica system.  
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6.2. Results and Discussion 
Synthesis of large pore MSNs 
For the immobilization of alkyne-functionalized enzymes by a bio-orthogonal click chemistry 
approach, core-shell mesoporous silica nanoparticles with large pores and azide groups on the 
internal and phenyl groups on the external surface (LP-MSN-N3) were synthesized using the 
delayed co-condensation procedure developed in our group following a modified protocol 
from Zhang et al..
18
 
46
 
In brief, a delayed co-condensation approach was chosen to introduce small amounts (5 mol% 
of the original TEOS amount) of azide-functionality into the inside of the mesoporous 
framework of the LP-MSNs and to obtain a homogeneous distribution of organic moieties 
within the silica material to ensure immobilization of the enzymes only inside the pores of the 
particles. Higher degrees of organo-modification can result in a reduction of the pore diameter 
and would thus impede the diffusion of enzyme molecules into the mesoporous channels and 
increase the likelihood of pore blocking. For the introduction of azide-moieties in the core, the 
silica source tetraethyl orthosilicate (TEOS) was co-condensed with (3-azidopropyl) 
triethoxysilane (AzTES, 5 mol% of total silane content) while PhTES (1 mol% of total silane 
content) and TEOS were used to generate phenyl groups on the external surface. A shell of 
pure TEOS was condensed in-between to create an interlayer between the two different 
functional groups. Additionally, we found that the introduction of organo-moieties in the case 
of azide-silanes has no negative effect on the formation of the mesoporous structure, whereas 
amine-functionalities easily disrupt the large-pore nanoparticle formation. TEM and SEM 
micrographs (Figure 6-1a-c) of the resulting core-shell particles (MSN-N3,in-Phout) show a 
stellate morphology and a conical-like pore structure. 
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Figure 6-1 Characterization of LP-MSN-N3. a) Transmission electron microscopy (TEM) image, b) Scanning 
electron microscopy (SEM) image and c.) Scanning transmission electron microscopy (STEM) image of 
template-extracted LP-MSN-N3, d) dynamic light scattering (DLS) data showing a narrow size distribution, e) 
nitrogen sorption isotherm and f) pore size distribution obtained from nitrogen sorption measurement for LP-
MSN-N3. 
Transmission electron microscopy images show spherically shaped nanoparticles with a fairly 
homogenous particle size distribution within a size range of 60 – 90 nm (Figure 6-1a). The 
large pores are present in each LP-MSN and evenly distributed over the entire nanoparticle. 
The particle size distribution data are in good accordance with the values obtained by 
dynamic light scattering, exhibiting a maximum at 150 nm (Figure 6-1d). We explain the 
moderately increased apparent size obtained by DLS measurements compared to the TEM 
measurements with the larger hydrodynamic diameter of the LP-MSN-N3 in comparison to 
their real size - possibly weak agglomeration is also present. The mesoporous framework is 
well-defined and clearly present in all particles (Figure 6-1a-c). The pore sizes are in a range 
of about 6 – 10 nm (deduced from TEM measurements) and consistent with the wide pore 
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size distribution of about 2.5 – 12 nm obtained from nitrogen sorption measurements (Figure 
6-1f). The corresponding sorption data show a hybrid isotherm of type IIb combined with a 
certain fraction of type IV. The narrow hysteresis can be characterized as an H3 hysteresis 
loop that results from aggregation and inter-granular pores and thus from a significant degree 
of textural porosity, indicated by the long tail in the pore size distribution (Figure 6-1f). 
Monolayer formation of the adsorbate can be observed between p/p0 = 0 and 0.2, followed by 
multilayer adsorption over a broad range. The apparent lack of saturation (pore filling) at high 
p/p0 could be due to a broad distribution of textural porosity between the dried particles. The 
inter-particle voids, which are visible in the micrographs (Figure 6-1a-c), are within a size-
range of 10 – 30 nm. Summarizing, we obtained LP-MSNs exhibiting a pore size in the range 
of mesoporous materials (Figure 6-1f, maximum around 7 nm), with a pore volume of 1.6 
cm3/g and a BET surface area of As = 670 m2/g. In addition, infrared spectroscopy was 
carried out and verified the presence of azide-moieties within the pore system of LP-MSN-N3 
(Figure S 6-1).  
Immobilization of alkyne-functionalized carbonic anhydrase and horseradish 
peroxidase onto LP-MSN-N3 via a click chemistry approach 
Two different enzymes, namely carbonic anhydrase (CA, 30 000 Da, 4.0x4.2x5.5 nm3)
47
 and 
horseradish peroxidase (HRP, 44 000 Da, 4.0x4.4x6.8 nm3)
48
, were immobilized in the 
mesoporous nanoparticles. Specifically, a modified click chemistry approach was used to 
immobilize the enzymes within the mesoporous framework of our newly generated LP-
MSNs, which required prior alkyne functionalization of the enzyme (for details see Methods 
section and Scheme 6—1).
39, 42
 The latter was achieved by the EDC-activated attachment of 
4-pentynoic acid to the amine moieties of CA or HRP, respectively (Scheme 6—1). The 
reaction took place in MES buffer (pH 6.0) and at 4°C. 
Results and Discussion 
198 
 
Scheme 6—1 Alkyne-functionalization of enzymes 
 
Scheme 1: EDC activated attachment of 4-pentynoic acid to the respective enzyme (carbonic anhydrase or 
horseradish peroxidase; here shown with bovine carbonic anhydrase II). The reaction was carried out in MES 
buffer (pH 6.0) at 4 °C. The accession number from the protein data bank (PDB) for the X-ray structure of 
BCAII is 1V9E.
49
 
In a second synthesis step, the LP-MSN-N3 particles were incubated with the alkyne-
functionalized enzymes for 30 minutes to ensure their diffusion into the large mesopores 
before the click reaction catalysts were added to the reaction mixture, in order to avoid pore 
blocking (for details see Methods section). Subsequently, a click reaction was performed 
according to a slightly modified procedure published by Himo et al., employing sodium 
ascorbate as reducing agent for Cu(II) (CuSO4) (Scheme 6—2).
50
 The nanoparticles were 
washed several times with water in order to remove excess and unbound enzyme molecules.  
Scheme 6—2 Covalent attachment of sp-enzymes into LP-MSN-N3 
 
Scheme 2: Scheme for protein immobilization in LP-MSNs using click chemistry. Cu(II) was reduced with 
sodium ascorbate resulting in Cu(I), the actual catalyst. 
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Figure 6-2 Nitrogen sorption data of LP-MSN-N3 with immobilized enzymes. a) Isotherm of LP-MSN-N3 
(black), LP-MSN-CA (purple) and LP-MSN-HRP (cyan). b) Pore size distribution for LP-MSN-N3 (black), LP-
MSN-CA (purple) and LP-MSN-HRP (cyan). c) Thermogravimetric analysis data of LP-MSN-N3 (black), LP-
MSN-HRP (cyan) and LP-MSN-CA (purple). All TGA curves are normalized to 100% at 130 °C. 
All obtained nitrogen sorption data show isotherms that appear as hybrids between type II and 
type IV isotherms, with a narrow H3 hysteresis loop. After the attachment of sp-enzymes the 
calculated BET-surface decreased significantly (Figure 6-2a and Table 6-1 respectively). This 
can be attributed to the uptake and covalent immobilization of the enzyme molecules within 
the large mesopores of the nanoparticles and the resulting partial pore filling. Accordingly, the 
pore volume decreased likewise (Figure 6-2b). A strong reduction of the very small pore sizes 
can be observed. We attribute this to the conical-like shape of the pores: enzymes that diffuse 
entirely into the pore, block the small end of it and thereby the parts of the pores representing 
small pore sizes. Carbonic anhydrase shows a stronger reduction of the smaller pore sizes than 
horseradish peroxidase, possibly due to their different shape: the shape of CA is close to a 
square and thus, when it gets stuck in a pore due to size limitations, it may block the entire 
pore uniformly in all directions. HRP is rod-shaped, if it blocks a pore there is space on its 
sides that allows for BET measurements to still access and probe the pore. We assume that the 
decrease in pore volume in case of the sample LP-MSN-CA is stronger than in LP-MSN-HRP 
because a larger amount of sp-CA could be incorporated into the mesoporous framework of 
our nanoparticles. These results are in good accordance with the thermogravimetric analysis 
(TGA) data (Figure 6-2c and Table 6-1 for relative mass loss), showing that more carbonic 
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anhydrase than horseradish peroxidase was immobilized in the LP-MSNs. The higher degree 
of immobilization of CA as compared to HRP is attributed to its smaller dimension; the 
enzyme can diffuse more easily into the mesopores without having as much contact with the 
pore walls and the attached organic moieties, while HRP is bigger and thus has a higher 
likelihood to touch the pore walls, bind to them and block access to the pore for additional 
molecules.  
Table 6-1 Nitrogen physisorption and thermogravimetric analysis data of LP-MSN-N3 and LP-MSN-Enzyme. 
Sample 
BET surface 
area [m²/g] 
Pore size range 
a
 
[nm] 
Pore 
volume 
[cm
3
/g] 
Relative mass loss
b
 
[%] 
 
LP-MSN-N3 
670 2.5-12 nm 1.6 9.2  
(7.7% for N3-moieties) 
LP-MSN-CA 389 5.5-12 nm 1.2 20.7 
LP-MSN-HRP 423 5.3-12 nm 1.4 18.6 
a
DFT pore size range refers to the main range  of the pore size distribution.
 b
Relative mass loss obtained by 
TGA; all curves are normalized to 130 °C 
From the additional mass loss of 11.5% for the sample LP-MSN-CA compared to 
LP-MSN-N3, the amount of attached enzyme can be estimated to be 4.7 µmol per g silica (for 
calculation see Calculation A 6—1, Appendix), which corresponds to 141 mg carbonic 
anhydrase per g silica support. The amount was additionally determined via Bradford assay, 
resulting in 99 mg CA per g silica (see Appendix, Figure S 6-10). This deviation of almost 
28% is attributed to additional components in the channels of the mesoporous silica that 
contribute to weight changes during TGA measurements. The determined amount indicates 
that 0.5% of all azide-moieties have reacted with sp-CA, as the amount of azide-moieties was 
estimated to 1.02 mmol per g silica. From the additional mass loss of 9.4% for the sample LP-
MSN-HRP compared to the azide-functionalized LP-MSNs, the amount of immobilized 
horseradish peroxidase can be estimated to 2.6 µmol per g silica (see Appendix, Calculation A 
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6—1), or to 114 mg HRP per g silica support. The amount determined with the additionally 
performed Bradford assay (see Appendix, Figure S 6-11) differs very little from the above 
TGA results and corresponds to 103 mg HRP/ g silica. This indicates that a smaller amount of 
sp-Horseradish peroxidase molecules was able to diffuse into the large mesopores and reacted 
with 0.25% of all azide-moieties of LP-MSN-N3. A probable reason for this is the even larger 
molecular dimension of horseradish peroxidase (4.0 x 4.4 x 6.8 nm
3
),
48
 resulting in partial 
blocking of the pores by immobilized horseradish peroxidase. All nitrogen sorption data are 
supported by the corresponding thermogravimetric analysis and the calculated relative mass 
losses that are summarized in Table 6-1. As further proof for the successful attachment of sp-
enzymes via click chemistry, vibrational spectroscopy was performed with the respective LP-
MSN-enzyme samples (see Figure S 6-3 for CA and Figure S 6-4 for HRP). The symmetric 
and asymmetric CH2 stretching vibrations of the enzyme appear in the range of 2960–
2871 cm
-1
 in the spectrum of LP-MSN-CA and sp-CA and of LP-MSN-HRP and sp-HRP, 
respectively. The peak at 2105 cm
-1
 can be attributed to the asymmetric N3 stretching 
vibration of LP-MSN-N3 and can still be observed in LP-MSN-enzyme due to the small 
fraction of reacted (clicked) azide-moieties. At 1658 cm
-1
 (dashed line) the C=O stretching 
vibration appears in the spectrum of LP-MSN-CA/HRP, which is attributed to the amide 
bonds of the attached enzymes. The vibration at 1530 cm
-1
 (second dashed line) is only visible 
in the spectra of sp-enzyme and LP-MSN-enzyme and represents the N-H bending vibration 
of the peptide bonds of the enzyme. The peak at 1627 cm
-1
 in the spectrum of LP-MSN-N3 
indicates the presence of traces of water within the sample. Below 1300 cm
-1
, vibrations of the 
silica framework appear with strong intensity. Summarizing, the results obtained by nitrogen 
sorption, thermogravimetric analysis and vibrational spectroscopy all support the successful 
immobilization of carbonic anhydrase and horseradish peroxidase within the porous network 
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of LP-MSN-N3. In the following we address the catalytic properties of the immobilized 
enzymes. 
Catalytic activity determination of immobilized carbonic anhydrase 
To characterize the properties of immobilized CA, the catalytic activity of the hydrolysis of 
4-nitrophenylacetate (NPA) was studied colorimetrically by measuring the absorbance of the 
newly formed yellow nitrophenol at 400 nm (Figure 6-3a and Figure S 6-5, Appendix). To 
ascertain the robust attachment and stability of the enzyme inside the pores, multiple cycles 
were performed. After cycle 1, the reaction mixture was transferred to small Eppendorf tubes 
and centrifuged for 5 min (15 °C, 16900 g). The pellet was redispersed in water and 
centrifuged again. This washing step was conducted two times to remove (un)reacted 
substrate. Afterwards, the washed particles were redispersed in water and fresh substrate was 
added for the next cycle. In total eight such cycles with intermediate washing steps were 
performed (Figure 6-3a). The time-based measurements show a successful conversion of 4-
NPA to nitrophenol in all cycles, proving the continuous activity and stability of the 
immobilized carbonic anhydrase. Due to the washing steps in between the cycles, a certain 
loss of particles and therefore also enzyme can be seen by a decrease in pellet size and 
accordingly a decrease in absorbance and slope (Figure 6-3a). The self-hydrolysis of 4-NPA 
was measured separately (data shown in Figure S 6-6). The self-hydrolysis reaction data were 
subtracted from the raw data of the enzyme-catalyzed hydrolysis. In Figure 6-3a and Figure S 
6-7 the CA activity corrected for self-hydrolysis is shown. For quantitative determination of 
the reaction rate, the slope of one cycle at a reduced substrate concentration (1mM NPA) was 
converted into concentration vs. time (Figure S 6-7, Appendix) by using Lambert-Beer’s law 
(ε = 16 300 M
-1
 cm
-1
).
51
 According to Michaelis-Menten kinetics in the limit of low substrate 
concentrations, the kinetic constant kcat/Km was determined to be 74 M
-1
 s
-1
. There are large 
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differences in the kinetic constants for different CAs reported in the literature.
52
 Therefore, it 
is difficult to compare our result for immobilized bovine carbonic anhydrase to literature 
values.  
 
Figure 6-3 Activity determination for LP-MSN-CA and LP-MSN-HRP as well as for free versus alkyne-
functionalized enzymes. a) UV-Vis absorption measurement of catalyzed hydrolysis of the substrate 4-
nitrophenol acetate (NPA) by LP-MSN-CA within a period of 120 s (interval 1 s) at 400 nm with 10 mM NPA in 
TRIS buffer (pH 8, 50 mM) over eight cycles. b) Activity determination of LP-MSN-HRP by measuring the 
absorbance at 470 nm of emerging oxidized guaiacol (2-methoxyphenol) in potassium phosphate buffer (pH 7, 
0.2 M) for 100 s (interval 1 s) over eight catalytic cycles. The enzyme’s reaction rate was determined from the 
slope of the first cycle’s linear region (gray curve, from 0 s-15 s). c) Catalytic activity of native versus 
functionalized carbonic anhydrase (assay described in a)). Comparison of catalytic activity of native (free) CA 
(purple line ± SD light purple area) versus functionalized CA (sp-CA) (cyan line ± SD light cyan area). d) 
Activity comparison of native versus functionalized horseradish peroxidase (assay described in b)). Activity 
determination of native (free) HRP (purple line ± SD light purple area) versus sp-HRP (cyan line ± SD light cyan 
area) by measuring the absorbance of oxidized guaiacol at 470 nm for 100 s. 
The resulting activity of immobilized carbonic anhydrase was also determined in international 
units IU, which is described in the Appendix. The expressed activity of the biocatalyst LP-
MSN-CA results in 8.4 units (per 5 mg MSNs) i.e. 1680 units / g support. The corresponding 
amount of free enzyme shows an activity of 85.6 units and therefore performs one order of 
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magnitude faster than the immobilized enzyme, which might be attributed to partial blocking 
of the enzyme due to the statistical attachment of the enzyme molecules inside the pores. All 
in all, it could be shown that carbonic anhydrase was successfully immobilized inside the 
large pores of our MSNs and remained there stable and active. 
Horseradish peroxidase activity determination 
In order to determine the catalytic activity of the MSN-bound HRP molecules, an assay 
involving the oxidation of guaiacol was performed.
45
 Thereby, the catalyzed oxidation of 
guaiacol was measured by recording the absorption of the produced tetraguaiacol at 470 nm 
with UV-Vis spectroscopy (Figure 6-3b, for experimental details see Methods section and 
Figure S 6-8, Appendix). The remaining stability and activity of the immobilized enzyme 
could be shown over several cycles just as well as in the case of carbonic anhydrase. To 
determine the reaction rate, the slope in the linear region (0 s - 15 s) of the first cycle’s graph 
(gray graph) was used and converted into concentration vs. time (Figure S 6-9, Appendix) 
using Lambert-Beer’s law (with ε = 26.6 mM
-1
cm
-1
 from Maehly and Chance
45
 and d = 1 cm). 
The rate was calculated to be 2.5 x 10
4
 M
-1
 cm
-1 
according to Maehly and Chance.
45
 In 
comparison to the literature value
45
 of 3 x 10
5
 M
-1
 cm
-1
, our immobilized enzyme performs 
slower by about one order of magnitude than the free corresponding sp-enzyme. The resulting 
activity of immobilized horseradish peroxidase (definitions of IU at the end of the Appendix) 
is 0.86 units (per 0.16 mg MSN) i.e. 5343 units / g support. The corresponding amount of free 
enzyme shows an activity of 3.7 units, resulting in an only fourfold better performance than 
our immobilized HRP.  
Note that the enzyme concentration used in the calculations is the upper limit. Due to a 
necessary centrifugation step before the activity assay a small loss of particles and therefore 
enzyme is inevitable, thus reducing the enzyme concentration. Since the enzyme 
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concentration is inversely proportional to the calculated reaction rate, our value of the 
calculated reaction rate represents a lower limit. Additionally, some horseradish peroxidase 
molecules could be partially hindered or blocked due to the random attachment of the large 
enzymes into the rather tightly matching pores; the active center might not always be 
perfectly accessible for the substrates. This may explain the lower reaction rate in comparison 
to unbound HRP.  
To prove that alkyne-functionalisation of the enzymes does not impair their catalytic activity, 
the activity assays were performed with the native versus alkyne-functionalized enzymes. In 
both cases (Figure 6-3c and Figure 6-3d) it can be shown that the catalytic performance is 
maintained after enzyme-functionalization.  
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6.3. Conclusion 
We report a facile delayed co-condensation strategy for the synthesis of spatially segregated 
core-shell bi-functional large-pore MSNs. This direct approach towards introducing organo-
moieties into the mesopores is highly beneficial since different functionalities can be 
efficiently introduced at controlled concentrations. This method further avoids additional 
grafting steps that may be difficult with colloidal systems. Our synthesis yields mesoporous 
silica nanoparticles within a size range of about 100 nm exhibiting large pore sizes of up to 
12 nm and carrying azide-functionalities inside the pore system. This organo-functionalization 
makes the LP-MSNs suitable for a biocompatible modification via click chemistry. We 
covalently immobilized the two enzymes carbonic anhydrase and horseradish peroxidase in 
the interior of the LP-MSN-N3 host.  
The lyase carbonic anhydrase (CA) (4.0 x 4.2 x 5.5 nm
3
)
47
 and the peroxidase horseradish 
peroxidase (HRP) (4.0 x 4.4 x 6.8 nm
3
)
48
 were successfully modified with alkyne-linkers to 
enable grafting through a Cu-catalyzed click reaction. The enzymes were allowed to diffuse 
into the mesopores before the catalysts for the click reaction were added to the reaction 
mixture, thus avoiding unfavorable pore blocking and low catalytic activity. We could 
demonstrate in this study that both enzymes are still highly active in their immobilized state, 
and that they maintain high activity during activity assays over several cycles.  
Overall, we present a spatially structured colloidal MSN-based system with large pores for the 
immobilization of active biomolecules that holds promise as a versatile platform for numerous 
applications.  
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6.4. Experimental Part 
Materials. Tetraethyl orthosilicate (TEOS, Aldrich, ≥ 99%), phenyltriethoxysilane (PhTES, 
Aldrich, > 98%), cetyltrimethylammonium p-toluenesulfonate (CTATos, Sigma), 
triethanolamine (TEA, Aldrich, 98%), (3-chloropropyl) triethoxysilane (CPTES, Fluka, 95%), 
diethyl ether (Et2O, Sigma, >98%), sodium azide (Fluka, 99%), ethanol (EtOH, Aldrich, 
absolute), conc. hydrochloric acid (HCl, Aldrich, 37%), ammonium nitrate (NH4NO3, Sigma, 
99%), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDC, Alfa Aesar, 98%), 4-
pentynoic acid (Fluka, 97%,), tris(hydroxymethyl) aminomethane (TRIS, Sigma, 99.8 %), 2-
(N-morpholino)ethanesulfonic acid (MES, Sigma, 99.5 %), carbonic anhydrase from bovine 
erythrocytes (Sigma, ≥95% (SDS-PAGE), specific activity ≥3,500 W-A units/mg protein, 
lyophilized powder), peroxidase from horseradish (Sigma, Type VI-A, essentially salt-free, 
lyophilized powder, 950-2000 units/mg solid (using ABTS), ≥250 units/mg solid (using 
pyrogallol)), (+)-sodium L-ascorbate (Sigma, ≥98%), copper(II) sulfate (Sigma, ≥99.99%), 
disodium hydrogen phosphate (Na2HPO4, Sigma, >99%), monosodium hydrogen phosphate 
(NaH2PO4, Sigma, >99%), sodium hydroxide (1 M, Sigma), dipotassium hydrogen phosphate 
(K2HPO4, Sigma, >99%), monopotassium hydrogen phosphate (KH2PO4, Sigma, >99%), 4-
nitrophenyl acetate (Sigma, esterase substrate), guaiacol (Sigma, oxidation indicator, 
≥98.0%), hydrogen peroxide (Sigma, 30 wt%). Unless otherwise noted, all reagents were used 
without further purification. Bi-distilled water from a Millipore system (Milli-Q Academic 
A10) was used for all syntheses and purification steps. 
Methods. For transmission electron microscopy, samples were investigated with an FEI Titan 
80-300 transmission electron microscope (TEM) operating at 300 kV with a high-angle 
annular dark field detector. A droplet of the diluted MSN solution in absolute ethanol was 
dried on a carbon-coated copper grid. The TEM, SEM and STEM micrographs in Figure 
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6-1a-c show template-extracted mesoporous large pore silica particles (LP-MSN-N3) 
generated with the above described synthesis procedure (details below). Nitrogen sorption 
measurements were performed on a Quantachrome Instruments NOVA 4000e and on an 
Autosorb iQ instrument. All samples with attached enzyme (15 mg each) were treated at 298 
K (12 h in vacuo), whereas the sample LP-MSN- N3 was heated to 393 K for 12 h in vacuo 
(10 mTorr) to outgas the samples before nitrogen sorption was measured at 77 K. For 
calculations of pore sizes and volumes a non-local density functional theory (NLDFT) 
equilibrium model of nitrogen on silica was used. The obtained physisorption data for LP-
MSN-N3 are shown in Figure 6-1e (nitrogen sorption isotherm) and Figure 6-1f (pore size 
distribution) and in Figure 6-2a (isotherms) and Figure 6-2b (pore size distribution) for LP-
MSN-CA and LP-MSN-HRP. Dynamic light scattering (DLS) measurements were performed 
on a Malvern Zetasizer-Nano instrument equipped with a 4 mW He-Ne laser (633 nm) and an 
avalanche photodiode. The hydrodynamic radius of the particles was determined by dynamic 
light scattering in water. The data are shown in Figure 6-1d. Thermogravimetric analysis of 
the bulk samples LP-MSN-N3, LP-MSN-CA and LP-MSN-HRP was performed on a Netzsch 
STA 440 C TG/DSC with a heating rate of 10 K / min in a stream of synthetic air of about 25 
mL/min. The mass was normalized to 100% at 130 °C for all samples and the resulting data 
are presented in Figure 6-2c. All IR measurements were performed on a Thermo Scientific 
Nicolet iN10 IR Microscope in reflection-absorption mode with a liquid nitrogen-cooled 
MCT-A detector. All spectra are background corrected. UV-Vis measurements were 
performed on a Perkin Elmer Lambda 1050 spectrophotometer with a deuterium arc lamp 
(UV region) and a tungsten filament (visible region). The detector was an InGaAs integrating 
sphere detector. Time-based enzyme activity assays were performed in macro PMMA-
cuvettes (path length 10 mm). For small sample amounts (2 µl of the sample) a NanoDrop 
2000c spectrometer from Thermo Scientific Fisher was employed for UV-Vis measurements. 
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The absorbance at 280 nm (mode A280) was used to determine carbonic anhydrase 
concentrations.  
Buffer preparation. 
MES buffer (0.1 M, pH 6.0). 2-(N-morpholino)ethanesulfonic acid (MES, 9,76 g) was 
dissolved in water (500 mL). The pH was adjusted to 6.0 using sodium hydroxide (1 M).  
Sodium phosphate buffer (5 mM, pH 7.4). Monosodium hydrogen phosphate (2.92 g) and 
disodium hydrogen phosphate (7.74 g) were dissolved in 10 L of water (5 mM). The pH was 
fine-adjusted to 7.4 with NaOH or HCl using a pH-meter. 
Potassium phosphate buffer (0.2 M, pH 7.0). Monopotassium hydrogen phosphate 
(13.61 g) and dipotassium hydrogen phosphate (17.40 g) were dissolved in water (500 mL). 
The pH was fine-adjusted to 7.0 with NaOH or HCl using a pH-meter. 
TRIS buffer (0.1 M, pH 8.0). Tris(hydroxymethyl)aminomethane (TRIS, 6.075 g) was 
dissolved in water (500 mL). The pH was adjusted to 8.0 using HCl (1 M). 
Synthesis of alkyne-modified enzymes (sp-enzymes).  
Carbonic Anhydrase (sp-CA). To a freshly prepared, cooled solution (4 °C) of carbonic 
anhydrase (40 mg, Mw = 29000 g/mol, 1.38 µmol) in MES buffer (pH 6, 18.7 mL, 0.1 M), an 
aqueous solution (1 mL) of 4-pentynoic acid (0.1 M, 9.81 mg, 0.1 mmol) was added. The 
resulting mixture was vortexed for 2 min and then stored at 4 °C for 15 min. Subsequently, 
EDC (11.5 mg, 0.07 mmol) was added to the solution. The reaction was vortexed again for 
2 min and then kept at 4 °C for 4 h without stirring. Afterwards, the obtained solution was 
dialyzed in a cold room at 4 °C against sodium phosphate buffer (5 mM, pH 7.4, 10 L) for a 
period of 24 h. The concentration of sp-CA (3.027 mg/mL) was determined with Nanodrop. 
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The alkyne-functionalized carbonic anhydrase was used for click reactions without further 
purification.  
Horseradish peroxidase (sp-HRP). Alkyne-functionalized horseradish peroxidase was 
synthesized according to Gole et al. as described above.
42
 The concentration of sp-HRP 
(1,32 mg/mL) was determined with UV-Vis spectroscopy (calibration curve, Figure S 6-2). 
Synthesis of (3-azidopropyl) triethoxysilane. (3-Azidopropyl)triethoxysilane was 
synthesized according to a procedure published by Nakazawa et al..
43
 (3-
chloropropyl)triethoxysilane (10 g, 41.7 mmol) and sodium azide (10 g, 154 mmol) were 
heated in anhydrous DMF (100 mL) under inert gas conditions at 90 °C for 4 h. Low boiling 
materials were removed from the mixture under reduced pressure. The crude oily product was 
dissolved in diethyl ether, resulting in the precipitation of salts, which were removed by 
filtration. Et2O was removed in vacuo and the residual oil was distilled (95 °C).  
(3-azidopropyl)triethoxysilane was obtained as colorless liquid and used without further 
purification.  
Synthesis of azide functionalized large pore mesoporous silica nanoparticles (LP-
MSN-N3). Core-shell bi-functional (MSN-N3,in-Phout) MSNs were synthesized through a 
delayed co-condensation approach based on an adapted recipe reported in the literature.
18
 In 
brief, TEA (0.047 g, 0.32 mmol), CTATos (0.263 g, 0.58 mmol) and H2O (13.7 g, 
0.77 mmol) were mixed in a 100 mL round bottom flask and stirred vigorously (1250 rpm) at 
80 °C until the surfactant solution became homogeneous. TEOS (1.71 g, 8.2 mmol) and 
AzTES ((3-azidopropyl)triethoxysilane) (120 µL, 0.41 mmol; 5 mol%) were mixed and added 
to the surfactant solution and the mixture was stirred (1250 rpm) at 80 °C for 1 h. Afterwards, 
201 mg of TEOS (0.96 mmol) was separated into 4 aliquots and added to the mixture every 
3 minutes. The solution was further stirred for 1 h at 80 °C. A mixture of TEOS (20.1 mg, 
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0.096 mmol) and PhTES (phenyltriethoxysilane) (22.9 mg, 0.096 mmol, 1 mol%) was then 
added to the solution to generate the outer shell of the MSNs. The resulting solution was 
continuously stirred at 80 °C for 1 h. The as-synthesized particles were collected by 
centrifugation (7197 g, 20 min) and were subsequently template extracted (see below). 
Template removal from LP-MSN-N3. The organic template was removed via extraction 
from LP-MSN-N3. Thus, 1 g of the as-synthesized particles was heated in an ethanolic 
solution (150 mL) containing 3 g ammonium nitrate at 90 °C under reflux for 1 h, cooled and 
collected by centrifugation (7197 g, 20 min) and extracted by a second reflux at 90 °C using a 
2 M HCl/ethanolic solution (150 mL) for 1 h. Afterwards, samples were washed in the 
sequence EtOH, H2O, EtOH (100 mL per wash) and were finally kept in 20 mL EtOH. 
Particles were collected by centrifugation (7197 g, 20 min) after each template extraction and 
washing step.  
Immobilization of alkyne-functionalized carbonic anhydrase in LP-MSN-N3 (LP-MSN-
CA). An ethanolic suspension containing 50 mg LP-MSN-N3 was centrifuged (10 min, 7197 
g), washed with 15 mL sodium phosphate buffer (0.2 M, pH 7.2) and re-dispersed in 2.5 mL 
sodium phosphate buffer as well as 2 mL water. The suspension was vortexed for 2 minutes 
and put into an ultrasonic bath for 10 minutes to remove agglomerates. Subsequently, the 
buffered solution of sp-CA (containing 9 mg, 0.3 µmol sp-CA) was added and the resulting 
mixture was stirred for 30 minutes at room temperature. In the meantime, sodium ascorbate 
(1 mg, 5.05 µmol) was added to a solution of Cu(II)SO4 (1.25 mg, 1 mmol) dissolved in 5 mL 
water and stirred for 10 min at ambient temperature. 12 µL of this freshly prepared solution 
was added to the reaction mixture containing LP-MSN-N3 and sp-CA to catalyze the covalent 
attachment of the enzyme via click chemistry. The resulting suspension was shaken (600 rpm) 
for 30 minutes at room temperature. Subsequently, the particles were collected by 
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centrifugation (10 min, 5500 g, 15 °C) and re-dispersed in 30 mL water. This washing 
procedure was repeated three times. LP-MSN-CA were obtained as colloidal solution in water 
and were stored at -20 °C until further use.  
Horseradish peroxidase (LP-MSN-HRP). Sp-Horseradish peroxidase was immobilized onto 
LP-MSN-N3 via a click chemistry approach according to the synthesis procedure described 
above for sp-CA. An ethanolic suspension containing 50 mg LP-MSN-N3 was centrifuged 
(10 min, 7197 g), washed and re-dispersed as described above. Afterwards, the buffered 
solution of sp-HRP (containing 9 mg, 0,2 µmol sp-HRP) was added and the mixture was 
stirred for 30 minutes at room temperature before the freshly prepared catalyst solution 
consisting of sodium ascorbate and Cu(II)SO4 (see above) was added. LP-MSN-HRP 
nanoparticles were obtained as colloidal solution in water after several washing steps. 
Catalytic activity determination of LP-MSN-CA. The catalytic activity of LP-MSN-CA 
was determined by an adapted method published by Shank et al..
44
 Fresh solutions of 4-
nitrophenyl acetate (NPA, 10 mM, 18.1 mg, 0.1 mmol in 10 mL EtOH) and TRIS buffer 
(50 mM, pH 8) were prepared shortly before the experiment. 500 µl of an aqueous suspension 
of LP-MSN-CA (containing 5 mg particles and therefore 0.71 mg carbonic anhydrase, 
calculated from TGA-data) were mixed in macro PMMA-cuvettes with 400 µL TRIS buffer. 
Subsequently, 100 µl NPA-solution were added quickly before the time-dependent hydrolysis 
of the substrate was determined by measuring the absorbance of the formed 4-nitrophenol 
(400 nm, 120 s and intervals of 1 s). All spectra were background corrected. After a finished 
cycle, the assay mixture was centrifuged (10 min, 16900 g, 15 °C) and washed with 1 mL 
water. The washing procedure was repeated three times before the particles were redispersed 
in 500 µl water and used for the next cycle. 
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Catalytic activity determination of LP-MSN-HRP. To determine the catalytic activity of 
immobilized horseradish peroxidase (LP-MSN-HRP) a slightly modified assay following the 
published protocol of Maehly and Chance was used.
45
 All substrate solutions and potassium 
phosphate buffer (pH 7.0, 0.2 M) were freshly prepared. 5 mg LP-MSN-HRP were 
resdipersed in 100 µL H2O and 3 mL buffer as well as 50 µL guaiacol solution (0.5 mM, 
2.8 µL in 50 mL water) added and mixed. Subsequently, 20 µL H2O2 (12.3 mM) were added, 
the cuvette once inverted and the time-dependent formation of the coloured product 
determined by UV-VIS spectroscopy (470 nm, 100 s, intervals of 1 s). All spectra were 
background corrected.  
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6.6. Appendix 
 
Figure S 6-1 Infrared spectrum of LP-MSN-N3. The asterisked peak indicates the typical vibration arising from 
the azide-functionality. 
IR spectroscopy was carried out to verify the presence of azide moieties in LP-MSN-N3. The 
asymmetric CH2 stretching vibrations of the azidopropyl-moieties are visible between 
2990 cm
-1
 and 2940 cm
-1
. Furthermore, the CH2 bending vibration appears at 1451 cm
-1
. The 
asterisked strong vibration at 2105 cm
-1
 is attributed to the stretching vibration of the N3-
groups. The vibration at 1633 cm
-1
 appears with lower intensity and can be attributed to the 
vibrations of residual amounts of water in the sample. Vibrations of the silica framework are 
visible below 1300 cm
-1
 with strong intensities. 
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Figure S 6-2 Calibration curve of sp-HRP. Absorbance of different concentrated solutions of alkyne-
functionalized horseradish peroxidase was measured at 403 nm via UV-Vis and fitted linearly with Origin 9.0 
(inserted box). 
To estimate the amount of sp-enzyme attached on the solid support, thermogravimetric 
analyses of the samples LP-MSN-N3, LP-MSN-CA and LP-MSN-HRP were performed 
(Figure 6-2c). From the additional mass loss of 11.5% for the sample LP-MSN-CA the 
amount of attached enzyme can be estimated to be 4.7 µmol per g silica (for calculation see 
Calculation A 6—1 below). This indicates that 0.5% of all azide moieties have reacted with 
sp-CA, as the amount of azide-moieties was estimated to be 1.02 mmol per g silica. From the 
additional mass loss of 9.4%, the amount of immobilized HRP can be estimated to be 
2.6 µmol per g silica (see Calculation A 6—1) and the amount of azide-moieties can be 
estimated at 1.02 mmol per g silica. Horseradish peroxidase is sterically somewhat more 
demanding than CA due to its larger dimensions (4.0 x 4.4 x 6.8 nm
3
)
1
 and was only able to 
react with 0.25% of all azide moieties of LP-MSN-N3.  
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Calculation A 6—1 Example for the calculation for thermogravimetric analysis (TGA) of sample LP_MSN-N3 
and LP_MSN-CA 
1 g sample LP_MSN-N3 contains 77 mg azide-residues (mass loss 9.2%, 
Mw (C3H6N3) = 81,05 gmol
-1
 5:1 Mw (C6H5) = 77,1 gmol
-1
 mass loss for azide-moieties 
7.7%)  
77 𝑚𝑔
(100% − 7.7%) 𝑔
= 83 𝑚𝑔 𝑎𝑧𝑖𝑑𝑒 − 𝑟𝑒𝑠𝑖𝑑𝑢𝑒𝑠 / 𝑔 𝑠𝑖𝑙𝑖𝑐𝑎 
0.083 𝑔 
81.05 
𝑔
𝑚𝑜𝑙
= 1.02 𝑚𝑚𝑜𝑙 𝑎𝑧𝑖𝑑𝑒 − 𝑟𝑒𝑠𝑖𝑑𝑢𝑒𝑠 / 𝑔 𝑠𝑖𝑙𝑖𝑐𝑎 
 
1 g sample LP_MSN-CA contains 115 mg CA (additional mass loss 11.5%, 
Mw(CA) = 30 000 gmol
-1
) 
 
115 𝑚𝑔
(100% − 7.7% − 11.5%) 𝑔
= 142 𝑚𝑔 𝐶𝐴 / 𝑔 𝑠𝑖𝑙𝑖𝑐𝑎 
0.142 𝑔 
30 000 
𝑔
𝑚𝑜𝑙
=  4.7 µ𝑚𝑜𝑙 𝐶𝐴 / 𝑔 𝑠𝑖𝑙𝑖𝑐𝑎 
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Figure S 6-3 IR spectra of sp-CA (pink), LP-MSN-CA (purple) and LP-MSN-N3 (black). The spectrum of LP-
MSN-CA was shifted along the y-axis by a value of 0.5 and the spectrum of sp-CA by a value of 1.5 for clarity 
reasons. The peak at 1658 cm
-1
 (dashed line) can be attributed to the C=O stretching vibration and that at 
1530 cm
-1
 (dashed line) to the N-H bending vibration of the peptide bonds in sample LP-MSN-CA. Due to the 
large portion of unclicked azide-groups inside the particles, the N3-stretching vibration at 2105 cm
-1
 can be seen 
in both samples – the particles without and with carbonic anhydrase. 
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Figure S 6-4 IR spectra of sp-HRP (blue), LP-MSN-HRP (cyan) and LP-MSN-N3 (black). The spectrum of LP-
MSN-HRP was shifted along the y axis by a value of 0.5 and the spectrum of sp-HRP by a value of 1.25 for 
clarity reasons. The modes at 1658 cm
-1
 (dashed line) can be attributed to the C=O stretching vibration and those 
at 1534 cm
-1
 (dashed line) to the N-H bending vibration of the peptide bonds in sample LP-MSN-HRP. The 
stretching of the azide-moieties can also be observed at 2105 cm
-1
 (see explanation above). 
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Figure S 6-5 Image and reaction scheme of catalytic activity assay for immobilized carbonic anhydrase. On the 
left: Sample LP_MSN-CA at the time points t = 0 sec (colourless) and t = 120 sec after the start of the hydrolysis 
reaction of 4-nitrophenyl acetate (4-NPA) in water and TRIS buffer (pH 8). 
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Figure S 6-6 Comparison of 4-NPA’s self-hydrolysis and catalytic performance of LP-MSN-CA. UV-Vis 
absorption measurement of LP-MSN-CA (Cycle 1; black curve) within a period of 120 s at 400 nm with 10 mM 
NPA and TRIS buffer versus 10 mM NPA only and TRIS buffer (red curve). 
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Figure S 6-7 Activity determination for LP-MSN-CA. UV-Vis absorption measurement of LP-MSN-CA within a 
period of 120 s at 400 nm with 1 mM NPA converted into concentration vs. time via Lambert-Beer law 
(ε = 16 300 M
-1
 cm
-1
).
2
 The rate of 4-NPA’s self-hydrolysis is considered and already subtracted from the 
measured curve (not shown here). 
 
Figure S 6-8 Activity determination for LP-MSN-CA. UV-Vis absorption measurement of LP-MSN-CA within a 
period of 120 s at 400 nm with 1 mM NPA converted into concentration vs. time via Lambert-Beer law 
(ε = 16 300 M
-1
 cm
-1
).
2
 The rate of 4-NPA’s self-hydrolysis is considered and already subtracted from the 
measured curve (not shown here). 
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Figure S 6-9 Activity determination for LP-MSN-HRP. Activity determination of LP-MSN-HRP by measuring 
the absorbance at 470 nm and converting the linear region of the first cycle into concentration via Lambert-Beer 
law (ε = 26.6 mM
-1
cm
-1
).
3
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Figure S 6-10 Standard curve of carbonic anhydrase for Bradford assay.
4-5
 The amount of immobilized carbonic 
anhydrase determined via the standard curve (shown above) is 3.4 µmol CA per g silica. In comparison to the via 
TGA determined amount of 4.7 µmol CA per g silica a deviation of almost 28% is asserted. This deviation is 
attributed to additional components in the channels of the mesoporous silica that contribute to weight changes 
during TGA measurements.  
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Figure S 6-11 Standard curve of horseradish peroxidase for Bradford assay. In the case of immobilized 
horseradish peroxidase the amount determined with the Bradford assay differs very little in comparison to 
carbonic anhydrase. Evaluation of the protein assay results in 2.4 µmol HRP per g silica whereas the amount 
determined with TGA is 2.6 µmol HRP per g silica which corresponds to a deviation of only ~ 8%. 
The expressed activity of the biocatalysts was determined according to the following 
definitions: 
1. Carbonic anhydrase: One international unit of activity (IU) was defined as the amount of 
enzyme that hydrolyzes 1 µmol of 4-NPA per liter per minute under the conditions 
described in the manuscript. 
The resulting activity of immobilized carbonic anhydrase is 8.4 units (per 5 mg MSNs), 
i.e. 1680 units / g support. The respective amount of free enzyme shows an activity of 
85.6 units. 
2. Horseradish peroxidase: One international unit of peroxidase activity is defined as the 
amount of enzyme catalyzing the oxidation of 1 µmol of guaiacol per liter per minute 
under the conditions described in the manuscript. 
The resulting activity of immobilized horseradish peroxidase is 0,86 units (per 0,16 mg 
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MSN) i.e. 5343 units / g support. The respective amount of free enzyme shows an activity 
of 3.7 units. 
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7. Biocompatible crosslinked β-cyclodextrin nanoparticles as 
multifunctional carriers for cellular delivery  
 
This chapter was published as:  
Stefan Datz, Bernhard Illes, Dorothée Gößl, Constantin v. Schirnding, Hanna Engelke*, 
Thomas Bein* Nanoscale, 2018, 10, 16284-16292. Reproduced with permission from The 
Royal Society of Chemistry. 
 
Abstract 
Nanoparticle-based biomedicine has received enormous attention for theranostic applications, 
as these systems are expected to overcome several drawbacks of conventional therapy. 
Herein, effective and controlled drug delivery systems with on-demand release abilities and 
biocompatible properties are used as a versatile and powerful class of nanocarriers. We report 
the synthesis of novel biocompatible and multifunctional material, entirely consisting of 
covalently crosslinked organic molecules. Specifically, β-cyclodextrin (CD) precursors were 
crosslinked with rigid organic linker molecules to obtain small (~150 nm), thermally stable 
and highly water-dispersible nanoparticles with an accessible pore system containing β-CD 
rings. The nanoparticles can be covalently labeled with dye molecules to allow effective 
tracking in in vitro cell experiments. Rapid sugar-mediated cell-uptake kinetics were observed 
with HeLa cells, revealing exceptional particle uptake within only 30 minutes. Additionally, 
the particles could be loaded with different cargo molecules showing pH-responsive release 
behavior. Successful nuclei staining with Hoechst 33342 dye and effective cell killing with 
doxorubicin cargo molecules were demonstrated in live-cell experiments, respectively. This 
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novel nanocarrier concept provides a promising platform for the development of controllable 
and highly biocompatible theranostic systems. 
7.1. Introduction 
Cancer therapy is currently shifting from a standardized systemic approach to a more 
personalized and specifically customized disease treatment. Such personalized treatments use 
multifunctional drugs in combination with carrier systems and are ideally based on molecular-
level diagnosis.
1
 After decades of research, the demand for innovative biocompatible 
nanomaterials for the transport of therapeutic agents is still growing. In particular, 
nanoparticle-based targeting of tumor cells has emerged as a potential therapeutic approach to 
release effective drug doses within the tumorous tissue.
2-6
 Because of the prolonged blood 
circulation time combined with nonspecific accumulation in tumors through the enhanced 
permeability and retention (EPR) effect, nanoparticles have been regarded as a suitable 
candidates in pharmaceutical fields, especially for targeted and personalized cancer therapy. A 
number of different carrier systems have been investigated in the field of nanobiosciences 
with differing results in the last decade. Besides inorganic materials, such as mesoporous 
silica nanoparticles (MSNs),
7-15
 periodic mesoporous organosilica nanoparticles (PMOs),
10, 16-
20
 or metal-based materials, e.g. Au-
21-23
 or iron oxide nanoparticles,
24-29
 polymeric 
micelles,
30-32
 lipids,
33-35
 and DNA origami are other examples for potential drug delivery 
systems used in fundamental biomedical research,
36-38
 However, some of these materials have 
certain drawbacks, e.g. polymeric micelles and lipids often need specific formulations for 
different cargos, and may face stability issues. Besides small magnetic iron-oxide based 
materials, none of the other larger solid nanoparticles, such as silica materials, have reached 
clinical trials, partially due to concerns about the unknown fate of these particles in the human 
organism.
39
 In contrast to the ever-growing number of sophisticated nanoparticle-based cell-
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targeting strategies that effectively target tumor cells in vitro, only few studies showed 
successful tumor-cell specific targeting and controlled cancer cell killing in vivo. Even fewer 
nanoformulations have found their way into clinical studies and practice.
40
 Ligand-assisted 
targeting of cancer cells with nanoparticles in vivo through specific receptor-mediated uptake 
can be limited due to protein corona formation.
41
 Therefore, there is a rapidly growing interest 
in new nanomaterials which can overcome some of the aforementioned limitations. Sugar-
based materials are promising candidates since cancer cells are known to have a faster 
glycolysis metabolism that selectively leads to an increased glucose uptake compared to 
healthy cells.
42-45
  
Here, we present a novel class of biocompatible multifunctional nanomaterials consisting of 
cross-linked β-cyclodextrin molecules. Cyclodextrins (CDs) are a family of cyclic 
oligosaccharides composed of six, seven, or eight D(+)-glucose units linked by α-1,4-
linkages, which are named α-, β-, and γ-CD, respectively.
46
 These different oligosaccharides 
are frequently used in the medical field because of their biocompatibility and their low 
toxicity.
47-50
 CDs have a hydrophilic exterior and a hydrophobic cavity inside the 
oligosaccharide rings that can be used to encapsulate different kinds of guest and cargo 
molecules.
51-54
 This encapsulation is based on supramolecular host-guest interactions such as 
hydrogen bonding, van-der-Waals forces or hydrophobic interactions, and is used in various 
applications including biomedicine, catalysis, environmental protection and separation 
processes.
55
 Although the use of different CDs in the medical field has been documented for 
decades, their application is still rather limited due to significant synthetic challenges, hence 
motivating the development of more specific and controllable CD-containing nanoparticles. 
Until now, a variety of supramolecular nanoparticles (SNPs) with CD-building blocks have 
been investigated. However, SNPs are particles in which different building blocks are brought 
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together by non-covalent interactions resulting in larger assemblies.
56
 The assembly is either 
based on electrostatic interactions or host-guest interactions.
57, 58
 The non-covalent 
interactions limit their use for drug delivery applications, since they might degrade easily 
before they reach their target. Furthermore, any new guest molecule that is incorporated or 
loaded into the particle needs to be optimized regarding its interactions with the particle 
structure. Thus, a covalently crosslinked CD nanoparticle is viewed as an enabling concept 
that could facilitate a breakthrough for drug delivery applications. Recently, different 
approaches were used to prepare covalently crosslinked CD molecule-containing materials. 
One is defined by crosslinking α-CD-poly-ethyleneglycol (PEG) inclusion complexes by 
using epichlorohydrin. The nanomaterial was obtained after extracting the PEG chains that 
penetrated the hydrophobic cavity.
59
 In another approach, Dichtel et al. polymerized β-CD in 
a nucleophilic aromatic substitution reaction with tetrafluoroterephthalonitrile and obtained 
mesoporous bulk material that was used to rapidly remove organic micropollutants from 
waste water.
60
 However, no nanoparticles of covalently crosslinked CD molecules were 
obtained yet. 
Here, we combined these different approaches to crosslink β-CD-PEG inclusion complexes 
with rigid aromatic groups providing for the first time small, dispersible, and thermally stable 
nanoparticles. These NPs can be covalently labeled with dye molecules exploiting simple 
click-chemistry to track them effectively in in vitro cell experiments. β-CD NPs are rapidly 
taken up by cancer cells and can efficiently release different cargo molecules. This novel and 
biocompatible nanocarrier concept provides a promising platform for the development of 
controllable and efficient theranostic systems. 
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7.2. Results and Discussion 
Highly dispersible and thermally stable β-CD NPs for drug delivery applications were derived 
from a carefully controlled nucleophilic aromatic substitution reaction with 
tetrafluoroterephthalonitrile (TFTN, see Figure 7-1A).  
 
 
Figure 7-1: Synthesis scheme of β-CD NPs following a nucleophilic aromatic substitution reaction with TFTN 
(A), SEM images of β-CD NPs showing spherical particles with a narrow particle size distribution (B). 
Since cyclodextrins (CDs) are known to form inclusion complexes with certain linear polymer 
chains such as poly(ethylene glycol) (PEG), this approach was used to create self-assembled 
aggregates of CD nanostructures.
61
 By modifying previously described synthesis procedures, 
these polyrotaxane structures were reacted with the rigid aromatic linker TFTN to form small 
and water-dispersible spherical nanoparticles. The β-CD-PEG inclusion complexes self-
assembled with the help of CTAB surfactant into spherical nanostructures and were 
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subsequently polymerized and cross-linked with TFTN in a suspension of K2CO3 in 
dimethylsulfoxide (DMSO) at 80 °C. Several washing steps were essential to remove the 
excess of precursors, salt and the included PEG chains, resulting in a pale yellow suspension 
of β-CD NPs with a yield of 25 %. As can be seen in the scanning electron microscopy (SEM) 
images in Figure 7-1B the obtained nanoparticles exhibit diameters of 150 to 200 nm with a 
narrow particle size distribution. Additional transmission electron microscopy (TEM) images 
can be found in the Appendix. Further characterization of the obtained nanomaterial is shown 
in Figure 7-2. Dynamic light scattering (DLS, Figure 7-2A) measurements reveal a high 
colloidal stability with hydrodynamic particle diameters of about 180 nm in water, rendering 
the obtained β-CD NPs useful for cellular delivery applications. Because of their exceptional 
colloidal stability without agglomeration in aqueous solutions, no additional hydrophilic 
coating such as PEGylation is necessary to use them in biotheranostics.
62
 Infrared 
spectroscopy (Figure 7-2B) was used to follow the formation of β-CD NPs with TFTN as the 
rigid organic crosslinker. The strong signal (a) at 1035 cm
-1
 corresponds to characteristic 
R3C-OH stretching vibrations due to the oligosaccharide rings of the incorporated 
β-cyclodextrin compounds. Signal (b) at 1260 cm
-1 
is due to saturated aliphatic C-O-C ether 
vibrations of the sugar rings and newly formed asymmetric alkyl-aryl-ether =C-O-C 
vibrations of the crosslinked material. The aromatic system of TFTN incorporated into the 
nanostructure of β-CD NPs is also confirmed by the signals (c) corresponding to aromatic -
C=C- stretching vibrations and (d) corresponding to the strong nitrile vibration. The very 
broad band (e) around 3200 cm
-1
 is attributed to O-H absorption of the incorporated 
oligosaccharide building blocks. Additional solid-state nuclear magnetic resonance (ssNMR) 
characterization reveals the presence of both TFTN and β-cyclodextrin in the crosslinked 
material (see Appendix). Figure 7-2C displays nitrogen sorption experiments of freeze-dried 
β-CD NPs and reveals an isotherm with a calculated specific Brunauer-Emmett-Teller (BET) 
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surface area of about 140 m
2
/g. The cumulative pore size distribution (inset) shows pore sizes 
ranging from 1 to 6.5 nm comprising the majority of the accessible pore volume of 
0.26 cm
3
/g. Thermogravimetric analysis (TGA) of β-CD NPs (Figure 7-2D) indicates the 
presence of a thermally stable material up to 285 °C and a complete mass loss of almost 
100 % up to 900 °C. Zeta potential measurements show that the nanoparticles have a negative 
surface charge of about -35 mV at pH 7 due to the free hydroxyl groups of the oligosaccharide 
compounds. This zeta potential is comparable to other nanocarriers such as unfunctionalized 
mesoporous silica nanoparticles.
63
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Figure 7-2: Characterization of β-CD NPs. A) Dynamic light scattering (DLS) revealing hydrodynamic particle 
diameters of about 180 nm in aqueous solution. B) Infrared spectroscopy data of β-CD (blue), TFTN (red) and β-
CD NPs (black) with characteristic vibrations. Spectra were normalized and shifted for clarity by 0.75 a.u. along 
the y-axis. C) Nitrogen sorption isotherm and pore size distribution (inset) of β-CD NPs. D) Thermogravimetric 
analysis (TGA) up to 900 °C of β-CD NPs. 
With this size and zeta potential as well as their porosity maintained even in the (partially 
collapsed) dry state, the particles reveal promising properties for drug delivery purposes. 
Therefore, the synthesized nanoparticles were subsequently used for in vitro drug delivery 
experiments. First, the cell uptake kinetics of rhodamine-labeled β-CD nanoparticles was 
studied on HeLa cells. To obtain labeled nanoparticles, the free nitrile groups of the 
incorporated organic crosslinker can be used to covalently attach specific dye molecules. 
Here, the fluorescent tetramethylrhodamine (TAMRA) azide was used under mild reaction 
conditions in a zinc-catalyzed formation of a tetrazole-ring with the free nitrile groups of β-
CD nanoparticles.
64
 The formation of the compound was followed with IR spectroscopy (see 
Appendix). After several washing steps the particles were used for in vitro experiments. 
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Figure 7-3: Upper panel: In vitro cell uptake of rhodamine-labeled β-CD nanoparticles (red) without additional 
coating (A, B) and with lipid coating (C) after 30 min of incubation on WGA-stained HeLa cells (green). The 
blurry red spot in C) results from an accumulation of particles on top of the cells. Lower panel: In vitro cell 
uptake of rhodamine-labeled β-CD nanoparticles (red) without additional coating (D, E) and with lipid coating 
(F) after 24 h of incubation on WGA-stained HeLa cells (green). Scale bar represents 10 μm, respectively. 
The upper panel of Figure 7-3 shows representative confocal microscopy images of particle 
uptake by HeLa cells after just 30 min of incubation. The red-fluorescent material was 
efficiently internalized by cancer cells - even after very short incubation times of 30 minutes 
(Figure 7-3 A, B). Compared to the uptake of other nanomaterials, the internalization was 
very fast, possibly due to the oligosaccharide nature of the particles and sugar-receptor 
mediated endocytosis.
65, 66
 As a reference experiment, the particles were coated with a lipid 
bilayer in order to compare cell uptake kinetics with as-synthesized β-CD nanoparticles (see 
Figure 7-3 C and F, synthesis and characterization of lipid coating see Appendix). After 
30 min, exclusively uncoated β-CD nanoparticles were taken up by HeLa cells, whereas after 
24 h of incubation both particle types are internalized. The experiment leads us to the 
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assumption that the oligosaccharides are effectively taken up via sugar receptors and that the 
oligosaccharides can be shielded by the lipid coating resulting in slower cell uptake compared 
to the sugar-receptor mediated endocytosis of the uncoated particles. This suggests that a 
surface coating for as-synthesized β-CD nanoparticles is counterproductive for cellular 
uptake.  
In order to obtain more insights into the endocytosis pathway of β-CD nanoparticles, an in 
vitro competition experiment was performed. For this purpose, prior to the particle incubation 
the sugar receptors on the external cell surface of HeLa cells were saturated by adding 
concentrated aqueous solutions of different mono- and oligosaccharides, namely D-glucose, 
D-L-arabinose, 2-deoxy-D-glucose and β-cyclodextrin (see Appendix, Figure S 7-3). In all 
cases the particle uptake was hindered when the receptors were blocked, confirming our 
hypothesis that the endocytosis of β-CD nanoparticles is mediated via a specific sugar-
receptor mediated cell uptake.  
Next, the drug delivery and release properties of β-CD nanoparticles were evaluated by the 
loading and release of different guest molecules, namely Hoechst 33342 as nuclei staining dye 
and doxorubicin as model chemotherapeutic agent. Rhodamine-labeled β-CD NPs were 
loaded with Hoechst 33342 or doxorubicin and subsequently used for in vitro release 
experiments. 
First, we studied loading and release of Hoechst 33342. Strikingly, the benzimidazole-
containing compound is effectively loaded and efficiently released after particle endocytosis 
due to the acidification in the lysosomal compartments that destroys the hydrophobic 
interaction of Hoechst 33342 and the particle cavities (Figure 7-4). 
67, 68
 Since Hoechst 33342 
is membrane-permeable, it is able to penetrate the lysosomal membrane and to efficiently 
stain the nuclei of HeLa cells within very short time periods of less than 10 minutes.  
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Figure 7-4: In vitro HOECHST33342 release on HeLa cells. A) Rhodamin-labelled β-CD NPs (yellow) released 
HOECHST33342 nuclei staining (red) on WGA-stained HeLa cells (green) after just 2 h of incubation time. B) 
As a control experiment the supernatant of centrifuged particles (after 2 h) was added to HeLa cells showing no 
nuclei staining, i.e. no premature release of cargo molecules. Scale bar represents 10 μm. 
As a reference experiment, the particle solution used for the cell experiments was centrifuged 
after 2 h and the supernatant was incubated on HeLa cells. No nuclei staining could be 
observed. Since Hoechst 33342 is a live cell stain, any molecules in the solution would have 
stained the nuclei. The absence of any staining resulting from the supernatant demonstrates 
that no cargo molecules were released prematurely and that the in vitro nuclei staining is due 
to the acidification of nanoparticles in the endosomal compartments that triggers the release of 
the dye. This rapid and efficient delivery and release of Hoechst 33342 as model cargo 
suggests that the newly synthesized particles can serve as a promising drug delivery platform 
with controlled release mechanism.  
In order to investigate the ability of our newly developed drug delivery system to transport 
and release chemotherapeutics and to affect cancer cells with their cargo, we replaced the 
model cargo Hoechst 33342 with doxorubicin (DOX), a classic cytostatic agent. DOX is 
known to form inclusion complexes based on hydrophobic interactions with β-cyclodextrin 
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structures similarly to Hoechst 33342 and should therefore exhibit a similar loading and 
release behavior. Additionally, it should reveal a pH-responsive release behavior due to 
enhanced solubility when protonated.
69-71
 Hence, the loading and release behavior was first 
measured with fluorescence spectroscopy in a cuvette experiment.  
Figure 7-5: Time-based release measurements of doxorubicin at pH 7 (black curve) and pH 5 (red curve) in the 
fluorescence spectrometer. 
 
For this, we used our custom-made cuvette setup to measure the time-based pH-dependent 
release of fluorescent doxorubicin.
72
 DOX-loaded nanoparticle suspensions were placed into a 
dialysis membrane-sealed compartment (molecular weight cutoff = 14,000 Da) on top of a 
solvent-filled cuvette. Only released doxorubicin was able to diffuse through the pores of the 
membrane and was measured with the fluorescence spectrometer, while the nanoparticles are 
prevented from diffusing into the cuvette by the dialysis membrane. To prove successful 
loading without leakage of the cargo, a control experiment was performed in HBSS buffer at 
pH 7.4. Furthermore, to prove the efficient release of doxorubicin at lower pH, a second 
experiment was performed in parallel with Citric Acid Phosphate Buffer at pH 5. The 
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corresponding release curves are shown in Figure 5. They indicate only a small amount of 
residual DOX released at pH 7.4 and efficient release at pH 5. Next, the effect of DOX-
containing particles on HeLa cells was investigated. 
 
Figure 7-6: Dose-dependent cell-viability study with HeLa cells after 24 h of incubation with β-CD NPs, DOX-
loaded β-CD NPs and the supernatant after centrifugation as a reference. 
 
Free DOX is membrane-permeable and is able to induce an uncontrolled cell death within a 
few hours. Thus, we expected it to escape from the endosomal membrane when released from 
the particle in the lysosome and to subsequently induce cell death within a few hours after 
endosomal escape. Indeed, our newly developed β-CD NPs provided intracellular DOX 
release and caused efficient cell death after 24 h of incubation with a calculated IC50 value of 
7.23 μg/mL for the DOX-loaded β-CD particles. In addition, the nanoparticles exhibited a 
high DOX-loading capacity of about 23 wt% (see Appendix, Figure S 7-4). The dose-
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dependent cell viability assay demonstrates that DOX was delivered in a controlled manner 
via the particles and released only after endosomal acidification. In contrast, as-synthesized β-
CD NPs without any cargo show good biocompatibility in the dose-dependent cell viability 
studies (Figure S 7-7). As a control experiment the DOX-loaded nanoparticles were 
centrifuged after 24 h storage and the respective amount of supernatant was incubated on 
HeLa cells. This control revealed good biocompatibility, i.e. no prematurely released cargo 
molecules were present. This experiment shows the great potential of β-CD NPs to efficiently 
deliver chemotherapeutics to cancer cells without premature release. This newly developed 
biocompatible carrier system provides an attractive platform for cellular delivery applications 
with exceptionally fast cell uptake kinetics. 
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7.3. Conclusion 
To conclude, we have developed a novel nanomaterial consisting of covalently crosslinked β-
cyclodextrin molecules as the main organic component. The obtained nanoparticles are small 
(~150 nm) and highly dispersible in aqueous solutions. They exhibit very fast cell uptake 
kinetics due to sugar-receptor mediated endocytosis and can be covalently labeled with dye 
molecules to effectively track them in in vitro experiments. Furthermore, the porous cavities 
of the particles can be loaded with cargo molecules, which are subsequently released in the 
endosomal cell compartments due to acidification. This triggered release mechanism allowed 
us to show efficient nuclei staining with Hoechst 33342 dye and effective cancer cell killing 
with doxorubicin as cargos, respectively. Thus, the nanoparticles show great potential for 
future applications as a biocompatible drug carrier system.   
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7.4. Experimental Part 
Materials. β-Cyclodextrin (97 %, Sigma Aldrich), tetrafluoroterephthalonitrile (TFTN, 98 %, 
Alfa Aesar), polyethylene glycol 2000 (PEG2000, BioUltra, Sigma Aldrich), potassium 
carbonate (K2CO3, 99.5 %, Grüssing GmbH), tetramethylrhodamine 5-carboxamido-(6-
azidohexanyl) (TAMRA azide, Base click), doxorubicin hydrochloride (98 % HPLC, Sigma 
Aldrich), D-glucose (Sigma Aldrich), D-L-arabinose (Sigma Aldrich), 2-deoxy-D-glucose 
(Sigma Aldrich), Hoechst 33342 trihydrochloride (ThermoFisher Scientific), cetyl 
trimethylammonium bromide (Sigma Aldrich), wheat germ agglutinin, Alexa Fluor® 488 
conjugate (lifeTechnologies), Dulbecco’s modified Eagle’s medium (DMEM) 
(lifeTechnologies), Hank´s balanced salt solution (HBSS-buffer, Sigma Aldrich) were used as 
received. Ethanol (EtOH, absolute, Aldrich), hydrochloric acid (1 M, Bernd Kraft), 
dimethylsulfoxide (DMSO, anhydrous, >99.9 %, Sigma Aldrich) and dimethylformamide 
(DMF, >99.9 %, anhydrous, Sigma Aldrich) were used as solvents without further 
purification. Bidistilled water was obtained from a millipore system (Milli-Q Academic A10).  
Characterization. DLS and zeta potential measurements were performed on a Malvern 
Zetasizer Nano instrument equipped with a 4 mW He-Ne-Laser (633 nm) and an avalanche 
photodiode detector. DLS measurements were directly recorded in diluted colloidal 
suspensions of the particles at a concentration of 1 mg/mL. Zeta potential measurements were 
performed using the add-on Zetasizer titration system (MPT-2) based on diluted NaOH and 
HCl as titrants. For this purpose, 1 mg of the particles was diluted in 10 mL bi-distilled water. 
Thermogravimetric analyses (TGA) of the bulk-extracted samples (approximately 10 mg) 
were recorded on a Netzsch STA 440 C TG/DSC. The measurements proceeded at a heating 
rate of 10 °C/min up to 900 °C in a stream of synthetic air of about 25 mL/min. Nitrogen 
sorption measurements were performed on a Quantachrome Instrument NOVA 4000e at -
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196 °C. Sample outgassing was performed for 12 hours at a vacuum of 10 mTorr at 120 °C. 
Pore size and pore volume were calculated by a QSDFT equilibrium model of N2 on carbon, 
based on the adsorption and desorption branch of the isotherms. A BET model was applied in 
the range of 0.05 – 0.20 p/p0 to evaluate the specific surface area. Infrared spectra of dried 
sample powder were recorded on a ThermoScientific Nicolet iN10 IR-microscope in 
reflection-absorption mode with a liquid-N2 cooled MCT-A detector. Cross-polarized 
13
C-
MAS NMR measurements were performed on a Bruker DSX Avance500 FT spectrometer 
(11.74 T) in a 4 mm ZrO2 rotor. The spinning rate was 10 kHz and a total number of 256 
scans was recorded. The used contact time was 2 ms and the recycle delay was 1 s. Scanning 
electron microscopy (SEM) was performed on a FEI Helios instrument at an acceleration 
voltage of 2.5 kV. For this purpose the samples were put on an adhesive graphite film and 
sputtered twice with carbon with a BALTEC MED 020 Coating System. Transmission 
electron microscopy (TEM) data were obtained with a FEI Titan Themis 60–300 microscope 
at an acceleration voltage of 80 kV. UV/Vis measurements were performed on a Perkin Elmer 
Lambda 1050 UV-Vis/NIR spectrophotometer with a deuterium arc lamp and a tungsten 
filament equipped with a 150 mm integrating sphere and an InGaAs detector. Time-based 
fluorescence release experiments were performed at 37 °C on a PTI spectrofluorometer 
equipped with a xenon short arc lamp (UXL-75XE USHIO) and a photomultiplier detection 
system (Model 810/814). 
Synthesis of β-CD NPs. In a 40 mL polypropylene reactor, 400 mg β-cyclodextrin 
(0.35 mmol), 200 mg tetrafluoroterephthalonitrile (TFTN, 1.00 mmol), 600 mg K2CO3 
(4.34 mmol), 50 mg polyethylene glycol (PEG2000) and 50 mg cetyltrimethylammonium 
bromide (CTAB, 0.14 mmol) were mixed with 15 mL anhydrous DMSO. The mixture was 
sonicated (15 min) and subsequently stirred at 900 rpm and 80 °C for 3 h. The orange 
suspension was cooled to room temperature and 15 mL bidistilled water and 15 mL 
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hydrochloric acid (1 M) were slowly added to the reaction mixture. After centrifugation for 15 
minutes at 7830 rpm (7197 rcf) the isolated light yellow solid was washed extensively with 
water (2 x 40 mL), HCl (1 M, 2 x 40 mL) and ethanol (2 x 40 mL) followed by centrifugation 
steps (15 min, 7197 rcf), respectively. Finally, the pale yellow powder was dispersed in 
10 mL bidistilled water and used for further characterization (150 mg, 25 % yield).  
Rhodamine-labelling of β-CD NPs. 1 mg of β-CD NPs in ethanolic solution were mixed 
with 2 μL TAMRA-azide (2 mg/mL in anhydrous DMF) and a catalytic amount of zinc(II) 
acetate dihydrate. The mixture was shaken at 37 °C for 12 h and afterwards washed 
extensively with ethanol and water (centrifugation steps: 14,000 rpm, 16,837 rcf, 4 min) until 
no fluorescence could be detected in the supernatant. Finally, the particles were redispersed in 
1 mL H2O and used for in vitro uptake experiments. 
Cargo loading of β-CD NPs. An aqueous solution of 1 mg/mL β-CD NPs was centrifuged 
(14,000 rpm, 16,837 rcf, 4 min), washed once with 500 μL HBSS buffer and redispersed 
again in a mixture containing 500 μL HBSS buffer with either 5 μL doxorubicin 
hydrochloride (100 mg/mL in DMSO) or 500 μL Hoechst 33342 (10 mg/mL in water), 
respectively. The nanoparticles were incubated for 3 h and subsequently washed extensively 
with HBSS buffer (14,000 rpm, 16,837 rcf, 4 min) until no fluorescence could be detected in 
the supernatant. Finally, the loaded nanoparticles were redispersed in 1 mL HBSS buffer and 
used for further in vitro release experiments. As a reference sample the particles were 
centrifuged (14,000 rpm, 16,837 rcf, 4 min) after certain time points and the corresponding 
amount of supernatant was used on HeLa cells. 
Lipid preparation. The following lipids were used: DOPC (1,2-dioleoyl-sn-glycero-3-
phosphocholine, Avanti Polar Lipids), DOTAP (1,2-dioleoyl-3-trimethylammonium propane, 
Avanti Polar Lipids). The amount of 2.5 mg of the individual lipids was dissolved in a 1 mL 
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mixture of 40 %vol absolute ethanol and 60 %vol MQ water (conc. 2.5 mg/mL). The amount 
of 1 mg of nanoparticles in aqueous solution was centrifuged (4 min, 8609 rcf, at 15 °C) and 
redispersed in 100 µL of the above DOTAP solution. Upon addition of 900 µL MQ water (pH 
adjusted to 9.4 with sodium hydroxide) the formation of the first SLB layer on the external 
surface of the nanoparticles was induced. After centrifugation (4 min, 8609 rcf, at 15 °C) and 
redispersion in 100 µL of a 1:1 mixture of the above DOPC/DOTAP solutions, the formation 
of a second layer around the nanoparticles was induced by adding 900 µL HBSS buffer. 
Cell Culture. HeLa cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
(lifeTechnologies) supplemented with 10 % fetal bovine serum (FBS) and incubated at 37 °C 
under a 5 % CO2 humidified atmosphere. For live cell imaging the cells were seeded on ibidi 
8-well µ-slides 24 h before adding particles, at a cell density of 5000 cells per well. 
Uptake studies and in vitro Cargo release. The cells were incubated with 2 µL or 5 µL of a 
1 mg/mL β-CD NPs solution for 0.5 – 24 h prior to the measurements at 37 °C under a 5% 
CO2 humidified atmosphere. During the measurements all cells were kept on a heated 
microscope stage at 37 °C under a 5% CO2 humidified atmosphere. For imaging, the cells 
were stained with 1 μL of a WGA solution and were incubated for 2-5 min at 37°C in a 5% 
CO2 humidified atmosphere and then washed twice with DMEM. In addition to the uptake 
studies, the supernatant of the stock solution was similarly investigated for fluorescence and 
nucleus staining. The subsequent imaging was performed as described in the spinning disk 
confocal microscopy section.  
Spinning disc confocal microscopy. Confocal microscopy for live-cell imaging was 
performed on a setup based on the Zeiss Cell Observer SD utilizing a Yokogawa spinning 
disk unit CSU-X1. The system was equipped with a 1.40 NA 63x Plan apochromat oil 
immersion objective from Zeiss. For all experiments the exposure time was 0.2 s and z-stacks 
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were recorded. Hoechst 33342 was imaged with light at 405 nm and a power density of 
approximately 0.16 W/mm
2
, WGA was imaged at 488 nm with approximately 0.48 W/mm
2
, 
and Rhodamin was excited at 561 nm with 11 mW/mm
2
. In the excitation path a quad-edge 
dichroic beamsplitter (FF410/504/582/669-Di01-25x36, Semrock) was used. Separate images 
for each fluorescence channel were acquired using two separate electron multiplier charge 
coupled device (EMCCD) cameras (PhotometricsEvolveTM). 
Cuvette release experiments. To show the successful uptake and release of the cargo, the 
doxorubicin loaded particles were transferred to a custom made Teflon cap fitting on a 
fluorescence cuvette. The cap was sealed with a dialysis membrane (ROTH Visking type 
8/32, MWCO 14,000 g/mol) and placed on top of a fluorescence cuvette filled with 3 mL of 
HBSS buffer to show the successful uptake of doxorubicin and with 3 mL of citric acid 
phosphate buffer at pH 5 to prove the pH-dependent release. The excitation wavelength was 
set to λ = 488 nm and the emission fluorescence intensity was recorded at λ = 590 nm. All 
slits were adjusted to 2.0 mm. The measurement was continuously run for more than 40 hours 
(Figure 7-5). 
Cell viability studies. For MTT-Assays we seeded 5000 HeLa cells per well containing 
100 μL of high glucose DMEM medium and treated them with particles 24 h after seeding. 
After 24 h of incubation the cells were washed twice with HBSS buffer. 100 μL of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 0.5 mg/mL in DMEM) was 
added to each well of the nanoparticle-treated cells and incubated for further 2 h. Unreacted 
MTT and medium were removed and the 96-well plates were stored at -80 °C for at least 1 h. 
Then, 100 μL DMSO was added to each well. The absorbance was read out by a Tecan plate 
reader at 590 nm with a reference wavelength of 630 nm. All studies were performed in 
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triplicates. The IC50 and the standard mean deviations were calculated using the Origin 9.0 
software. 
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7.6. Appendix 
 
Figure S 7-1: A) Transmission electron microscopy (TEM) image of spherical β-CD NPs revealing a narrow 
particle size distribution around 100 nm. B) 
13
C-MAS solid-state nuclear magnetic resonance (ssNMR) spectrum 
of β-CD NPs indicating the successful incorporation of the oligosaccharide compounds and the rigid organic 
linker into the crosslinked material. 
 
Figure S 7-2: A) IR spectroscopy data of as-synthesized β-CD NPs (black) and rhodamine-labeled nanoparticles 
(violet). The successful attachment can be followed by the vanishing nitril stretching vibration at 2245 cm
-1
 due 
to the covalent binding of the dyes azide groups to form tetrazole rings in a 1,3-dipolar cycloaddition. Spectra 
were normalized and shifted due to clarity reasons by 1.0 along the y-axis. B) Photograph of 1 mg of as-
synthesized pale yellow β-CD NPs (I) and pink labeled Rho-β-CD NPs (II) in water after centrifugation, 
respectively. 
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Figure S 7-3. Fluorescence microscopy of HeLa cells incubated with rhodamine-labeled β-CD NPs (red) after 30 
min (A), or pretreated with free inhibitors (e.g. β-cyclodextrin) for 30 min and incubated with rhodamine-labeled 
β-CD NPs for 30 min afterwards (B). Cell membranes are stained with WGA (green). Scale bar represents 
10 μm, respectively. 
To test the targeting of sugar receptors with β-CD nanoparticles on HeLa cells, the receptors 
were either blocked or kept free. The functionality was evaluated in a receptor competition 
experiment (Figure S3). For this purpose, one part of the HeLa cells was pre-incubated with 5 
µL of an inhibitor solution (10 mM aqueous solutions of D-glucose, D-L-arabinose, 2-deoxy-
D-glucose or β-cyclodextrin, respectively), to block the receptors, for 30 min at 37 °C under a 
5% CO2 humidified atmosphere. Then the HeLa cells were incubated with 5 µg of rhodamine-
labeled β-CD-NPs for 30 min at 37 °C under a 5% CO2 humidified atmosphere. For staining 
the cell membrane, the cells were incubated with WGA for 2 min. The cells were washed 
three times with PBS, fresh medium was added and subsequently the cells were imaged. 
Clearly an enhanced sugar receptor-mediated cell uptake can be seen when the sugar receptors 
are available on the cell surface (A) compared to blocked receptors (B). 
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Figure S 7-4: Calibration curve for doxorubicin loading capacity measured at 500 nm. 
The concentration of the DOX loading solution was 0.5 mg/mL with 0.5 mg nanoparticles. 
After several washing steps the supernatants were collected and revealed an added-up 
absorbance of 0.750±0.008. By using the linear regression fit of the calibration curve (Figure 
S4), this leads to a DOX content of 383 μg/mL in the collected supernatants. Therefore, the 
total amount of loaded DOX was 117 μg per 0.5 mg nanoparticles leading to a loading 
capacity of 23 wt%. 
To test the pH-responsive release of Hoechst dye from the nanoparticles, Hoechst-loaded 
particles were redispersed in 1 ml potassium phosphate buffer at pH 7.4, 6.0, and 4.0, 
respectively. After a 20-minute incubation period, particle solutions were centrifuged to 
separate particles and supernatant and the UV-Vis spectrum of the supernatant containing the 
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released Hoechst dye was measured. Release increased with decreasing pH as shown in 
Figure S5. 
 
Figure S 7-5: UV-Vis measurement of Hoechst dye released from nanoparticles at different pH values. 
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Figure S 7-6: Fluorescence colocalization images of the liposome-coated CD NPs. A) Liposomes labeled with 
WGA 488, B) CD NPs labeled with TAMRA, C) merged image of both channels. 
To investigate if the coating of the particles with liposomes was successful, fluorescence 
colocalization experiments were performed (Figure S 7-6). For this purpose, β-cyclodextrin 
particles were stained with TAMRA, a rhodamine dye, and the liposomes were marked with 
WGA 488. In the case of a successful coating the dyes should be colocalized, while an 
independent distribution indicates a failure to coat the particles. The images (A, B) show that 
both the liposomes and particles were stained successfully and the merged image (C) shows 
that both fluorescent stains are colocalized, proving that the particles were successfully coated 
with liposomes. The slight offset in the positions of the particles and the liposomes between 
both channels is caused by the Brownian motion of the particles, while switching to a 
different excitation wavelength to take the second image. Control experiments confirmed that 
there is no spectral overlap between both dyes, confirming that the observed colocalization of 
the signals is caused by the successful coating.  
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Figure S 7-7: Titration curves of coated and non-coated CD NPs. 
A further proof for successful lipid coating is a comparison of the zeta potentials of lipid-
coated and non-coated particles (Figure S7). The β-CD-NPs without any coating show a more 
or less constant zeta potential over the whole pH-range from 3 to 8 of around 0 mV. After 
successful lipid coating the measured zeta potential increased significantly. This results from 
the positive charge of the DOTAP lipid and thus confirms successful coating. 
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8. Conclusion and Outlook 
This thesis focused on the implementation of well-known tailor-made mesoporous silica 
nanoparticles (MSNs) in various fields. As a highlight, MSNs were successfully applied as 
drug delivery vehicle in the field of cancer immunotherapy. Furthermore, the diversity of 
MSNs could be demonstrated by their use as enzyme support. To expand the horizon of 
promising nanoparticles, an innovative organic material and its application in cellular delivery 
was introduced. 
The first project described in this work (in chapter 3) is a preceding study of chapter 4. Here, 
small-pore MSNs with and without a pH-responsive polymer capping system were assessed 
regarding their biocompatibility, toxicity, and immune-modulatory properties. It was shown 
that the particles were rapidly and efficiently taken up by specialized antigen-presenting cells 
(APCs). Furthermore, MSNs did not show any cytotoxicity in the commonly applied 
concentration range meaning induced apoptosis was only observed when the particles were 
used in very high concentrations of 200 µg mL
-1
. To investigate if unloaded particles already 
induce an immune response, the activation markers, namely co-stimulatory molecule CD80 
and proinflammatory cytokines IL-6 and IL-12p70, were measured on different APCs. In both 
cases no significant upregulation could be observed upon addition of the MSNs to the primary 
immune cells and thus showing that cargo-free particles could not induce an innate immune 
response. To prove further that they also have no impact on B and T lymphocytes from the 
adaptive immune system, the respective early activation marker CD69 was measured and it 
was shown that neither of them shows an upregulation. Summarizing, the particles represent a 
non-toxic and non-inflammagenic delivery system which is preferably taken up by specialized 
antigen-presenting cells. To assess if this MSN system can principally function as carrier for 
immune-modulatory cargo with regard to cancer immunotherapy applications, the particles 
were loaded with resiquimod (R848) and coated with the pH-responsive polymer PVP as 
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capping system. It could be shown that the particles were internalized via endocytosis and that 
the capping system opened up in the local acidic environment allowing R848 release. This 
was measured with the upregulation of the above mentioned activation markers. In summary, 
it was demonstrated that MSNs possess indeed the appropriate characteristics for an optimal 
carrier system of immune-modulatory cargo.  
To implement the gained knowledge and explore the possibilities of MSNs as drug delivery 
system, MSNs were investigated in detail as pH-responsive carrier system for R848 as 
described in chapter 4. To examine the full potential of the drug delivery system, the 
aforementioned polymer cap was compared to a protein-based one in respect to their R848 
loading and release behaviour. The two different capping systems differed in their opening 
and closure mechanisms. Whereas the polymer system works reversibly upon pH-dependent 
(de-) protonation of the PVP groups, the biotin-avidin complex is irreversibly detached 
through pH-dependent cleavage of the connecting acetal linker. Time-based fluorescence 
release measurements in cuvette demonstrated that the R848 release of the avidin-capped 
system was superior over that of the PVP-coated MSNs. This was further confirmed in a cell-
based assay. Subsequently, the loading behaviour of R848 into MSN-avidin was optimized by 
introducing phenyl moieties inside the pores and applying SSC20x as loading buffer. The 
long-term stability and the tight capping of the MSN-avidin system was demonstrated with 
time-dependent release experiments. This optimized R848 delivery system was further 
assessed in vitro and in vivo. Rapid and efficient uptake of unloaded MSN-avidin into 
dendritic cells (DCs) was observed. Loaded particles induced a potent DC activation as shown 
in cytokine production and upregulation of co-stimulatory and MHC molecules. Notably, the 
supernatant of the loaded particles did not induce an immune response, proving the tightness 
of the capping system. To explore the possibilities of the MSN system further, the antigen 
OVA peptide was attached to the avidin surface of the loaded particles and the resulting T cell 
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activation measured. Comparison with free R848 and OVA or the combination thereof, 
showed that the highest effect in T cell proliferation was achieved through the simultaneous 
delivery of antigen and adjuvant with the MSN system. To prove that the carrier is applicable 
in vivo, the safety and biodistribution of the avidin-coated MSNs were examined in mice. The 
particles did not induce any observable toxicity, they were mainly taken up by migratory 
dendritic cells and delivered to the next draining lymph organ. In sum, it was demonstrated 
that MSNs hold indeed great promise as carrier system for immune-stimulant R848 and even 
the simultaneous delivery of adjuvant and antigen. It thus shows high potential to be used in 
further cancer vaccine applications to achieve a locally induced immune activation while 
preventing adverse systemic effects. Further work will address the in vivo application of the 
described cancer vaccine system.  
Chapter 5 demonstrates the diversity of MSNs regarding their tunable pore size and 
morphology. Large-pore stellate MSNs (LP-MSNs) with different functionalities were 
synthesized and the impact of the incorporated organosilanes on the mesopore structure as 
well as the particle morphology was investigated in detail. Furthermore, an adapted version of 
the co-condensation method for small-pore particles, was applied to create spatially-
segregated core-shell large pore MSNs. To exploit the potential of these multifunctional 
MSNs, the interior of the pore was functionalized with DBCO derivatives allowing for mild 
cargo conjugation via copper free click chemistry. Attachment of the DBCO molecules was 
performed with stimuli-responsive linkers, namely the pH-responsive acetal linker described 
in chapter 4 and a redox-sensitive disulfide linker, to enable triggered release via specific 
buffer or redox conditions. The successful stimuli-responsive release of the model cargo 
TAMRA dye was proven with in cuvette time-based fluorescence experiments as well as in 
vitro fluorescence microscopy experiments. Future work will be dedicated to the conjugation 
and release of real drugs within the established system. 
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The described large-pore MSNs offer, in combination with the introduced click-chemistry, 
new possibilities in immobilizing large biomolecules. These were investigated in chapter 6 of 
this work. Large-pore MSNs were synthesized with an azide functionality on the inner walls 
of the pores and a phenyl functionality on the exterior MSN surface to guide the positively 
charged enzymes horseradish peroxidase and carbonic anhydrase into the pores. Both 
enzymes were alkyne-functionalized prior to covalent attachment via copper-click chemistry 
on the inner pore walls of the LP-MSNs. The successful immobilization of the biomolecules 
inside the silica support was characterized with several methods including IR-spectroscopy, 
gas sorption, and TGA measurements as well as the study of their catalytic behaviour. Here, 
colorimetric assays were applied for the respective enzymes to monitor their activity over 
several cycles with simple washing and centrifugation steps in between. It was shown that the 
enzymes remained stable and active in the pores and thus proving the benefits of covalent 
immobilization inside a host system like increased stability and efficient workup. A future 
development based on this work could be to test its application, for example in the removal of 
toxic phenols from polluted water. 
The last chapter of this thesis introduces a novel biocompatible drug carrier which is not 
based on silica but on crosslinked β-cyclodextrins (CDs). This soft, organic material consists 
of small nanoparticles with sizes of ~ 150 nm, which are highly water-dispersible. Covalently 
labeled CD nanoparticles showed rapid uptake in HeLa cells within 30 minutes. Particles 
coated with a lipid bilayer, in contrast, were not taken up in this short period of time, 
suggesting a sugar-receptor mediated endocytosis of the CD NPs. Their ability to form 
inclusion complexes between the cyclodextrin rings and various cargos was demonstrated 
with the uptake of the nuclei staining dye Hoechst and the chemotherapeutic doxorubicin. 
Both cargos were efficiently delivered without notable premature leakage. Upon acidification 
in the endosomes both cargos were successfully released resulting in efficient nuclei staining 
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or cell death, respectively. Thus, the novel sugar-based material holds great promise as 
biocompatible drug carrier, which has to be evaluated in further studies. 
In summary, the great potential of multifunctional MSNs as carrier system in various fields 
was illustrated in this work. MSNs with different pore sizes, morphologies, and post-synthetic 
functionalizations were tailored to meet the requirements of a non-toxic and non-
inflammagenic carrier system as well as a support material for large biomolecules. The 
promising potential as stimuli-responsive drug delivery system was shown in vitro and in 
vivo. Nevertheless, there are still some hurdles to overcome to enable the clinical entry of 
MSNs as biocompatible drug carrier. One of the great challenges in the transition from 
laboratory to clinics will be the development of a simple, cheap and reproducible upscaling 
process of highly functionalized MSNs. Furthermore, more uniform studies have to be 
performed in vivo to assess the fate, toxicity and full impact on and in living organisms of the 
promising drug vehicles. 
 
To expand the spectrum of promising biocompatible carriers and to view the drug delivery 
field from a different angle, a novel crosslinked organic carrier system was also introduced 
with a simple synthesis route devoid of several following functionalization steps and 
encouraging cellular delivery characteristics.  
 
Overall, this thesis demonstrates the great potential of biocompatible nanocarriers, which still 
has to be fully exploited in the future. 
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